| Title of Invention | "A SUBSTITUTED IMIDAZOLES COMPOUND OF FORMULA-1" |
|---|---|
| Abstract | ABSTRACT "A SUBSTITUTED IMIDAZOLE COMPOUND OF FORMULA (I)" A substituted imidazoles compound of formula (I): R' R' R' R' Formula (I) wherein: R', R^, R^, R'*, R^ are independently selected from the group consisting of hydrogen, halo, CM alkyl, Cj^ cycloalkyl. CM alkoxy, CM haloalkyl. CM haloalkoxy, and SR"', where R'° is CM alkyl or CM haloalkyl; R^ is selected from the group consisting of hydrogen, -Co-2alkyleneR'', -Ci. 2alkyleneOR^ -C,.2alkyleneOC(0)R^, -Co-2alkyleneC(0)OR^ -Ci.2alkyleneOC(0)NHR^ and -C,.2alkyleneOC(0)NR'^R'^; where each R^, R'^ and R^^, where chemically possible, is independently selected from the group consisting of hydrogen, Ci^ alkyl, and CM alkylene(C3.6 cycloalkyl); R* and R^ are independently selected from the group consisting of hydrogen, CM alkyl, CM alkoxy. CM haloalkyl, and C0-4 alkylenephenyl but with the proviso that R^ and R^ are not both hydrogen; R" and R''^ are independently selected from the group consisting of hydrogen, halo, cyano, CM alkyl. CM alkoxy. CM haloalkyl, and CM haloalkoxy; or a pharmaceutical ly acceptable salt thereof. |
| Full Text | SUBSTITUTED imidazolS AND THEIR USE AS PESTICIDES This invention relates to imidazols having parasiticidai properties. The compounds of interest are substituted imidazols and, more particularly, the invention relates to alpha substituted 2-benzyi imidazols. There Is a need for improved antiparasitic agents for use with mammals, including humans and animals, and In particular there fe a need for improved insecticides and acaricides. Furthermore there is a need for improved topical products with convenient administration and which contain one or more of such antipcirasitic agents which can be used to effectively treat ectoparasites, such as Insects and acarids, and particularly aracids such as mites and ticks. Such products would be particularly useful for the treatment of companion animals, such as cats, dogs and horses, and livestock, such as cattle. There is equally a need for agents to control parasitic infestations in animal hosts other than mammals, including insects such as bees, which are susceptible to parasites such as varroa mites. The compounds currently available for insecticidal and acaricidal treatment of companion animals and livestock do not always demonstrate good activity, good speed of action, or a long duration of action. Most treatments contain hazardous chemicals that can have serious consequences when either used too' often or when used in excess of recommended quantities. Many products have toxic side effects and some are lethal to cats when accidentally ingested. They are not always suitable for use as a topical or spot-on formulation and some topical and spot-on formulations are disadvantaged by common side effects in animals and owners. Persons applying these insecticide! and acaricidal agents are advised to limit their exposure to the chemicals by wearing gloves and avoiding Inhalation of the chemical vapours. Pet collars and tags have been utilised to overcome some problems, but these are susceptible to chewing and therefore are disadvantageous since the compound may be accidentally orally ingested. Thus, treatm ents currently achieve varying degrees of success depending on a variety of factors including toxicity and the method of administration. In some cases toxicity may be attributed to their non-selective activity at various receptors. In addition it has recently been shown that some current agents are becoming ineffective as the parasites develop resistance. The present invention overcomes one or more of the various disadvantages of, or improves upon, the properties of existing compounds. In particular the present invention develops some new alpha substituted 2-benzyl imidazols which demonstrate such properties. Heterocyclic derivatives have been disclosed in the prior art as having insecticidal and acaricidal activity against agricultural pests, for example International patent application publication no. WO 03/092374. Generic disclosures also exist In the prior art of heterocyclic derivatives which optionally encompass alpha substituted 2-benzyl imidazols. For example, international patent application publication no. WO 2005/007188 describes a generic structure, which optionally encompasses alpha substituted 2-benzyl imidazols for the inhibition of the hatching of an ectoparasite egg; international patent application publication no. WO 2004/103959 describes a generic structure which optionally encompasses alpha substituted 2-benzyl imidazols for use as antibacterial agents; international patent applications publication nos WO 01/00586 and WO 99/28300 both describe a generic structure which optionally encompasses alpha substituted 2-benzyl imidazols and discloses their adrenergic activity; and US patent US 6,103,733 describes a generic structure which optionally encompasses alpha substituted 2- benzyl imidazols for increasing blood serum and HDL cholesterol levels. However, none of this prior art exemplifies any alpha substituted 2-benzyl imidazols, nor does the prior art Indicate that such compounds would be useful against a spectrum of parasites relevant to companion animals and livestock or against the range of ectoparasite lifecycle stages. Thus, it is an aim of the present invention to overcome one or more of the various disadvantages of, or improve on the properties of, known compounds. In particular it is an aim of the Invention to develop some new alpha substituted 2-benzyl substituted imidazols. It is a further aim that such new compounds have the same or improved activity when compared to the prior art compounds against parasites. It is another aim of the present invention to develop compounds which have a similar or decreased toxicity profile when compared to the prior art compounds. It is yet another aim to develop compounds which demonstrate selectivity for the octopaminergic receptor, a known invertebrate neurotransmitter, over the ubiquitous animal adrenergic receptor. Furthermore, it is an aim of the invention to reduce the exposure of both humans and animals to the treatment by developing compounds which can be dosed as a low volume spot-on or topical application. The compounds of the present invention have especially good ability to control arthropods as shown by the results of tests demonstrating their potency and efficacy. In particular, the compounds of the present Invention are active against ticks and they are able to prevent ticks from attaching to, and feeding from, the host annnai. It is yet another aim of the present invention to provide compounds which have good speed of action when compared to those of the prior art and hence an improved efficacy against the transmission of tick borne diseases. It is alsio desirable that the compounds of the present invention should have one or more of the same or improved duration of action, an improved pharmacokinetic profile, improved safety, improved persistence, improved solubility or other improved physicochemical and formulation properties such as good spreading after topical application compared to those of the prior art Thus, according to the present invention, there is provided a compound of formula (I): (Formula Removed) wherein: R1, R2, R3r R4, Ra are independently selected from the group consisting of hydrogen, cyano, nitro, halo, hydroxy, C1-4 alkyl optionally substituted by one or more hydroxy groups, C1-4 cycloalkyf optionally substituted by one or more C1-4alkyl or halo groups, C1-4alkoxy, C1-4hatoalkyl, C1-4 haloalkoxy, phenyl, amino, NRxRy, and S(0)nR10; R6 is selected from the group consisting of hydrogen, - C0-2alkyteneR7, - C1-2alkyleneOR7, "Co-2alky!eneC(0)R7, - C0-2alkyleneOC(0)R7, -C1-2alkyleneOC(O)OR7, - C0-2alkyleneC(O)OR7, -C1. 2alky!eneN(H)C{0)R7 -C1-2alkyleneN(R7)C(0)R7 -C0-2alkyleneC(0)NHR7, -C0-2-alkyleneCCO)NR15R18, -C1-2alkyleneNHC(0)NR15R18, -C12alkyleneNR7C(0)NR1sR1B, C1-2alkyleneOC(0)NHR7, -C1-2alkyleneOC{0)NR15R16, -C0.2alkyleneCH=N(R7)1 "C1-2alkyleneP(=0)(NR15R16)(NR15R16), -Co-2alkyleneSi(R7)3 and -C0-2alkyleneS(0)nR10; wherei the C0-2alkylene or C1-2alkytene of R6 may, where chemically possible, optionally be substftulted by one or more subslituents selected from the group consisting of C1-6alkyl, C3-6cydoalkyl, C1-4 aikylene(C3-6 cydoalkyl),C0-6 alkylenephenyl, which C0-2alkylene or C1-2alkylene substituent may in turn be optionally further substituted, where chemically possible, by one or more substituents selected from the group consisting of hydrogen, cyano, nitro, halo, formyl, oxo, hydroxy, C(0)OH,C1-4alkyl C1-4 alkyleneC3-6 cyclaalkyf, C1-4alkoxy, C1-4alkyleneC1-4 alkyoxy, -C(0)OC1-4lkyl, C1-4 haloalkyl, C1-4haloalkoxy, amino, C1-4 alkylamino, C1-4dialkylamino, and S(0)nR1°; where each R7, R1S and Rt6, where chemically possible, is independently selected from the group consisting of hydrogen, C1-8 alkyl,C2-6 alkenyl,C2-6 alkynyl,C3-8cycloalkyl, C1-4 alkylene(C3-6 cydoalkyl), C1-4 alkyleneC1-4alkoxy, C1-6 haloalkyl, C0-6 alkylenephenyl, C0-6alkylenenaphthyl, C0-6 alkylene(tetrahydronaphthyl), and C0-2 alkylene(Het), where Het is selected from oxetanyl, tetrahydropyranyl, piperidinyl, morpholinyl, furyl, pyridyl, benzofuranyl, benzothiazolyl, indolyl, 2,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, indolyl and 1,5-naphthyridinyl; or R15 and R16 together with the nitrogen to which they are attached may form a three to seven -membered saturated or unsaturated heterocyclic ring optionally containing one or more further N, O or S atoms or S02 groups; where each of the above R7, R1S or R16 groups may independently include one or more optional , substituents where chemically possible selected from hydrogen, cyano, nitro, halo, formyl, oxo, hydroxy, C(0)OH, C1-4 alkyl, C2-4alkenyl, C1-4 alkynyl,C3-6 cydoalkyl, C1-4alkylened-s cycloalkyl, C1-4 alkoxy, C1-4 alkyleneC1-4 alkyoxy, C1-4 alkoxyC1-4 alkoxy, C1-4. alkanoyl, -C(O)C1-4 alkyl, C1-4 haloalkyl, C1-4 halocycloaikyl, C1-4 haloalkoxy, C1-4 haloalkanoyl, -C(0)OC1-4 haloalkyl, phenyl, 4-halophenyl, 4-alkoxyphenyl, 2-cyanophenyl, phenoxy, 4-haiophenoxy, benzyloxy, 4-halobenzyloxy, benzoyl, pyrazolyl, triazolyl, 2-halo-4-pyrimidinyl, 2-phenylethyl, amino, dialkylamino, C1-4dialkylamino, C(0)N(C1-4alkyl):,, N(C1-4 alkyIene)C(0)( C1-4 alkyl) and S(0)nR10; RB and R9 are independently selected from the group consisting of hydrogen,C1-4 alky], C1-4 alkoxy,C1-4 haloalkyl, C1-4 haloalkoxy and C0-4 alkylenephenyl but with the proviso that R8 and R9 are not both hydrogen; where each of Ra and R9 may independently include one or more optional substituents where chemically possible selected from hydrogen, cyano, halo, hydroxy, C1-4 alkyl, C3-8 cycloaikyl, C1-4 alkoxy, -C(0)OC1-4 alkyl, C1-4haloalkyl, C1-4 haloalkoxy, and S(0)nR10; or R6 and R9 together with the carbon to which they are attached may form a three to six membered carbocyclic, saturated ring, which ling is optionally substituted with one or more substituents selected from the group consisting of halo, C1-2alkyl,C1-2alkoxy, C1-2 haloalkyl, C1-2 haloalkoxy R11 and R12 are independently selected tram the group consisting of hydrogen, hato, cyano, CC1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, and C1-4haloalkoxy; where Rx and Ry are independently selected from hydrogen, C1-4 alkyl, C1-4 haloalkyl, and S(0)nR10; each n is Independently 0,1 or 2; and each R10 is independently hydrogen, hydroxy, C1-4alkyl, C1-4haloalkyl, 4-halophenyl, amino, C1-6 alkyl amino and di C1-6 alkyl amino; or a pharmaceutically acceptable salt or a prodrug thereof. In particular, there is provided a compound of formula (I): (Formula Removed) wherein: R1, Ra, R3, R4, R5 are independently selected from the group consisting of hydrogen, cyano, nltro, halo, hydroxy, C1-4alkyl, C1-4 cycloalkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 haloalkoxy, amino, NRXRy, and S(0)nR10; R6 is selected from the group consisting of hydrogen, -Co.2alkyIeneR7, -C1-2alkyleneOR7, -Co-2alkyleneC(0)R7, -C1-2alkyleneOC(0)R7, -C1-2alkyleneOC(0)OR7, -C0-2alky!eneC(0)OR7, -C1-2alkyleneN(H)C(0)R7, -C1-2alkyleneN(R7)C(0)R7 -C0-2alkyleneC(O)NHR7, -C0-2aJkylerteC{0)NRl5R16, -C1-2alkyleneNHC(0)NR15R16, -C1-2alkyleneNR7C(0)NR15R16, -C1-2alkyleneOC{O)NHH7,-C1- 2alkyleneOC(0)NR15R16, -C0-.2alkyleneCH=N(R7)J C-1.2alkyleneP{=0)(NR15R16)(NR18R1B), -Co- 2alkyteneSi(R7)3, and -C0-.2alkyleneS(0)nR1°; where theC0-.2alkylene or C1-.2alkylerte of R8 may, where chemically possible, optionally be substituted by one or more substituents selected from the group consisting of C1-6alkyl, C3-6 cycloalkyl, C1-4aIkyfene(Ca. B cycloalkyl),C0-.2 alkylenephenyl, which C0-.2alkylene or 1-2alkylene substituent may in lum be optionally further substituted, where chemically possible, by one or more substituents selected from the group consisting of hydrogen, cyano, nitro, halo, formyl, oxo, hydroxy, C(0)OH, C1-4 alkyl, C1-4alkyleneC3-6 cycloalkyl, C1-4alkoxy, C1-4 alkyleneC1-4alkyoxy, -C(0)OC1-4 alkyl, C1-4 haloalkyl, C1-4haloalkoxy, amino, C1-4alkylamino, C1-4 dialkylamino, and S(0)nR10; where each R7, R15and R16, where chemically possible, is independently selected from the group consisting of hydrogen, C1-8 alkyl, C2-6 alkenyl, C2.6 alkynyl, C3-8 cycloalkyl, C1-4alkyleneC3-6 cycloalkyl), C1-4 alkyleneC1-4 alkoxy, C1-6 haloalkyl, C0-6 alkylenephenyl; or R15 and R18 together with the nitrogen to which they are attached may form a three to seven -membered saturated or unsaturated heterocyclic ring optionally containing one or more further N, O or S atoms;; where each of the above R7, R1s or R16 groups may independently include one or more optional substituents where chemically possible selected from hydrogen, cyano, nltro, halo, formyl, oxo, hydroxy, C(0)OH, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-6cycloalkyl, C1-4 alkyteneC3-6cycloalkyl, C1-4 alkoxy, C1-4 alkyleneC1-4 alkyoxy, C1-4 alkanoyl, -C(0)OC1-4 alkyl, C1-4 haloalkyl, C3-6 halocycloalkyl, C1-4 haloalkoxy, C1-4 Haloafkanoyl, -C(O)0C1-4 haloalkyl, phenyl, 4-halophenyl,4-alkoxyphenyI, amino, C1-4 alkylamino, C1 4 dialkylamino, C(0)N(C1-4 alkyl)a, N(C1-4 alkylene)C(0)( C1-4 alkyl) and S(0)„R10; Ra and R9 are independently selected from the group consisting of hydrogen, C1-4 alkyl, C1-4 alkoxy, C1-4 haloallkyl, C1-4 haloalkoxy and C3-4 alkylenephenyl but with the proviso that Ra and R9 are not both hydrogen; where each of R8 and R9 may independently include one or more optional substituents where chemically possible selected from hydrogen, cyano, hafo, hydroxy, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkoxy, -C(0)OC1-4 alkyl, C1-4 haloalkyl, C1-4 haloalkoxy, and S(0)nR10; or R8 and R9 together with the carbon to which they are attached may form a three to six m embered carbocycllc, saturated ring, which ring is optionally substituted with one or more substituents selected from the group consisting of halo, C1-2 alkyl, C1-2 alkoxy, C1-2haloalkyi,C1-2haloatkoxy, R11 and R12 are independently selected from the group consisting of hydrogen, halo, cyano, C1-4 alkyl, C1-4alkoxy, C1-4 haloalkyl, and C1-4haloalkoxy; where Rx and Ry are independently selected from hydrogen, C1-4alkyl, C1-4 haloalkyl, and S(0)nR10; each n is independently 0,1 or 2; and each R10 is independently hydrogen, hydroxy, C1-4 alfcyl, C1-4 haloalkyl, amino,C1-6 alkyl amino and dl C1-6 alkyl amino; or a pinarimaceuticaliy acceptable salt or a prodrug thereof. In the definition of R1, R2, R3, R4 and R5, "C1-4 alkyl optionally substituted by one or more hydroxy groups" means an alkyl group with between one and four carbon atoms, which may be unsubstituted or maybe substituted at any available position with a hydroxy group. For reasons of chemical stability, it is preferred that no carbon atom should be substituted with more than one hydroxy group. Accordingly, alkyl groups with up to four hydroxy substituents are foreseen. Preferred are alkyl groups with no more than two hydroxy substituents. Examples include hydroxymethyi, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyJ and 2,3-dihydroxypropyl. In the definition of R1, R2, R3, R4 and R5, "C3-6 cycloalkyl optionally substituted by one or more C1-4 alkyl or halo groups" means a cycloalkyl group with between three and six carbon atoms in the ring, which may be unsubstituted or may be substituted at any available position with an alkyl group of between one and four carbon atoms or a halogen atom. In the case of alkyl substituents, it is preferred that not more than four such substituents be present, and more preferred that not more than two such substituents be present. Examples include 1 -methylcyclopropyl, 2,5-dimethylcyclopentyi and 4-tert-butylcyctohexyl. In the case of halo substituents, any degree of substitution up to complete substitution is foreseen. In the case of cyciohexyl therefore, up to eleven halo substituents may be present. White each halo group may be independently selected, it may be preferred to have all halo substituents the same. Preferably the halo is chloro or fluoro. Geminal disubstitution at any methylene position may be preferred ver monosubstitution. Examples include 2,2-dichlorocyclopropyl and perfluorocydohexyl. Substitution with both alkyl and halo groups is also foreseen. An example is 2,2-difluoro-1 -methylcyctobutyf. Preferably, each of R1, R2, R3, R4, R5 are independently selected from hydrogen, halo eg chloro or fluoro, C1-4alkyl eg methyl or ethyl, C3-4 cycloalkyl eg cyclopropy], C1-4 alkoxy eg methoxy or ethoxy, C1-4 haioalkyl eg trlfluoromethyl, trifluoroethyl, C1-4 haloalkoxy eg trifluoromethoxy or trifluoroethoxy, and S(0)„R10 where n is 0 and R10 is preferably selected from C1-4 alkyl such as methyl or ethyl or C1-4 haioalkyl such as trrfjuoromethyl or trifluoroethyl to form for example trifluoromelhylthio or trif luoroethylthio. More preferably each of R1, R2, R3, R4, Rs are independently selected from hydrogen, halo eg chloro, C1-4 alkyl eg methyl or ethyl, C1-4 alkoxy eg methoxy or ethoxy, and C1-4 haloalkyl eg trifluoromethyl, trifluoroethyl. Most preferably each of R1, R2, R3, R4, Rs are independently selected from hydrogen, andC1-4alkyl eg methyl or ethyl. Most preferably two of R1, R2, R3, R4, and Rs are independently selected from C1-4 alkyl eg methyl or ethyl, preferably methyl, and three of R1, R2, R3, R4, and R5 are H. Even more preferably R1 and R2 are selected from C1-4 alkyl eg methyl or ethyl, preferably m ethyl, and R3, R4 and Rs are H. Further suitable compounds Include those where at least one of R1, R2, R3, R4, and R5 Is Independently selected from C1-4haloalkyl eg trifluoromethyl, trifluoroelhyl, preferably trifluoromethyl, with the others of R1, Ra, R3, R4, and R5 being H. Preferably R2 is C1-4 haloalkyl eg trifluoromethyl, trifluoroethyl preferably trifluoroethyl, wtth the others of R1, R3, R4, and R5 being H. Other suitable compounds include those where at least one of R1, R2, R3 R4, and Rs Is Independently selected from C1-4 alkoxy eg methoxy or ethoxy preferably methoxy, with the others of R1, R2, R3, R4, and R5 being H. Preferably Rs and R3 are selected from C1-4 alkoxy eg methoxy or ethoxy preferably methoxy, and R1, R4 and R6 are H. Other suitable compounds include those where at least one of R1, R2, R3, R4, and Rs is independently selected from halo eg chloro or fluoro, with the others of R1, Ra, R3, R4, and R5 being H. Other suitable compounds include those where at least one of R1, R2, R3, R4, and Rs is Independently selected from halo eg chloro or fluoro, and another one of R1, R2, R3, R4, and R5 is independently selected from C14 alkyl eg methyl or ethyl, with the others of R1, R2, R3, R4, and R5 being H. Most preferred compounds are those where Rf and Ra are methyl and R3, R4, and Rs are hydrogen. Preferably R6 is selected from the group consisting of hydrogen; -C0-2alkyteneR7; -C1-2alkyleneOR7; -C1-2alkyleneOC(0)R7; -C1-2lkyleneOC(0)OR7; -C1-2alkyleneC(0)OR7; -C1-2alkyleneOC(0}NHR7; -C1-2alkyleneOC(0)NR15R18; and -Co-2a1kyleneS(0)nR10. More preferably R6 is selected from the group consisting of hydrogen;-C1-2alkyleneR7; -C1-2alkyleneOR7; -C1-2alkyleneOC(0)R7; -C1-2alkylene0C(0)0R7; and -C0-2alkyleneC(0)OR7. Even more preferably RB is selected from the group consisting of hydrogen; -Co-2alkyleneR7; -C1-2alkyleneOC(0)R7 and -C0.2alkyleneC(O)OR7. Most preferably R6 is hydrogen. Preferably R7, R15 and R16are, where chemically possible, independently selected from the group consisting of hydrogen; C1-6 alkyl for example methyl; ethyl, n-propyl, isopropyi, butyl, isobutyl, tert-butyl, n-penty), n-hexyl; C3-6 cycloalkyl for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl; C1-4 alkylene(C3-6cycloalkyl) for example cyclopropylmethyl, cyclopropylethyt, cyclobutylm ethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cydohexylethyf; C1-6 haloalkyl for example fluorornethyl, trifluoromethyl, chloromethyl, fluorcethyl, chloroethyl, trffiuoroethyl and trifiuoropropyl; and Co-6 alkylphenyl for example phenyl, phenyrmethyl and phenylethyi. More preferably R7, R1S and R16are, where chemically possible, independently selected from the group consisting of hydrogen; C1-6 alkyl for example methyl, ethyl, n-propyl, isopropyi, butyl, tert-butyl, n-penty!, n-hexyl; C1-4 alkylene(C3-s cycloalkyl) for example cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl. Even more preferably R7, R15 and R16are, where chemically possible, independently selected from the group consisting of hydrogen and C1-4 alkyl for example methyl, ethyl, propyl, isopropyi, n-butyl and tert-butyl. Further suitable compounds include those where R7, R1B and R16are, where chemically possible, optionally substituted with one or more substituents selected from the group consisting of halo for example f luoro or chloro,C1-4alkyl for example methyl or ethyl preferably methyl, C3-6cycloaikyl, lor example cyclopropyi, cyclobutyl or cyclopentyl preferably cyclopentyl, C1-4 alkoxy for example methoxy or ethoxy, C1-4 haioalkyl for example fluaromethyl, chlaromethyl, trifluoromethyl, fluaraethyl, chloraethyl or trifluoroethyl, preferably trifluoroethyl or trifluoromethyl, and Sf,0)„R10 for example methyteulphonyl or dimethyl amido sulphonyl. Examples of R7, R,s and R1s groups which have then been so substituted include far example branched alkyt groups such as 2-methylbutyl, 3-metriylbuty!, substituted sulphonyl groups such as methylsulphonylmethyl, methylsulphonytethyl, dimethyfamidosulphonylrnethyl and dimethyiamidosulphonylethyl and substituted phenyl groups such as 4-chtorophenyt, 4-nitrophenyl, 4-fluorophenyl, 4-methoxyphenyf, 2,4-dichlorophenyl, 4-ch!orophenyimethyi, 4-nitrophenylmethyl, 4-fluorophenylmethyl, 4-methoxyphenyl methyl, 2,4-dichlorophenylmethyf, 4-chlorophenylethyl, 4-nitro phenyl ethyl, 4-fluorophenytethyl, 4-methoxyphenylethyl, and 2,4 -dichlorophenylethyl. Suitably when R1B and R16 together with the nitrogen to which they are attached form a three to seven -membered saturated or unsaturated heterocycfic ring optionally containtng one or more further N, O or S atoms it is preferred that the ring is a five or six membered ring, is saturated and comprises one further heteroatom selected from N, O or S. Suitable examples of such rings include pyrrofidinyl, pyrazolidinyl, imidazolinyl, thiazolidinyl, isoxazolidinyl, piperidinyl, piperazinyl, morpholinyl, or thiomorpholinyl. Preferred rings include pyrrolidlnyl, thiazolidinyl, morpholinyl, or thiomorpholinyl- Such rings may optionally be further substituted with one or more groups, preferably selected from the group consisting of oxo, C(0)OH, halo for example fluoro or chloro, andC1-4 alkyl for example methyl or ethyl preferably methyl. For example any heterocyclic sulphur atoms may be optionally substituted with one or more oxo groups to form for example 1,1-dioxothiazolidinyl or 1,1-dioxothiomorphoBnyi subsMutents. Suitable compounds include those where, when the R8 group comprises a one carbon alkylene moiety, that said alkylene moiety is optionally substituted with one or two substituents. Further suitable compounds also include those where, when the Ra group comprises a two carbon alkylene moiety, that said alkylene moiety is optionally substituted with one, two, three or four substituents which may be Independently orientated on either the alpha or beta carbon positions with respect to the imidazol nitrogen to which the Re substituted Is bound. Suitably when the C0-2alkylene or C1-2alkyiene of R6 Is substituted with one or more substitutents it is preferred that such substituents are independently selected from the group consisting of hydrogen; C1-4 alkyl for example methyl or ethyl; C3-6 cycloaikyl for example cyclopropyi; C1-4 alkyleneC3-6 cycloaikyl for example cyclopropylmethy! or cyclopropylethyl; C1-4 alkoxy for example methoxy or ethoxy;C1-4 alkyleneC1-4 alkyoxy for example methoxy methyl, methoxy ethyl, ethoxy methyl or ethoxy ethyl; C1-4 haloaikylfor examplelluoromethyl, trifluromethyl,ftuoroethy! or 1,1,1-trifluoroethyl; phenyl, benzyl and 4-trifluoromethylbenzyl. More preferably such substituents are independently chosen from the group consisting of hydrogen; C1-4alkyl for example methyl or ethyl; C3-6cycloaikyl for example cyclopropyi; C1-4 alkyleneC3-6 cycloaikyl for example cyclopropylmethyl or cyclopropylethyl; C1-4 haloalkyl for example lluoromethyl, trifluromethyl, fluoroethyl or 1,1,1 -trifluoroethyl; and phenyl. Suitable compounds include those where R8 is selected from the group consisting of -Co-2alkylenefl7, preferably where R8 is CH2R7, and where R7 is selected from the group consisting of C1-6 alkyl for example methyl, ethyl, n-prapyt, isopropyl, butyl, tert-butyl; C3-6 cycloatkyf for example cydopropyf, cyctobutyl, cyclopentyi; C1-6 haloalkyl for example trifluoromethyl, and trifluoraethyl; and C^ afaylene-phenyi for example phenyl which is optionally substituted to form for example 4-methoxy phenyl, 4-trlfluoromethylphenyl. Further suitabfe compounds also include those where R6 fs selected from the group consisting of -Co-2alkylenefl7, preferably where R6 does not comprise an additional alkylene moiety (ie is C0alkyleneR7)7, and where R7 is selected from the group consisting of C1-6 alkyl for example methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, preferably methyl and ethyl; C3-6 cydoalkyi for example cyclopropyl, cyclobutyl, cyctoperttyl, preferably cycloprapyt; C1-6 haloalkyl for example trtfluoromethyl, and trffiuoroethyl; and Co-8 alkylenephenyl for example phenyl which is optionally substituted to form for example 4-methoxy phenyl, 4-trifluoromethylphenyl. A further group of suitable compounds include those where R6 is selected from the group consisting of-C1-2alkyleneOR7, preferably where R6 is CH2OR7, and where R7 is selected from the group consisting of C1-6alkyl for example methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl. Examples of such so substituted R6 groups include methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, propoxymethyl, propoxy-ethyl, Isopropoxyethyl, butoxymethyl, seobutoxyoxym ethyl, isobutoxymethyl, rert-butoxymethyl, butoxy-ethyl, sec-butoxyoxyethyl, isobutoxyethyl, fe/frbutoxyethyl, pentyloxymethyl, pentyioxyethyt, hexyloxy-methyl, hexyloxyethyl. A still further group of suitable compounds include those where R6 fs selected from the group consisting of -C1-2alkyleneOG{0)R7, preferably where R6 is CH2OC(0)R7, and where R7 is C1-6 alkyl for example methyl, ethyl, n-propyf, Isopropyl, butyl, tert-butyl, which R7(n turn maybe optionally further substituted. Examples of such so substituted R6 groups include acetyloxymethyl, acetyloxyethyl, propionyloxymethyl, propionyloxyethyl, butyryloxymethyl, butyryloxyethyt, isobutyryloxymethyl, isobutyryloxyethyl, perttanoyl-oxymethyl, pentanoyloxyethyl, 2-methylbutyryloxymethyl, 2-methylbutyryloxyethyl, 3-methylbutyryloxy-methyl, 3-methylbutyrylcarbonyloxy)elhyl, 2,2-dimethylpropionyloxymethyl, 2,2-dimethylpropionyloxyethyl hexanoyloxymethyl, hexanoyloxyethyl, heptanoyloxymethyl, heptanoyloxyethyi. Further suitable examples of compounds where R8 Is selected from the group consisting of C1-2alkyteneOCtOJR7, preferably where R6 Is CH2OC(0)R7, also include those where R7 is C1-4 alkyteneC3-6 cycloalkyl} for example cyclopropyfrnethyf, cycfopropyfethyl, cyclobutylmethyl, cyclobutyfethyl, cycfopentylmetnyl, cyclopentylethyl, cyclopentylpropyl, cycfohexylmethyl, and cyclcohexylethyl. Examples of such so substituted R8 groups include cyclopropylacetyloxymethyl, cyclopropylproplonyloxymethyl, cyclobutyl-acetyloxymethyl, cyclobutylpropionyloxymethyl, cyclopentylaoetyloxyrnethyl, cyclopentylpropionyloxy-methyl, cyclopentylbutyryloxymethyl, cyclohexylacetyloxymethyl, and cyclcohexylpropionyloxymethyl, cyclopropylacetyloxyethyl, cyclopropylpropionyloxyethyi, cyclobutyiacetyloxyethyl, cyclobutyfpropionyloxy-ethyl, cyclopentylacetyloxyethyl, cyclopentyipropionyloxyethyl, cyclopentylbutyrybxyethyl, cyclohexyl-acetyloxyethyl, and cyclcohexylpropionyloxyethyl. preferably R6 is 3-cyclopentylpropionyloxymethyl. It is preferred that in such compounds R7 is preferablyC1-6 alkyl, more preferably ethyl or tert-butyl, and most preferably tert-butyl. A yet further group of suitable compounds Include those where R Is selected from the group consisting of -C1-2alkyleneOC(0)OR7, preferably where Ra is CH2OC(0)OR7, and where R7 is C1-6 alkyl tor exarnpie methyl, ethyl, n-propyl, isopropyl, butyl, tert-buiyl, which may in turn be optionally further substituted. Examples of such so substituted R6 groups include methoxycarbonytoxymethyl, methoxycarbonyiaxy-ettiyl, ethoxycarbonyloxymethyl, ethoxycarbonytoxyethyl, propoxycarbonyloxymethyi, propoxycarbonyl-oxyethyl, isopropoxycarbonyloxymethyl, isopropoxycarbonyioxyethyt, butoxycarbonyloxymethyl, butoxycarbonyloxyethyl, isobutoxycarbonyioxymethyl, isobutoxycarbonyloxyethyl, pentyJoxycarbonyioxy-methyf, pentyloxycarbonyloxyethyl, 2-methyibutoxycarbonyloxymelhylr 2-me1hyibutoxycarbonylaxyetnyl, 3-methylbutoxycarbonyloxymethyl, 3-methyibutoxycarbonyloxyethyl, 2,2-dImethyipropoxycarbonykJxy-methyi, 2,2-dimethylpropoxycarbonyloxyethyl, hexytaxycarbonytoxymethyl, hexykjxycarbonyloxyethyl. Further suitable examples of compounds where R6 is selected from the group consisting of -C1-2alky!eneOC(0)OR7, preferably where Rs is CH2OC(0)OR7, also include those where R7 is selected from the group consisting of C3-6cycloalkyl for example oyclopropyi, cyclobutyl, cyclopentyl or cyolohexyt; C1-4 a!kylelne(C3-6 cycloalkyl) for example cyclopropylrnethyl, cyclopropylethyl, cyclobulyirnethyl, cydobutyl-ethyl, cyclopentylmethyi, cyclopentylethyl, cyclohexylmethyi, cycfohexyiethyl; C1-6 haloalkyl for example trifluoromethyl, and 2,2,2-trifluoroethyi; and C0-6 alkylphenyi for example phenyl which Is optionally further substituted to form for example 4-melhoxyprtenyl, 4-trifluoromethylphenyl4-methoxybenzyl. . Examples of such so substituted Ra groups include cyclopropyloxycarbonyloxymethyl, cyclobutyioxycarbonyloxy-rnethyl, cyclopentyloxycarbonyioxymethyl or cyclohexyloxycarbonyloxymelhyi cyclopropytaxycarbonylaxy-ethyl, cyclabutyloxycarbonytoxyethyl, cyclopentyloxycarbonyloxyethyl or cydohexyloxycarbonytoxyethyl; C1-4 silkylene(C3-6cycloalkyl) for example cyclopropylmethyloxycarbonyloxymethy], cyctopropylethyloxy-carbonyloxymethyl, cycloburyim emyloxycarbonyloxyrnethyi, cyclobutylethyloxycarbonyioxymethyl, cyclopenryJmethyloxycarbonyloxymethyl, cyclopentylethyloxycarbonyloxymethyl, cyclohexyJmethyloxy-carbonytoxymethyJ, cyclohexyielhyloxycarbonyJoxymefhyl, cyclopropylmethyloxycarbonyioxyethyt cyclopropylethyloxycarbonyloxyethyl, cyclobutyimethyloxycarbonyioxyethyl, cyclobutytethyloxycarbonyi-oxyelhyi, cyclopentylmethyloxycarbonyloxyethyi, cyclopentylethyioxycarbonyJoxyethyi, cyclohexylmethyJ-oxycarbonyloxyethyl, cyciohexylethyfoxycarbonyloxyethyl; C1-6 haloalkyl for example trifluoromethyloxy-carbonyloxymethyl, and 2,2,2-trifluoroethyloxycarbonyloxymethyt, trifluorometiyloxycarbonyloxyethyl, and 2,2,2-trifluoroethyloxycarbonyloxVethyl; and Co-6 alkylphenyi for example phenyJoxycarbonyloxymethyl which is optionally further substituted to form for example 4-methoxyphenyloxycarbonyloxymetriyi, 4-trlfluoromethylphenyloxycarbonylcjxymethyl,4-methoxybenzyloxycarbonyJciixymethyl. A still yet further group of suitable compounds include those where R6 is selected from the group consisting of-C0-2alkyleneC(O)OR7, preferably where R6 is C(0)OR7 and where R7 is C1-6 alkyl for example methyl, ethyl, n-propyl, isopropyl, butyl, tort-butyl, which may in turn be optionally further substituted. Examples of such so substituted RB groups include methoxycarbonyl, methoxycarbonyl-methyl, methoxycarbonyiethyl, ethoxycarbonyl, ethoxycarbonyimethyl, ethoxycarbonylethyl, propoxy-carbonyt, propoxycarbonylmethyl, propoxycarbonyiethyt, isopropoxycarbonyi, isopropoxycarbonylmethyl, isopropoxycarbonylethyl, butoxycarbonyf, butoxycarbonyimethyl, butoxycarbonylethyl, isobutoxycarbonyl, isobutoxycarbonylmethyl, isobutoxycarbonylethyl, pentyloxycarbonyl, pentyloxycarbonylmethyl, pentyloxycarbonylethyl, 2-methylbutoxycarbonyl, 2-methylbutoxycarbonyimethyl, 2-methyibutoxy- carbonyiethyl, 3-methyibutoxycarbonyl, 3-methylbutoxycarbonylmethyl, 3-methylbutoxycarbonylethyl, 2,2 -dimethylpropoxycarbonyl, 2,2 -dimethylpropoxycarbonylmethyl, 2,2-dimelhylpropoxycarbonylethyl, hexyloxycarbonyl, hexyloxycarbonylrnethyl, hexyloxycarbonylethyl. Further suifabfe examptes of compounds include those where Ft6 is selected from the group consisting of -C0-2.alkyleneC(0}ORr7 preferably where R6 is C{0)OR7, also include those where R7 is selected from the group consisting ol C^ alkylphenyl for example phenyl which In turn is optionally substituted to form for example 4-methoxy phenyl, 4-trifluoromethyl phenyl. Examples of such so substituted R8 groups include phenyloxycarbonyl, phenyloxycarbonyfmethyi, phenyloxycarbonytethyt. An even further group of suitable compounds include those where Ra is selected from the group consisting of -C1-2alkyieneOC(0)NHR7, preferably where R6 is CHaOC(0)NHR7, and where R7 is selected from the group consisting of C1-6 alkyl for example methyl, ethyl, n-propyl, tsopropyl, butyl, tart-butyl; C3-6 cycioalkyl for example eyclopropyl, cyclobutyl, cycloperrtyl or cyclohexyt; C1-6haloalkyt for example trifluoromethyl, and trifluoroethyi; and C0-6alkylphenyl for example phenyl, phenytmethyl or phenytethyl which Co-6 alkylphenyl is optionally substituted to form for example 4-methoxyphenyl, 4-trilluoromethyl-phenyl, 2, 4-dichlorophenyl, 4-methcwyphenyJntethyf, 4-trlfluoromethylphenylrnethyi, 2, 4-dichtorophenyl-methyl, 4-methoxyphenylethyl, 4-trifluoromethylphenylethyf, or 2, 4-dfchlorophenytethyI, Preferred are those compounds where RB is selected from the group consisting of hydrogen, -Co-2alkyleneR7 and -C1.aalkyleneOC(O)R7 and where R7 is selected from the group consisting of C1-8 alkyl Even more preferred compounds are those where R6 is hydrogen. Preferably, each Ra and R9 are independently selected from the group consisting of hydrogen; C1-4 aikyl eg methyl or ethyl, preferably methyl; C1-4 haloalkyl for example trifluoromethyl, trichloromethyl, trichloroethyl or trifluoroethyi, preferably trifluoromethyl; C1-4 alkoxy for example methoxy or ethoxy, preferably methoxy; and C0-4 alkylenephenyl for example phenyl, phenylmetrryl or phenylethyl, but with the proviso that Rs and R9 are not both hydrogen. More preferably each RB and R9 are independently selected from the group consisting of hydrogen and C1-4ailkyl eg methyl or ethyl, preferably methyl but again with the proviso that R8 and R9 are not both hydrogen. Most preferably R8 is methyl and R8 is hydrogen. Suitably when either one or more of Ra or R9 are phenyl, the phenyl group is optionally substituted with one or more substitutents selected from the group consisting of fluoro, chloro, methoxy or trifluoromelhyl. Suitably when R8 and R9 together with the carbon to which they are attached may form a three to six membered carbocyciic, saturated ring ft is preferred that the ring is a three membered ring. Preferably each of R11 and R12 are Independently selected from the group consisting of hydrogen, C1-2 alkyi eg methyl or ethyl, preferably methyl, and C1-2alkoxy for example methoxy or ethoxy, preferably methoxy. More preferably at least one of R11 and R12 is hydrogen. Most preferably both of R11 and R12 are hydrogen. A further group of suitable compounds of the present invention are those of formula (LV) where: each of R1. R2, R3, R4, R5 are independently selected from hydrogen and C1-4 alkyl eg methyl or ethyl, preferably methyl; each R8 and R9 are independently selected from the group consisting of hydrogen and C1-4 alkyl eg methyl or ethyl, preferably methyl; and each R11and R12 are hydrogen or a pharmaceurically acceptable salt or a prodrug thereof, Preferably, in compounds of formula (LV): R1, Ra and RB are selected from C1-4alkyl eg methyl or ethyl, preferably methyl, R3, R4, R5 and R'are H. It will be understood that throughout the application ail references to formula (!) apply equally to compounds of the formula (LV). Furthermore, it will be understood that all the suitable groups and preferences applied to R1 - R12, Ra, Rb and n for formula (I) apply equally to compounds of the formula (LV). A further group of preferred compounds are the compounds of formula (XXXX) (Formula Removed) wherein R1 to Rs are selected from hydrogen, halo,C1-4 alkyl,C1-4haloalky! and CN, and Ra is C1-4 alkyL Preferably, at least two of R1 to RB are hydrogen, and more preferably at least three of R1 So RB are hydrogen. Preferably, the groups from R1 to R5 that are not hydrogen are selected from chloro, fluoro, methyl, ethyl, difluoromethyl and trifluoromethyl, and more preferably from fluoro, chloro and methyl. Preferably R8 Is methyl or ethyl, and more preferably R8 is methyl. A further group of preferred compounds are the compounds of formula (XXXXl) (Formula Removed) wherein R1 to R5 are selected from hydrogen, halo, C1-4alkyl.C1-4haloalkyl and CN, R7 is phenyl optionally substituted by one or more groups selected from cyano, nitro, halo, formyl, hydroxy, C(0)OH, C1-4 alkyl, C2-4 alkenyl, C2-4alkynyl, C3-6 cycloalkyl, C1-4 alkyleneC3-6 cycloalkylC1-4alkoxy, -C(0)OC1-4 alkyl, C1-4 haloalkyl, C1-4 haloalkoxy, pyrazolyl, triazoryl, amino, C1-4 alkylamino, andC1-4dialkylamino, and R8 isC1-4alkyl. Preferably, at least two of R1 to R5 are hydrogen, and more preferably at least three of R1 to R6 are hydrogen. Preferably, the groups from R1 to R5 that are not hydrogen are selected from chloro, fluoro, methyl, ethyl, difluoromethyl and trifluoromethyl, and more preferably from fluoro, chloro and methyl. Preferably R7 is phenyl optionally substituted by one or two groups selected from cyano, chloro, fluoro, hydroxy,C1-3alkyi,C1-3 alkoxy and C1-2 haloalkyi. Preferably R8 is methyl or ethyl, and more preferably R8 is methyl. A further group of preferred compounds are the compounds of formula (XXXXJI) (Formula Removed) wherein R1 to Rs are selected from hydrogen, halo, C1-4 alkyl, C1-4haloalky! and CN, R? is selected from Ci^alkytenephenyl optionally substituted by on the phenyl ring by one or more groups selected from cyano, halo, hydroxy, C(0)OH, C1-4alkyl, C3-6 cycloalkyl, C1-4alkyteneC3-6 cycloalkyl, C1-4 alkoxy, -C(O)0C1-4 alkyl,C1-4 haloalkyl, and C1-4 haloalkoxy, C1-6 alkyl optionally substituted by one or two C1-4 alkoxy groups, C3-6 cycloalkyl, C1-3alkyieneC3-6cycloalkyl, and C1-6 haloalkyi, and RB is C1-3 alkyl. Preferably, at least two of R1 to Rs are hydrogen, and more preferably at least three of R1 to R5 are hydrogen. Preferably, the groups from R1 to R5 that are not hydrogen are selected from chloro, fluoro, methyl, ethyl, difluoromethyl and trifluoromethyl, and more preferably from fluoro, chloro and methyl. Preferably R7 is C1-6alkyl or C1-6haloalkyl. Preferably R8 is methyl or ethyl, and more preferably R8 is methyl. A further group of preferred compounds are the compounds of formula (XXXXIII) (Formula Removed) wherein R' to R5 are selected from hydrogen, halo, C1-4 alkyl, C1-4 haloalkyi and CN, R7 is selected from C1-3alkylenephenyl optionally substituted by on the phenyl ring by one or more groups selected from cyano, halo, hydroxy, C(0)OH, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkyleneC3-6cycloalkyl, C1-4 alkoxy, -C(0)OC1-4 alkyl, C1-4haloalkyli, and C1-4 haloalkoxy, C1-6 alkyl optionally substituted by one or two C1-4 alkoxy groups, C3-6 cycloalkyl, C1-3alkyleneC3-6cycloalkyl, and C1-6 haloalkyi, and R8 isC1-3 alkyl- Preferably, at least two of R1 to Rs are hydrogen, and more preferably at least three of R1 to R5 are hydrogen. Preferably, the groups from R1 to Rs thai are not hydrogen are setected from chloro, fluoro, methyl, ethyl, difluoromethyl and trifluoromefhyl, and more preferably from fluoro, chloro and methyl. Preferably R7 is C1-6alkyl or C1-6haloalkyl. Preferably R8 is methyl or ethyl, and more preferably Ra is methyl. A further group of preferred compounds are the compounds of formula {XXXX1V) (Formula Removed) wherein R1 to R5 are selected from hydrogen, halo,C1-4alkyl, C1-4 haloalkyi and CIM, R7 is setected from C1-3alkylenephenyl optionally substituted by on the phenyl ring by one or more groups selected from cyano, halo, hydroxy, C(0)OH, C1-4 alkyl, C3-6 cycloalkyl, C1-4 alkylenC3-6cyctoalkyl C1-4 alkoxy, -C(0)OC1-4 alkyl, C1-4 haloalkyl, and C1-4 hafoalkoxy, C1-6 alkyl optionally substituted by one or two C1-4 alkoxy groups, C3-6 cycloalkyl, C1-3alkyleneC3-6cycloalkyl, and C1-6 haloalkyi, and R6 isC1-3 alkyl. Preferably, at least two of R1 to R5 are hydrogen, and more preferably at least three of R1 to R5 are hydrogen. Preferably, the groups from R1to R6 that are not hydrogen are selected from chloro, fluoro, methyl, ethyl, difluoromethyl and trifluoromethyl, and more preferably from fluoro, chtoro and methyl. Preferabfy R7 is C1-6alky! or C1-6hafoalkyl, and more preferably R7 is isobutyi. Preferabfy R8 is methyl or ethyl, and more preferably R8 Is methyl. Preferred individual compounds of the invention are selected from the compounds of the Examples described herein. More preferred individual compounds of the Invention are selected from: 2-[(2,3-dtmethylphenyl)(methoxy)methyfI-1H-imidazol,- 2-[1 -(2,5-dlmethylphenyl)ethyl]-l H-lmidazole; 2-[1 -(2,4-dimethylphenyl)ethyl]-1 H-im idazole; 2-[1 -(3,4-dime1hyfphenyl)ethyII-1 H-im idazole; 2-{1-[2-(trifluaromethyl)phenyl]ethyl}-1 H-im idazole; (2,3-dimethylphenyl}(1H-imidazol-2-yl)metrianol; 2-{1-(2,3-dimethylphenyl)ethyl]-1H-imidazol; {2-[1 -{2,3-dimethylprienyl)ethylH H-imidazoi-1 -yl}methyl pivalate; {2-[l-(2,3-dlmethylphenyr)ethyl]-1H-imidazol-1-yI}methyl propionate; {2-[1 -(2,3-dimethylphenyl)ethyl]-1 H-imidazoM-yl}methyI 3-methylbutanoate; {2-[1-(2,3-dimethyiphenyl)ethyl]-1H-imidazol-f-yrimethy(butyrate; (2-[1 -(2,3-dimiethylphenyl)ethyl]-1 H-im ldazol-l-yl}m ethyl 3-cyclopentylpropanoate; {2-[1 -(2,3-dimethyfphenyl)ethyl]-1H-im idazol-1-yl}methylheptanoate; {2-[1 -{2,3-dimethylphenyl)ethyl]-1 H-imidazol-1 -yl]methyl pentanoate 2-[1-{4-chloro-3-methylphenyi}ethyr]-lH-irri idazole 2-[1 -{3,5-dimelhylphenyl)ethyU-1 H-lmidazole 1 -benzyl-2-[1-(2,3-dlmefhylphenyl)ethyl]-1 H-imidazol {2-[1-(2,3-dimethylphenyl)ethyl]-1 H-im idazol-1 -ylj]methyl-4-methoxybenzyl carbonate 1 -(cyclopropylmethyl)-2-[1 -(2,3-dirriethylphenyl)ethyl]-1 H-imidazol 2-[1 -(2,3-dimethylphenyl)ethyl]-1 -methyl-1 H-imidazol cyclopropylmethyl {2-[1-(2,3-dimethylphenvi)ethyr]-1 H-imidazol-1 -yljmethyl carbonate {2-[1l-(2,3-dimethylphenyl)ethyl]-1 H-mldazol-1-yl}methyl 3-methylbutyl carbonate {2-[l-{2,3-dimelhylphenyl)ethyl]-1H-imidazol-1-yl}methyl isopropyl carbonate cyclobutyl {2-[1-(2,3-dimethylpheny!)ethyr|-1 H-im idazol-1 -yljmethyl carbonate {2-[1 -{2,3-dimethylphenyl)ethyl]-1 H-lmidazal-1 -yljmethyl 2,2,2-trifluoroethyl carbonate 2-[1-{2,3-dfmetrry/pr(erry()etriy5-1-ethyl-1H imidazol 2-[1-{2,3-dimethylphenyl)etiiyrj-1 -(4-methoxybenzyl)-1 H-imldazole 2-[1 -(2,3-dimethylphenyI)ethyl]-1 -(methoxymethyl)-1 H-imidazol 2-[1-(2,3-dimetrtylphenyl)ethyl]-1 -[4-(trifluorornethyl)benzyI]-1 H-imidazol 4-fiuorophenyl 2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazote-1-carboxylate isobutyl 2-I1-(2,3-dimethyiphenyl)ethyfJ-1 H-imidazol-1-carboxyfate isopropyl 2-[1 -(2,3-dimethylphenyl)etriyl]-1 H-imidazol-1 -carboxylate 2-[1 -(3-methylphenyf)ethyl]-1 rt-imidazol or a pharmaceutically acceptable sait or prodrug thereof. More preferred individual compounds of the present invention are selected from: 2-[1-(2,3-dtmelriylphenyl)ethyll-1 H-imidazol; 2-[(1 S)-1 -(2,3-dimethylphenyi)ethyfl-1 H-im idazole; 2-[(1 fl)-1 -(2,3-dim ethylphenyJ)ethyi]-1 H-im idazole; {2-{1 -(2,3-dlmethylpheny))ethyl]-1 H-lmidazol-1 -yljmethyl pivalate; {2-1(1 S)-l -(2,3-dimethylphertyl)ethylJ-1 H-imidazol-1 -yl}methyipivalate; {2-[( 1 R)-1-(2,3-dimethylphenyl)etriyl]-1 H-im idazol-1-yl}methy[pivalate; {2-[1 -(2,3-dJmetbylphenyl)ethyrj-1 H-imidazol-1 -yljmethyl propionate; {2-[1 -(2,3-dimethylphenyl)ethyl]- H-imidazol-1 -yljmethyl 3-methylbutanoate; {2-[1-(2,3-dimethylphenyl)ethyl]-1 H-imidazol-1 -yljmethyl butyrate; {2-[1 -(2,3-dimethylphenyl)ethyl]-1 H-imidazol-1-yl]methyl 3-cyclopentylpropanoate; {2-I1-(2,3-dimethy!phertyl)ethyi]-1 H-imldazol-1-yljmethyl heptanoate; {2-[1 -(2,3-dimethylphenyl)ethyl]-1 H-imidazol-1 -yljmethyi pentanoate 2-{1 -[2-(trif luoromethyl)phenyl]ethyiJ-1 H-imidazol; 2-[1 -(2,5-dimethylphenyl)ethyl]-1 H-im idazole 2-[l-(4-chloro-3-methy/phertyl)ethyl]-1 H-imidazol 2-[1 -(3,5-dimethylphenyl)ethylJ-1 H-imldazoie 1 -benzyl-2-[l-(2,3-dimethylphenyl)ethyl]-1 H-imidazol {2-[1-{2,3-dimethyiphenyl}ethyiI-1 H-imidazof-l-yflmethyi 4-methoxybenzyl carbonate 1 -(cyclopropylmethyl)-2-[1 -(2,3-dirnethylphenyl)ethyl]-1 H-im idazole 2-[1-{2,3-dimethylphenyi)ethyl]-1-m ethyl-1 H-im idazole cycfopropylmel hyl {2-[1 -{2,3-dimethylphenyl)ethyll-1H-lmidazol-1 -yl]methyl carbonate {2-[1-(2,3-dimethylpheny0ethyl]-1 H-imidazol-1 -yljmethyl 3-methylbutyi carbonate {2-[1-(2,3-dimethylphenyl)ethyl]-1 H-imidazol-1-yl}melhyl isopropyl carbonate cyciabutyi {2-[1-(2,3-dSmethylphenyl}ethyI]-1H-lmida2ol-1-yf}methylcarbonate {2-[1 "(2,3-dimethyfphenyl)ethyl]-1 H-imidazol-1 -yftmethy] 2,2,2-trifluoroethyl carbonate 2-[1 -(2,3-dimethylphenyl)ethyl]-1 -ethyl-1 H-imidazol 2-[1 -(2,3-dimethylphenyl)etriyl]-1 -(4-methoxybertzyl)-1 H-imldazole 2-[1-(2,3-dimethylpheny1)ethyi]-1 -(methoxymethyl)-l H-imidazol 2-[1 -(2,3-dimethylphenyl)ethyll-1 -[4-(trif luoromethyl)benzyfl-1 H-imidazol 4-f luorophenyi 2-[1 -(2,3-dimethylphenyl)ethyl]-1 H-im idazole-1 -carboxylate isobutyl 2-[1 -(2,3-dimethylphenyi)etriyfI-1 H-imidazol-1 -carboxylate Isopropyl 2-[1 -(2,3-dimethylphenyl)ethyr]-1 H-imidazol-1 -carboxylate 2-[1-(3-methylphenyl)ethyl]-1 H-im idazole or a pharmaceutically acceptable salt or prodrug thereof. Even more preferred compounds of the present invention are 2-(l-{2,3-dimethy1phenyl)ethyl]-1H- im idazole, and {2-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazol-1-y)}methyl pivalate, or a pharmaceutically acceptable salt or prodrug thereof. The most preterred compound of the present invention is 2-[1-{2,3-dimethyiphenyl)ethyl]-1 H-imidazol, or a pharmaceutically acceptable salt or prodrug thereof. Included within the scope of the present invention are al) stereoisomers such as enantiomers and diasteromers, all geometric isomers and tautomeric forms of the compounds of formula (I), including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, D-lactate or L-tysine, or racemic, for example, DL-tartrate or DL-arginine. it is to be understood that compounds of formula (I) may contain one or more asymmetric carbon atoms, thus compounds of the Invention can exist as two or more stereoisomers. In particular it will be understood that when RB and R8 are different substitutents a stereocentre exists at the carbon atom to which ihey are attached - the benzylic carbon. Suitable compounds for use in this invention include those where the absolute stereochemistry at the benzyJic carbon has the "S configuration". Further suitable compounds for use in this invention include those where the absolute stereochemistry at the benzylic carbon has the "R configuration". Such stereoisomers can be resolved and identified by one skilled in the art using known techniques, The present invention includes the individual stereoisomers of the compounds of formula (I) together with mixtures thereof. Preferred compounds of formula (I) include those of formula (IA) and formula (IB) which possess the stereochemistry shown below. (Formula Removed) It will be understood that throughout the application all references to formula (1) apply equally to compounds of the formulae (IA) and (IB). Furthermore, it will be understood that all the suitable groups and preferences applied to R1 - R12, Ra, Rb and n for formula (I) apply equally to compounds oS the formulae (IA) and (IB). In one particular embodiment of the Invention preferred compounds are those of the formula (IA). In one particular embodiment of the invention preferred compounds are those of the formula (IB). Preferred compounds of the present invention include 2-[(1S)-1-(2)3-d!methylphenyl)0thy13-lH-imidazol, 2-[(1 fl)-1-(2,3-dimethy!phenyl)ethyi]-1 H-imidazol, (2-[(1 S)-1-(2,3-dimethylpheny[)ethy!]--t H-im idazole -yll]nethylpivalate, [2-[(1R)-1-(2,3-dimethylphenyl)ethyl]"1H-imidazol-1-yl}methvlpivalate or a pharmaceutically acceptable salt or prodrug thereof. Even more preferred compounds of the present invention are 2-{(1S)-1-(2,3-dimethy!phenyl)ethyl]-1H-imidazol, 2H[(1R)-1-{2,3-dimethylphenyl)ethyl]-1H-lmrdazole, or a pharmaceurically acceptable salt or prodrug thereof with the formulae shown below. (Formula Removed) Most preferred is 2-[(1 S)-1-(2,3-dimethylphenyl)ethyI]-1H-imidazol. Geometric isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation. Conventional techniques for the preparation/isolation of individual enantiomers include chlral synthesis from a suitable optically pure precursor, stereoselective synthesis from a prochiral precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, fractional crystallization or chiral high pressure liquid chromatography (HPLC). Reference is made herein 1o "Enantiomers, Racemates and Resolutions* J. Jacques and A. Collet, pubfished by Wiley, NY, 1981; and "Handbook of Chiral Chemicals" chapter 8, Eds D. Agar and M. Dekker, lSBN:0-8247-1058-4. Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of formula (!) contains an acidic or basic moiety, an acid or base such as tartaric acid or 1-phenytethyiarrtine. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person. Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-eroiched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% isapropanol, typically from 2 to20%, and from 0 to 5% of an alkylamine, iypically 0.1 % diethylamine. Concentration of the eluant affords the enriched mixture. Stereoisomer^ conglomerates maybe separated by conventional techniques known to those skilled in the art - see, for example, "Stereochemistry of Organic Compounds" by E L Ellel (Wiley, New York, 1994). In the compounds according to formula (I) the term 'halo' means a group selected (ram fluoro, chloro, bromo or iodo. Alkyl, alkylene, alkenyl, alkynyl and alkoxy groups, containing the requisite number of carbon atoms, can be unbranched or branched. Examples of alkyl include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl and t-butyl. Examples of alkoxy include methoxy, ethoxy, n-propoxy, l-propoxy, n-butoxy, i-butoxy, s-butoxy and t-butoxy. Examples of alkylene include -Chfc-, -CH(CH3)- and -Ca4H4-. Examples of cycloalkyl include cyclopropyf, cyclobutyl, cyclopentyi, cyclohexyl and cycloheptyl. For the avoidance of doubt, it will be understood that throughout the application all references to pharmaceutical^ acceptable compounds includes references to veterinary acceptable compounds or agriculturally acceptable compounds. Furthermore it will be understood that throughout the application all references to pharmaceutical activity includes references to veterinary activity or agricultural activity. Pharmaceutically acceptable salts of the compounds of formula (1} include the acid addition and base salts thereof. Suitable acid addition salts are formed from acids, which form non-toxfc salts. Examples Include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphatefeuiphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hlbenzate, hydrochloride/chlorlde, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, maiate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosytate and trifluoroacetate salts. Suitable base salts are formed from bases which form non-toxic salts, Examples include the aluminium, arginine, benzathine, calcium, choline, dlethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamlne and zinc salts. The pharmaceutically, veterinarily and agriculturally acceptable add addition salts of certain of the compounds of formula (I) may also be prepared in a conventional manner. For example, a solution of a free base may be treated with the appropriate acid, either neat or in a suitable solvent, and the resulting salt isolated either by filtration or by evaporation under reduced pressure of the reaction solvent For a review on suitable salts, see "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" by Staht and Wermuth (Wiley-VCH, Weinheim, Germany, 2002). The compounds of the invention may exist in both unsolvated and solvated forms. The term "solvate' Is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanoi. The term 'hydrate1 is employed when said solvent is water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, da-acetone, de-DMSO. Hereinafter and throughout the application all references to compounds of formula (I) include references to salts, solvates and complexes thereof and to solvates and complexes of salts thereof. As stated, the invention includes all polymorphs of the compounds of formula (I) as hereinbefore defined. Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non-stolchiometric amounts. Also included are complexes of the drug containing two or more organic and/or inorganic components which may be in stoichiometric or non-stoichioroeiric amounts. The resulting complexes may be ionised, partially ionised, or non-ionised. For a review of such complexes, see J Pharm Sci, 64 (8), 1269-1288 by Haleblian {August 1975). The present invention includes all pharmaceutically acceptable isotopicalty-labelted compounds of formula (!} wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass 0/ mass number usually found in nature. Examples of isotopes suitable for inclusion in the compounds of the invention Include isotopes of Within the scope of the invention are so-called 'prodrugs' of the compounds of formula (I). Thus certain derivatives of compounds of formula (I) which may have little or no pharmacological activity themselves can, when administered into or onto the body of an animal, be converted by the host or parasite into compounds of formula (I) having the desired activity, for example, by hydroiytic or enzymatic cleavage. Such derivatives are referred to as 'prodrugs'. It will be appreciated that certain compounds of formula (I) may themselves act as pro-drugs of other compounds of formula (J). Further information on the use of prodrugs may be found in 'Pro-drugs as Novel Delivery Systems, Vbf 14, ACS Symposium Series (T Higuohi and W Stella) and 'Bioreversible Carriers in Drug Design', Pergamon Press, 1987 (ed. E B Roche, American Pharmaceutical Association). Prodrugs In accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of formula (I) with certain moieties known to those skilled in the art as 'pro-moieties' as described, for example, In "Design of Prodrugs" by H Bundgaard {Elsevier, 1985). Some examples of prodrugs in accordance with the invention include: (i) where the compound of formula (I) contains a carboxylic acid functionality (-COOH), an ester thereof, for example, replacement of the hydrogen wtth {C1-CB)alkyl; (ii) where the compound of form ula (I) contains an alcohol functionality (-OH), an ether thereof, for example, replacement of the hydrogen with {C1-CB)alkanoyioxymethyl; and (in) where the compound of formula (I) contains a primary or secondary amino functionality (-N1H2 or -NHR where R * H), an amide thereof, for example, replacement of one or both hydrogens with (Cr Cio)alkanoyl. Prodrugs in accordance with the invention can, for example, be produced by reacting compounds of formula (I) wherein R8 is H with certain moieties known to those skilled in the art as 'pro-drug moieties' as described, for example, in "Design of Prodrugs" by H Bundgaard (Elsevier, 1985); "Design and application of prodrugs," Textbook of Drug Design and Discovery, {3,d Edition), 2002,410-458, (Taylor and Francis Ltd., London); and references therein. Examples of substituents include: alkyl amines, aryl amines, amides, ureas, carbamates, carbonates, imines, enamfnes, imides, suffenamides, and sulfonamides. The hydrocarbon portion of these groups contain C1-C6alky!, phenyl, heteroaryl such as pyridyl, C2-6 alkenyl, and C3-8 cycloalkyl; wherein each of the above groups may include one or more optional substituents where chemically possible independently selected from: halo; hydroxy; C1-6 alkyl, C1-6 haloalkyl and C1-6 alkoxy. Further examples of replacement groups in accordance with the foregoing example and exampies-of other prodrug types may be found in the aforementioned references. A prodrug that is administered to a test animal and metabolized by the host according to the invention can be readily identified by sampling a body fluid for a compound of formula (I). Finally, certain compounds of formula (I) may themselves act as prodrugs of other compounds of formula (I). In a further aspect, the present invention provides processes for the preparation of a compound of formula (I), or a pharmaceutical!/, veterinarily or agriculturally acceptable salt thereof, or a pharmaceutical^, veterinarily or agriculturally acceptable solvate (including hydrate) of either entity, as illustrated below. The following processes are illustrative of the general synthetic procedures which may be adopted in order to obtain the compounds of the invention. 2 It will be apparent to those skilled in the art that sensitive functional groups may need to be protected and deprotected during synthesis of a compound of the invention. This may be achieved by conventional methods, for example as described in "Protective Groups in Organic Synthesis" by TW Greene and PGM Wuts, John W3iley & Sons lnc {1999), and references therein. Thus, when one or mora of R*, Ft2, R3, R4, R5, R6, RT, R8r R9, R10, R11 R1a, R,s and R18 contain reactive functional groups then additional protection may be provided according to standard procedures during the synthesis oi compounds of formula (J). ]n the processes described below, for all synthetic precursors used In the synthesis of compounds of formula (I), the definitions of R\ R2, R3, R*. R6, R8, R7, R8, R9, R10 R11 R12, R15 and R16, wherein R1, R2, R3, R4, R5, Rs, R7, R8, R9, R10, R" R1a, R,s and R'6, are as defined for formula (I), are intended to optionally Include suitably protected variants, P\ P2, P3, P4, P5, Pfi, P7, P8, P3, Pm. P1t P12,P15 and P16. Such suitable protecting groups for these functionalities are described in the references listed below and the use of these protecting groups where needed Is specifically Intended to fall within the scape of the processes described in the present invention for producing compounds of formula (!) and its precursors. When suitable protecting groups are used, then these will need to be removed to yield compounds of formula (I). Depratection can be effected according to standard procedures including those described in the references listed below. When R6 is a protecting group it is preferred that it is chosen Irom benzyl, p-methoxybenzyl, diethcxymethyf, allyl and trityl. Compounds of formula (I) may be obtained from other compounds of formula (I) by standard procedures such as electrophilic or nucleophilic substitution, organometallic catalysed cross coupling reactions and functional group interconversions known to those skilled in the art. For example, compounds of formula (I) In which one or more of R1, Ra, R3, R4 and R5 are C02Rc wherein RC = aikyl, may be transformed into compounds of formula (I) in which one or more of R1, R2, R3, R4 and R6 are C02Rd wherein Rd = NH2 upon treatment with ammonium hydroxide at 85°C for 2 h. Similarly compounds of formula (I) wherein one or more of R1, R2, R3, R4 and R5 are C02Rd wherein Rd = NH2 upon treatment with a dehydrating agent such as thionyl chloride at low temperatures in an anhydrous solvent such as N,N-dimethylforrnamlde produce the corresponding nitrile compound. Compounds of fonnula (I), wherein R8 is C1-C4 aikyl, R9, R11 and R12 are hydrogen and R6 is hydrogen or alkyl and R1, R2, R3, R4 and R5 are as defined previously (Formula Removed) may be synthesised from compounds of formula (II) using standard hydrogenation procedures. For example, compounds of formula (II) wherein Ra is hydrogen, and Rb is hydrogen or alky) may be reduced to compounds of form ula (!) in a suitable protic solvent such as methanol or propan-2-ol under a hydrogen atmosphere at temperatures up to 60°C and elevated pressure up to 300 psi in the presence of 10% palladium on carbon or Freiborg activated 10% palladium on carbon lor up to 72 h. Compounds of formula (I) in which one or more of R1, R2, Ra, R4 and R6 are optionally halo, and the remainder of R1, R2, R3, R* and R5 are as previously defined, may be accessed from compounds of formula (II) in which one or more of R1, R2, R3, R4 and R5 are optionally hato by hydrogenation procedures. Thus, compounds of formula (II) may be reduced to give compounds of formula (I) under a hydrogen atmosphere at temperatures up to 60°C and elevated pressure up to 200psi In the presence of 10% palladium on carbon and a chelating agent such as zinc bromide in a standard protic solvent such as methanol or propan-2-ol. Alternatively, compounds of formula (I) may be obtained from compounds of form ula (II) by transfer hydrogenation conditions. For example, ammonium formale or formic actd or ammonium formate in the presence of formic acid may be used to generate an in situ source of hydrogen which when In the presence of a hydrogenation catalyst such as 10% palladium on carbon in an alcoholic solvent such as propan-2-ol, for 2 - 3 hours at temperatures up to 80°C can be used to effect the transformation of compounds of formula (II) to compounds of formula (I). Optionally reactions using formic add as the hydrogen source may be performed without alcoholic solvents. 1 Stereoselective hydrogenations may be performed to yield a preferred stereoisomer using chiraJ catalysts, in accordance with standard organic chemistry textbooks or literature precedent. For example there are many known homogeneous and heterogeneous catalytic methods using transition metals such as palladium, rhodium and ruthenium. One particularly preferred catalyst is bis(norbomadiene)rhodium(l) tetraf luoroborate. Enantiopure ligands that have been utilised to effect enantioselective hydrogenations have been referenced m the literature and illustrative examples of homochiral ligands include phospholanes such as Duphos and its analogues, ferrocenyl ligands such as Josiphos, H(R)-2-diphenylphosphino)feirocenyl]ethy!di-tert-butylphospriine, biphenyl ligands such as (+/-)-2,2-Bis(diphenylphosphino)-1,1'-brnaphthalene (BINAP) and miscellaneous ligands such as Prophos, Dtamp, Bicp, Monophos. References providing details of enantioselective hydrogenations include Y. Yamanori, T. Imamoto, Reviews on Heteraatam Chemistry, 1999, 20, 227; T. Clark, C. Landis, Tetrahedron : Asymmetry, 2004,15,14,2123; H. Blaser, Topics in Catalysis, 2002,19,1,3; H. Blaser et al, Synthetic Methods of organometaliic and inorganic chemistry, 2002,10,78; Pure and Applied Chemistry, 1999, 71, 8,1531; Pure and Applied Chemistry, 1998, 70,8,1477; U. Berens et a), Speciality Chemicals, 2000,20, 6, 210; M. T. Fteetz, Pure and Applied Chemistry, 1999,71,8,1503; D. J. Bayston et al, Speciality Chemicals, 1998,18,5,224; C. Saluzzo and M. Lemaire, Advanced Synthesis and Catalysis, 2002,344, 9, 915; H. Kumobayashi, Synlett, 2001, (Spec Issue) 1055. Thus, enantiomerically enriched compounds of formula (!) may be obtained from acMra! compounds of formula (II) by stereoselective hydrogenation. For example, compounds of formula (fl) wherein PJ? is hydrogen, and Rb is hydrogen or alkyl may be reduced to compounds of formula (1) in a suitable protlc solvent such as methanol under a hydrogen atmosphere at ambienl temperatures and elevated pressure up to 60 psi in the presence of a rhodium catalyst such as bis Alternatively, racemic compounds of formula (I) may be resolved using chiral HPLC procedures, known to those skilled in the art, to give enantiomerically pure compounds of formula (I). Compounds of formula (II) wherein R6 is a protecting group such as benzyl or substituted benzyl e.g. p-rnethoxybenzyl, may be deprotected and reduced under hydrogenation conditions to give compounds of formula (I) wherein R6 is hydrogen. (Formula Removed) imidazol ring formation can also be utilised to access compounds of formula {.!), other synthetic methods are precedented in textbooks and the literature. One illustrative example is from desirably substituted phenylacetonftrile reactants, for example a compound such as 2-(2,3-dimethylphenyl)propanenitrile may be reacted with an appropriately substituted ethylenediamine for example, the p-toluenesulfomc acid salt of ethylenediamine at elevated temperatures ranging from 140°-180°C to form the compound of formula (I) wherein R1R2 and R8 are methyl and R3, R4, Rs, R8 and R9, R1T and R12are hydrogen. Another example of imidazol ring formation is from the reaction of suitably 2-substituted 2-aryl-1 ,1-dibromoethenes and an appropriately substituted ethylenediamine at room temperature to give the intermediate 2-substituted 2-arylmethyiimidazoline. Standard oxidation procedures such as Swern oxidation can transform the Intermediate 2-substJtuted 2-arylmethyllmldazoline Into compounds oi formula (I) Compounds of formula (II) may be prepared fay Wittlg chemistry by the reaction of a compound of formula (X) with the appropriate alkylphoaphonium salt-derived phosphorus ylid. For example treatment of a methyJtriphenylphosphonium hallde with a strong base in a suitable solvent, followed by the addition of (X), will produce a compound of formula (II) wherein both Raand Rb are hydrogen. Preferably the base reagent is a solution of n-butyllithium in hexane, the soh/ent is ether or tetrahydrofuran and the reaction is conducted at from about room temperature to about 35°C. Compounds of formula (II) may undergo functional group tnterconversion into other compounds of formula (II). For example, wherein one or more of R1, Ra, R3, R* and RB are bromo or iodo, and R6 is protected with a suitable protecting group such as benzyl, palladium catalysed coupling reactions such as StiHe, Heck and Suzuki coupling reactions may be effected. For example, treatment of such organohalide compounds of formula (II) with a suitable boronic acid such as an aikyi or aryl boronic acid, in an inert solvent such as toluene, in the presence of a suitable base such as potassium phosphate, a suitable phosphlne ligand such as tricyclohexylphosphine and palladium acetate under an inert atmosphere at elevated temperatures up to 120 °C for up to 18 h provides the corresponding alkylated or arylated compound of formula (II). Similarly, compounds of formula (II) wherein one or more of R1, Ra, R3, R4 and R5 are bromo or iodo, and R6 is protected with a suitable protecting group such as benzyl, may undergo transmetallatlon reaction with a palladium catalyst such as [1,1- bis(diphenylphosphino)ferrocene]pa)ladium (II) chloride followed by cross coupling with a suitable boronic anhydride such as trialkytboroxine under an inert atmosphere, in the presence of a mild base such as sodium carbonate and a suitabie inert solvent such as dioxane and water at elevated temperatures up to 120°C. Alternatively, compounds of formula (II) wherein one or more of R\ R2, R3, R4 and R5 are bromo or iodo, and R6 is protected with a suitable protecting group such as benzyl, may undergo nucleophllic substitution reactions. For example, nitrite compounds may be formed upon treatment of such a halo compound of formula (II) in a polar solvent such as N,N-dirrsethylacetamide with a cyanide source such as copper cyanide at temperatures up to 150°C for 3 days to give the corresponding compound of formula (II) wherein one or more of R1 R2 R3, R4 and R5 are cyano, and R6 is protected with a suitable protecting group such as benzyl. Nitrite compounds of formula (II) may also be formed from the corresponding halo compound of formula (II) upon treatment with a cyanide source such as sodium cyanide in the presence of a suitable transmetallating agent such as nickel bromide in a polar solvent such as N-methylpyrrolidinone and healing in a 150 W microwave at up to 150°C for 5 min. Nitrile compounds of formula (II) may also be formed from the corresponding halo compound of formula (II) from the reaction of a suitable cyanide source such as potassium hexacyanoferrate, a transmetallating agent such as copper iodide, a salt such as potassium iodide, and a coordinating agent such as dimethylemylenediamine in a polar solvent such as N-methylpyrrolidinone under an inert atmosphere at elevated temperatures up to 140°C for up to 60 hours. Compounds of formula (II) may be prepared from compounds of formula (Ill) by standard dehydration conditions, optionally R8 may be a suitable protecting group e.g. benzyl, or substituted benzyl. (Formula Removed) Thus, dehydration may be effected under acidic conditions. For example compounds of formula (Hi) may be treated with an inorganic acid such as hydrochloric add (4 - 6N) or concentrated sulphuric add, for up to 72 h, optionally in an organic miscible solvent such as acetonitrlle, optionally at elevated temperatures up to 60DC. Alternatively, dehydration may result from heating compounds of formula (III) at reflux wfth an organic acid such as trifluoroacetie acid or p-toluenesulphonic acid in an aprotic solvent such as toluene. Othen/vlse, compounds of formula (111) may be dehydrated using Eaton's reagent, typicaity stirring at room temperature for several hours neat or in a polar solvent such as methanol. Dehydration may also be effected by treating a compound of formula (III) with thionyi chloride in a poiar solvent such as acetonitrlle. Compounds of formula (III) may be used to directly access compounds of formula (I) upon treatment with Pearlman's catalyst In a suitable protic solvent such as methanol under a hydrogen atmosphere, in cases wherein Ra is a benzylic protecting group a deprotected compound of formula (I) will be obtained wherein Rs is hydrogen. Alternatively, compounds of formula (HI) wherein R8 is a protecting group such as benzyl may be deprotected, dehydrated and reduced simultaneously by hydrogenation under acidic conditions. For example, upon treatment of compounds of formula (III) with a hydrogen source such as ammonium formate in the presence of an acid such as formic acid and 10% palladium on carbon, optionally for up to 72 h, compounds of formula (I) wherein R8 is hydrogen are obtained. Compounds of formula (II) may be obtained by dehydrohalogenation procedures, known !o the skilled man, from compounds of formula (III) for example by standard chlorination fallowed by dehydlrochlorination procedures. Alternatively, compounds of formula (II) can be obtained by transition metal catalysed cross-coupling reactions by utilizing methods known in the literature. For these reactions, it may be necessary to protect the basic imidazol, optionally R6 may include a suitable protecting group such as diethoxymethyb Thus, suitably protected organozincates such as compounds of formula (V), wherein X is halo for example chloro or bromo, can be coupled with suitably substituted styrenes such as compounds of formula (IV) wherein Y Is a group suitable for transmetallatlon such as OTf, CI, Br or 1 in the presence of a palladium catalyst such as Pd(PPh3)3. Standard deprotection of compounds of formula (II) wherein R6 is a suitable protecting group provides compounds of formula (II) in which R6 is hydrogen. For example, when R6 is diethoxymethyl treatment with an organic acid such as trifluoroacetie acid or an inorganic acid such as hydrochloric acid provides compound (II) wherein RBis hydrogen. Simifarfy, deprotection of compounds of formula (III) wherein Re is a benzyl moiety protecting group may easily be effected by hydrogenatian. (Formula Removed) Compounds of form ula (III) wherein R6 is a protecting group can be formed by 1,2-addition of a suitably protected organometallic compound (VI) to the corresponding ketone (Vtl) where chemically feasible for example wherein R1, R2, R3, R4 and Rs may be chosen independently from alkyt, chkiro, and Ra and Rb may be chosen from alkyl. (Formula Removed) For example, compound (VI) may be reacted with ketone (VII) in an aprotic solvent such as tetrahydrof uran at temperatures typically ranging from -80 to 0°C to give compounds of formula (111), which can be readily deprotected to give a compound of formula (III) wherein RB is H if desired. Alternative organometallic chemistry may be utilized to yield a compound of formula (III), wherein R8 is a suitable protecting group such as benzyl, when an organometallic compound of formula (VIII), wherein X may be a halo e.g. chloro or bromo, is added to a ketone of formula (IX) wherein R6 is a protecting group. (Formula Removed) Similarly, compounds of formula (III) wherein Re is optionally a suitable protecting group such as benzyl may also be accessed by organometallic addition to a protected ketone (X), suitable organometallic reagents include Grignard reagents and organolithium reagents. For example, a Grignard reagent such as methylmagnesium chloride may be added to a solution of compound (X) In an anhydrous, aproflc solvent such as telrahydrofuran, toluene or diethyl ether at -10o-0°C for up to 4 h to provide compounds of formula (III) wherein Ra and Rb are H. (Formula Removed) Compounds of formula (111) wherein R8 is a protecting group such as benzyl may be deprotected using standard hydragenation conditions such as 10% palladium on carbon in a protic solvent at elevated pressure and temperature to give deprotected compounds of formula (111) wherein R6 is hydrogen. Deprotecting compounds of formula (III) In a stepwise manner, before dehydration to produce compounds of formula (II), allows compounds of formula (II) to be stereoselectjvefy reduced to give compounds of formula (I) if desired. Compounds of formula (IV), (V), (VI), (VII), (VIII), and (IX) may readily be accessed by utilisation of literature methods or simple modifications thereof as would be routinely employed by a skied man. For example, compounds of formula (V) can be prepared by stirring a 1 -protected imidazol with n-butyllithium at reduced temperature, typically -60 to -20 °C followed by the addition of zinc chloride and allowing to warm to room temperature. For exsimple, compound (VI) may be obtained 'm situ by treatment of a protected imidazol reactant, with an organolithium reagent such as n-butylithium \n an aprotie solvent such as tetrahydrofuran at reduced temperatures typically ranging from -BO to 0°C. Suitable protecting groups Include diethoxymethy). For example, compounds of formula (IX) may be synthesised by acylating a suitably substituted imidazol using acid chlorides. Thus, heating for several hours a suitable acid chtoride with a 1-protected imidazol in the presence of a mild base such as triethylamine provides compounds of formula (IX). Compounds of formula (VII) may be accessed in a number of ways. Some methods utilise simple precursors as detailed below. (Formula Removed) Compounds of formula (VII) may be prepared by the addition of a chelating agent such as Fefacacfeand a Grignard reagent such as methylmagnesium bromide to a suitably substituted acid chloride (XI) at reduced temperatures, typically -20°C in a suitable aprottc solvent. Acid chlorides (XI) may be prepared by the reaction of the corresponding benzoic acid (XII) with thionyl chloride or oxalyf chloride, at elevated temperatures, typically 100°C for several hours. Compounds of formula (VIl) may also be prepared by reaction of an acid anhydride such as acetic anhydride, with a phenyl Grignard reactant (XIII) in an aprotic solvent. Altematlvety, amides, or acid chlorides may be used in place of the acid anhydride. Compounds of formula (Xfil) may be formed in situ by reacting a suitable bromobenzene derivative with magnesium turnings in an anhydrous, aprotic solvent such as tetrahydrofuran. Similarly, compounds of formula (VII) may be prepared by reacting a Grignard reactant eg. methylmagnesium bromide with an amide e.g. a suitably substituted benzoylmorpholine (XIV) at reflux in a suitable solvent such as tetrahydrofuran. Compounds of formula (VII) may also be obtained from reaction of a suitable benzoic acid (XII) with an organollthium reactant, for example methyUithium, at reduced temperatures in an anhydrous aprotic solvent such as tetrahydrofuran. Compounds of formula (Vll) may be obtained by Friedel Crafts acylation of suitably functionalized phenyl moieties. For example, a functiorialized phenyl reactant can be treated with a Lewis acid such as aluminium chloride, in the presence of a suitable acylatfng agent such as acetyl chloride, in an aprotic solvent such as dichloromethane at room temperature for up to 18 h to give the desired compounds of formula (Vll). Alternatively compounds of formula (Vll) may by obtained in a two step procedure from a suitably substiluted halobenzene, preferably bromo or lodo benzene. For example a bromobemzene compound may be transmetaJlated with an organometallic reagent such as rr-butylftthium in an anhydrous, apolar solvent such as tetrahydrofuran at low temperatures down to -80°C followed by electrophilic quenching with an aldehyde to give the corresponding secondary alcohol which may be oxidized under standard conditions, for example using Dess Martin periodinane, to give compounds of formula (VII) wherein Ra is selected from H,C1-4alkyl, or C0-4alkylenephenyl and Rb = C1-4alky!, or C0-4alkylenephenyl. Compounds of formula (Vll) may also be formed from the corresponding aryliodide and boaronlc acids using palladium chemistry in a carbon monoxide atmosphere. Thus, heating arylfodides with carbon monoxide, methylboronic acid and palladium tetrakis triphenyJphosphine provides compounds of formula (Vll) wherein R* and Rbare H. Compounds of formula (Vll) may undergo standard chemical reactions and functional group interonversion reactions known to the skilled man to give other compounds of formula (Vll). Thus, compounds of formula (Vll) may be chlorinated using standard reagents such as Selectafluor™ and sodium chloride. Also, suitably substituted halo compounds of formula (Vll) may undergo standard palladium catalysed cross coupling reactions such as Suzuki, Stifle, Heck reactions to give a variety of standard products. For example, bromo or iodo compounds of formula (Vll) may undergo alkylation and arylation reactions via Suzuki coupling reactions upon treatment with an organoborane e.g. triethyl borane in the presence of [l,1-bis(diphenylphosphino)ferocene]palladium (II) chloride, and potassium carbonate in an aprotic solvent such as ty/VWimethylformamide to give alkyl or aryl substituted compounds of formula (VII). Compounds of formula (X) may be obtained from Ihe reaction of acid chlorides of formula (XI) and imidazols of formula (XV) wherein R6 is a suitable protecting group In a suitable aprotic solvent such as toluene or acetonftrile in the presence of a mild base such as triethylamine at temperatures ranging from -10°-130°C. (Formula Removed) Suitably functionalised acid chlorides of formula (X!) may be synthesized from the corresponding acid upon treatment with thionyl chloride at 80°C for -1 hour. Alternatively, acid chlorides maybe synthesized from carboxylic acids upon treatment with oxalylchloride in an aprotic solvent such as toluene at room tem perature for up to 4 hours. Suitably functfonalized acids may be obtained by utlising standard literature procedures available to the sldiled man, thus substituents may be introduced via eledrophllic or nucleophiiic substitution or cross coupling reactions or via functional group interconversion. Compounds of formula (X) can also be synthesized by oxidation of compounds of formula (XVI) by suitable oxidising agents, wherein R8 is hydrogen or a suitable protecting group. (Formula Removed) One such oxidation may include Dess Martin oxidation conditions. For example, a compound of formula (X), may be prepared by stirring the corresponding compound of formula (XVI) at room temperature with Dess-Martin Periodlnane in a suitable polar solvent such as dlchloromethane. Compounds of formula (XVI) may be formed by the 1,2-addition of a suitably protected organometallic compound to a suitable aldehyde. Thus reaction of an organolithlum compound of formula (VI) and a corresponding aldehyde of formula (XVII), in an anhydrous, aprotio solvent such as tetrahydrofuran at temperatures ranging from -80-0°C provides compounds of formula (XVI). It is to be understood that precursors to compounds of formula (I) and compounds of formula (I) themselves may undergo functional group interconversion in order to deliver alternative compounds of formula (I). For example compounds of formula (I) wherein R6 is hydrogen may be reacted with alkylating agents of the formula L-C0-2alkyleneR7, LC1-2alkyleneOR7, L-C1-2alkvleneC{0)R7, L-C1-2alkyleneOC(O)R7, LC1-2alklene0C(O)0R7, L-C1-2atkyteneC(0)OR7', L-C1-2alkyleneN(H)C(0)R7, L-C1-2aikyleneN(R)C(O)R7, L-C1-2alkylerieC(0)NHR7, L-C1-2alkyteneNHC(0)NR15R16, L-C1-2kyleneNR7C(0)NR1sR1s, L-C1-aalkyteneC(O)NR15R18, L-C1-2alkyleneOC(0)NHRT, L-C1-2aikyleneOC(0)NR1sR16, to provide compounds wherein R6 is -Co-2alkyteneR7, -C1-2alkyleneOR7 C1-2alkyleneC(0)R7, -d-2alkyleneQC(Q)R7, C1-aalkylene0C(O)0R7, -C1-2alkyleneC(0)OR7r -C^alkyleneN(H)C(0)R7, -C1.2alkyleneN(R7)C(0)R7, -C1-zalkyleneC(0)NHR7, -C1-2alkyleneNHC(O)NR15R18, -C1-2alkyleneNR7C(0)NR15R16 C1-. aaIkyleneC(0)NR1sR1B, -d^alkyleneOC(0)NHR7 -C1-2alkylene0C(0)NR15R16. L is a suitable teavlng group such as CI, Br, I, or a sulfonate such as trifluoromethanesulfonate. For example compounds of formula (I) wherein Re is hydrogen may be reacted with alkylating agents in the presence of a mild base such as cesium carbonate, potassium carbonate, triethyiamine, or diisopropylethylamine, in an aprotic solvent such as acetone, 1-methyl-2-pyrrolidinone, dichloromethane, tetrahydrofuran, acetonitrile or N,N-dlmefriylformamide optionally In the presence of a salt such as sodium Iodide. Generally trie alkylation reaction will proceed for up to72hal room temperature, optionally the reaction may be heated to reflux or may be microwaved at 200W for up to 1 h. Alkylating agents of the form CJ-CHaOC(0)R7 may be produced from the reaction of the acid chloride CIC(0)R7 with paraformaldehyde tn the presence of a Lewis acid such as zfcnc chloride at temperatures up to 80°C for 2-3 hours. Under alkylating conditions such reagents give compounds of formula (I) wherein RaisCHaOC(0)R7. Alkylating agents of the form L- CHzOG{0)OR7may be produced from the reaction of the alcohol HOR7 with chtoromethyl chloroformate In an aprotlc solvent such as dichloromethane at temperatures ranging from 0°C to room temperature. Under alkylating conditions such reagents give compounds of formula (I) wherein R6 is CH2OC(CO)OR7. Alkylating agents of the form L- CH20C(O)NHR7 may be produced from the reaction of the amine R7NH2 with chloromethyl chloroformate in an aprotic solvent such as dichloromethane at temperatures ranging from -10°C to room temperature. Under alkylating conditions such reagents give compounds of formula (l) wherein Ra is CH2OC(O) NHR7. Alkylating agents of the form L- CH2OC(0)NR15R18, may be produced from the reaction of the amine R1SR16NH with chloromethyl chloroformate in an aprotic solvent such as dichloromethame optionally In the presence of a mild base such as diisopropyfethylamine at temperatures ranging from -0°C to' room temperature. Under alkylating conditions such reagents give compounds of formula (1) wherein Re is CH2OC(0)NR1sR16. Compounds of formula (I) wherein Re is hydrogen may be reacted with acylating agents of the formula CIC(0)R7,0[OC{0)R7]2, CIC(0)OR7. CIC(0)NHR7. C1C(O)NR15R16, to provide compounds wherein R6 is -C(0)R7, -0C(0)R7, -C(0)OR7, -C(0)NHR7 -C(0)NR15R1B. For example compounds of formula (I) wherein RB is hydrogen may be reacted with acylating agents in the presence of a mild base such as triethylamine, or pyridine in an aprotic solvent such as dichloromethane, tetrahdyrofuran or acetonrtrile at temperatures ranging from room temperature to 100oC for between 1 and 36 h. It is possible to form the acylating agent CIC(0)OR7 in situ. Thus a compound of formula (I) wherein R8 is hydrogen, may be reacted with phosgene or diphosgene in an anhydrous solvent such as dichloromethane or acetonitrile in the presence of a mild base such as pyridine in the presence of an alcohol R7OH at ambient temperature to give ihe compound of formula (I) wherein R6is C(0)OR7. Compounds of formula (I) wherein Re is hydrogen may be reacted with phosphorylaling agents of the formula CI-P(=0)[N{R7)a(R7)2] to give compounds o! formula (1) wherein R8 Is P(=0)[N(R7)a{R7)aI. For example reaction with a corresponding bis{dialkyiamino)phosphoryl chloride e.g. bis(dlmethylamino)phosphoryl chloride in an aprotic solvent such as dichloromethane. Compounds of formula (1) wherein R6 is hydrogen may be reacted with silating agents of the formula Cl-Si(R7) to give com pounds of formula (I) wherein R8 is Si(R7)3 For example reaction w'rth a corresponding alkylsilane or arylsilane e.g. chlorotrimethyisilane in an aprotic solvent such as dichloromethane or tetrahydrofuran. Compounds of formula (I) wherein R6is hydrogen may be reacted with sulphonafflng agents of the formula CI-S(=0)2R1° to give compounds of formula {I} wherein Rfl is S(=O)R10. For example reaction with a corresponding sulphonyl chloride e.g. methanesuJphonyl chloride fn an aproft'c solvent such as dichlorornethane, optionally with a weak base such as triethylamine. Compounds of formula (1) wherein R8 Is hydrogen may be reacted with cyanogen bromide in an aprotlc solvent such as dichlorornethane, optionally with a weak base such as dilsopropylethyiamine to give compounds of formula (I) wherein Re is CN. Compounds of formula (III) may be alkylated to give compounds of formula (I) wherein R9 is C1-C4 alkoxy. Thus, treatment of compounds of formula {III} with a strong base such as sodkim hydride in an aprotic solvent such as tetrahydrofuran followed by addition of an alkylating agent will provide compounds of formula (l) wherein R9 is C1-C4alkoxy. Compounds of formula (II) may be cyctopropanated to give compounds of formula (I) wherein Ft8 and R8 together form a cyclopropyl ring. Compounds of formula (I I) may be reacted with a carbenofd species, CRdRe. For example, when Rd=Re=F, a reactive sp'ecies such as'trimethylsilyl ' difluoro(fluorosulfonyl)acetate (TFDA) may be reacted with a compound of fomnufa(!l), with an optional apolar solvent at elevated temperature in the presence of sodium fluoride to yield a product of formula (I) after deprotection, wherein the cyclopropyl ring is substituted with fluoro. Other specific methods include treatment of chloroform with base, preferably under phase transfer catalysis conditions, thermolysis of a suitable organometallic precursor such as an aryl trifluorom ethyl, trichloramethyl, or phenyl(trifluoromethyl) mercury derivative or treatment with a dtazoalkane In the presence of a transition metal catalyst and treatment with a diazoalkane in the absence of a transition metal catalyst followed by thermolysis of the intermediate pyrazoline, or generation from a sulphur ylid. Moreover, persons skilled in the art will be aware of variations of, and alternatives to, the processes described which allow the compounds defined by formula (I) to be obtained. It will also be appreciated by persons skilled in the art that, within certain of the processes described, the order of the synthetic steps employed may be varied and will depend Inter alia on factors such as the nature of other functional groups present in a particular substrate, the availability of key intermediates, and the protecting group strategy (if any) to be adopted. Clearly, such factors will also influence the choice of reagent for use in the said synthetic steps. The skilled person will appreciate that the compounds of the invention could be made by methods other than those herein described, by adaptation of the methods herein described and/or adaptation of methods known in the art, for example the art described herein, or using standard textbooks such as "Comprehensive Organic Transformations • A Guide to Functional Group Transformations", RC Larock, Wiley-VCH (1999 or later editions). It Is to be understood that the synthetic transformation methods mentioned herein are exemplary onty and they may be carried out in various different sequences in order that the desired compounds can be efficiently assembled. The skilled chemist will exercise his judgement and skill as to the most efficient sequence of reactions for synthesis of a given target compound. Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references. The present invention also relates to intermediates of formula (LX) below: (Formula Removed) where: R1 - R12, Ra, Rb, and n are all as defined for formula (I) above or a pharmaceutical salt or a prodrug thereof. With reference to formula (LX), suitably R1 and Ra are selected from C1-4alkyl and R3, R*4 and R5 are hydrogen. The present invention also relates to intermediates of formula (LXV) below: (Formula Removed) where: R1 - R12, Ra, Rb, and n are all as defined for formula (1) above and where Pg is a chemical protecting group or a pharmaceutical salt or a prodrug thereof. With reference to formula (LXV), suitably R1 and R2 are selected from C1-4alkyl and R3, R4 and R5 are hydrogen. The present invention also relates to intermediates of formula (LXX) below: (Formula Removed) where: R1 - Rta, Ra, Rb, and n are all as defined for formula (I) above and where Pg is a chemical protecting group or a pharmaceutical salt or a prodrug thereof. With reference to formula (LXX), suitably R1 and Ra are selected from C1-4alkyl and R3, R4 and R5 are hydrogen. It will be understood that throughout the application ail references to formula (I) apply equally to compounds of the formulas (LX). (LXV) and (LXX) above. Furthermore, It will be understood that all the suitable groups and preferences applied to R1 - R12, Ra, Rb, and n for formula (I) apply equally to compounds of the formulas (LX), (LXV) and, (LXX} above. Finally, certain compounds of formula (I) may themselves act as intermediates in the preparation of other compounds of formula (I). One of ordinary skill In the art would understand that Pg in the formulas (LX), (LXV) and (LXX) above can represent a wide range of possible protecting group and the specific group required will depend on the final compounds to be made and can be readily selected by one of ordinary skitt. Preferred protecting groups include benzyl, para-methoxybenzyl, ally!, trityL OT 1,1-dielhoxymethyl, preferabty benzyl. This invention also relates to a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutical^ acceptable salt thereof, or a pharmaceuticaDy acceptable solvate of either entity, together with a pharmaceutical!/ acceptable diluent or carrier, which may be adapted for oral, parenteral or topical administration. Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art Such compositions and methods for their preparation may be found, for example, in 'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company, 1995). Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, or spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The methods by which the compounds may be administered include oral administration by capsule, bolus, tablet, powders, lozenges, chews, multi and nanoparticulates, gels, solid solution, films, sprays, or liquid formulation. Liquid forms include suspensions, solutions, syrups, drenches and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstftution of a solid, for example, from a sachet. Oral drenches are commonly prepared by dissolving or suspending the active ingredient in a suitable medium. Compounds of the present invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). The compounds may be administered alone or in a formulation appropriate to the specific use envisaged, the particular species of host mammal being treated and the parasite involved. Generally, they will be administered as a formulation in association with one or more pharmaceuticaliy acceptable excipients. The term "excipient* is used herein to describe any Ingredient other than the compoundfs) of the invention. The choice of excipient will to a large extent depend on factors such as Ihe particular mode , of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. Thus compositions useful for oral administration may be prepared by mixing the active ingredient with a suitable finely divided diluent and/or disintegrating agent and/br binder, and/or lubricant etc, Other possible ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents. For oral dosage forms, depending on dose, the drug may make up from 1 wt% to 80 wt% of the dosage form, more typically from 5 wt% to 60 wt% of the dosage form. Examples of disintegrants fciclude sodium starch glycolate, sodium carboxymethyi cellulose, calcium carboxymelhy! cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystaUine cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregeiatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 wr% to 25 wt%, preferably from 5 wt% to 20 wt% of the dosage form. Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystaUine cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregeiatinised starch, hydroxypropyl cellulose and hydroxypropyl mettiylcelluloae. Examples of diluents include lactose (monohydrate, spray-dried monofiydrate, anhydrous and the like}, mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystaUine cellulose, starch and dibasic calcium phosphate dihydrate. Oral formulations may also optionally comprise surface active agents, such as sodium buryl sulfate and polysorbate 80, and glidarrts such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 wt% to 5 wt% of the tablet, and glidants may comprise from 0.2 wt% to 1 wt% of the tablet. Lubricants include magnesium slearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 wt% to 10 wt%, preferably from 0.5 wt% to 3 wt% of the tablet. Exemplary tablets contain up to about 80% drug, from about 10 wt% to about 90 wt% binder, from about 0 wt% to about 85 wt% diluent, from about 2 wt% to about 10 wt% disintegrant, and from about 0.25 wt% to about to wt% lubricant. The formulation of tablets is discussed in "Pharmaceutical Dosage Forms: Tablets, Vol. 1", by H. Lieberman and L Lachman, Marcel Dekker, N.Y., 1980 (ISBN 0-8247-6918-X). The compounds may be administered topically to the skin or mucosa, that is dermally or transdermal!/. This Is a preferred method of administration and as such it is deslrabte to develop active compounds, which are particularly suited to such formulations. Typical formulations for this purpose include pour-on, spot-on, dip, spray, mousse, shampoo, powder formulation, gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and micraemulsions. Liposomes may also be used. Typical carriers Include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated • see, for example, J Pharrm Sci, §Q (10), 955-958 by Finnin and Morgan (October 1999). Pour-on or spot-on formulations may be prepared by dissolving the active ingredient in an acceptable liquid carrier vehicle such as butyl digol, liquid paraffin or a non-volatile ester, optionally with the addition of a volatile component such as propan-2-ol. Alternatively, pour-on, spot-on or spray formulations can be prepared by encapsulation, to leave a residue of active agent on the surface of the animal, thfe effect may ensure that the compounds of formula (I) have increased persistence of action and are more durable, for example they may be more waterfast. Agents may be added to the formulations of the present invention to improve the persistence of such formulations on the surface of the animal to which they are applied, for example to improve their persistence on the coat of the animal, it is particularly preferred to include such agents an a formulation which is to be applied as a pour-on or spot-on formutation. Examples of such agents acrylic copolymers and in particular fluorinated acrylic copolymers. A particular suitable reagent Is Foraperle™ (Redline Products Inc, Texas, USA). Certain topical formulations may include unpalatable additives to minimize accidental oral exposure. Injectable formulations may be prepared in the form of a sterile solution, which may contain other substances, for example enough salts or gJucose to make the solution isotonic wBlh Wood. Acceptable liquid carriers include vegetable oils such as sesame oil, glycerides such as trlacetin, esters such as benzyl benzoate, isopropyi myristate and fatty acid derivatives of propylene glycol, as well as organic solvents such as pyrrolidin-2-one and glycerol formal. The formulations are prepared by dissolving or suspending the active ingredient in the liquid carrier such that the final formulation contains from 0.01 to 10% by weight of the active ingredient. Alternatively, the compounds can be administered parenlerally, or by injection direcjly into the blood stream, muscle or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrastemat, intracranial, Intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques. Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as powdered a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water. The preparation of parenteral formulations under sterile conditions, for example, by lyophilisation, may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art The solubility of compounds of formula (I) used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents. Such formulations are prepared In a conventional manner In accordance with standard medicinal or veterinary practice. These formulations will vary with regard to the weight of active compound contained therein, depending on the species of host animal to be treated, the severity and type of infection and the body weight of the host. For parenteral, topical and oral administration, typical dose ranges of the active ingredient are 0.01 to 100 mgper kg of body weight of the animal. Preferably the range is 0.1 to lOmgperkg. Formulations may be immediate and/or modified controlled release. Controlled release formulations include modified release formulations including delayed-, sustained-, puised-, contrasted, targeted, or programmed release. Suitable modified release formulations for the purposes of the invention are described in US Patent No. 6,106,864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma etal. Pharmaceutical Technology On-line, 25(2), 1-14 (2001). The use of chewing gum to achieve controlled refease is described in WO 00/35298. Alternatively, compounds of the invention may be formulated as a solid, semi-solid, or thixotropic liquid for administration as an Implanted depot providing modified retease of the active compound. Examples of such formulations include drug-coated stents and PGLA microspheres. As an alternative the compounds may be administered to a non-human animal with the feedstuff and for this purpose a concentrated feed additive or premix may be prepared for miwng wflh the normal animal feed. All the aforementioned aqueous dispersions or emulsions or spraying mixtures can be applied, for example, to crops by any suitable means, chiefly by spraying, at rates which are generally of the order of about 100 to about 1,200 liters of spraying mixture per hectare, but may be higher or lower (eg. low or ultra-low volume) depending upon the need OT application technique. The compounds or compositions according to the invention are conveniently applied to vegetation and in particular to roots or leaves having pests to be eliminated. Another method of application of the compounds or compositfons according to the Invention is by chemigation, that is to say, the addition of a formulation containing the active ingredient to irrigation water. This irrigation may be sprinkler irrigation for foliar pesticides or it can be ground irrigation or underground irrigation for soil or for systemic pesticides. The concentrated suspensions, which can for example be applied by spraying, are prepared so as to produce a stable fluid product which does not settle (fine grinding) and usually contain from about 10 to about 75% by weight of active ingredient, from about 0.5 to about 30% of surface-active agents, from about 0.1 to about 10% of thixotropic agents, from about 0 to about 30% of suitable additives, such as anti-foaming agents, corrosion inhibitors, stabilizers, penetrating agents, adhesfves and, as the carrier, water or an organic liquid In which the active ingredient is poorly soluble or Insoluble. Some organic solids or inorganic salts may be dissolved in the carrier to help prevent settling or as antifreezes for water. The wettable powers (or powder for spraying) are usually prepared so that they contain from about 10 to about 80% by weight of active ingredient, from about 20 to about 90% of a solid carrier, from about 0 to about 5% of a wetting agent, from about 3 to about 10% of a dispersing agent and, when necessary, from about 0 to about 80% of one or more stabifizers and/or other additives, such as penetrating agents, adhesives, anti-caking agents, colorants, or the like. To obtain these wettable powders, the active ingredients) is(are) thoroughly mixed an a suitable blender with additional substances which may be impregnated on the porous flfter and is(are) ground using a mill or other suitable grinder. This produces wettable powders, the wettability and the suspendability of which are advantageous. They may be suspended in water to give any desired concentration and this suspension can be employed very advantageously in particular for application to plant foliage. The "water di'spersible granules (WG)' (granules which are readily dispersible in water} have compositions which are substantially close to that of the wettable powders. They may be prepared by granulation of formulations described for the wettable powders, either by a wet route (contacting finely divided active ingredient with the inert filler and a little water, ag. 1 to 20% by weight, or with an aqueous solution of a dispersing agent or binder, folfowed by drying and screening}, or by a dry route (compacting followed by grinding and screening). Depending on the method of application or the nature of the composition or use thereof, the rates and concentrations of the formulated composiSons may vary according. Generally spealdng, the compositions for application to control arthropod, plant nematode, helminth or protozoan pests usually contain from about 0.00001 % to about 95%, more particularly from about 0.0005% to about 50% by weight of one or more compounds of formula (I), or pesticidally acceptable salts thereof, or of total active ingredients (that is to say the compound of formula (I), or a pesticidally acceptable salt thereof, together with: other substances toxic to arthropods or plant nematodes, anthelmintics, anticocddiafs, synergists, trace elements or stabilizers). The actual compositions employed and their rate of application will be selected to achieve the desired effects) by the farmer, livestock producer, medical or veterinary practitioner, pest control operator or other person skilled in the art. The compounds of the invention may be combined with soluble macromotecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containihg polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration. Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes maybe used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma- cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94702518 and WO 98/55148. Compounds of the invention can also be mixed with one or more biologically active compounds or agents including insecticides, acarfcides, anthelmintics, fungicides, nematocldes, antiprotozoals, bactericides, growth regulators, entomopaihogenic bacteria, viruses or fungi to form a muHl-component pesticide giving an even broader spectrum of pharmaceutical, veterinary or agricultural utility- Thus, the present Invention also pertains to a composition comprising a biologically effective amount of compounds of the invention and 'an effective amount of at least one additional biologically active compound or agent and can further comprise one or more of surfactant, a sofid d fluent or a liquid dfluent SpecBte further active compounds Include those described in International Patent Application No WOO 2005/090313, at pages 39 to 44. It be may desirable to administer a combination of active compounds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the composftions. Thus the kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of formula (I) in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like. The kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid. The compounds of the invention, i.e. those of formula {I), possess parasiticidal activity in humans, animals, insects and plants. They are particularly useful In the treatment of ectoparasites. This invention also relates to a compound of formula (f), or a pharmaceutlcally acceptable salt thereof, or a pharmaceutlcally acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing, for use as a medicament. A further aspect of this invention relates to the use of a compound of formula (I), or a pharmaceutlcally acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, for the manufacture of a medicament for the treatment of a parasitic infestation. In one embodiment this invention is useful for the manufacture of a medicament for the treatment of a parasitic infestation In humans. In one embodiment this invention is useful for the manufacture of a medicament for the treatment of a parasitic infestation In animals. In one embodiment this invention is useful for the manufacture of a medicament for the treatment of a ., parasitic infestation in insects. In one embodiment this Invention Is useful for the manufacture of a medicament for the treatment of a parasitic infestation in plants. An even further aspect of this invention relates to a method of treating a parasitic infestation in a mammal which comprises treating said mammal with an effective amount of a compound of formula (I), or a pharmaceutical^ acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing. A yet further aspect of this invention relates to a method of preventing a parasitic Infestation in a mamma] which comprises treating said mamma} with an effective amount of a compound of form ula (I), or a pharmaceutical^ acceptable saft thereof, or a pharmaceutical!/ acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing. In a still further embodiment this invention also relates to a method of controlling disease transmission in a mammal which comprises treating said mammal with an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, or a pharmaceutical composition containing any of the foregoing. According to another aspect of the present invention, there is provided a method for the control of arthropod, plant nematode or helminth pests at a locus which comprises the treatment of the locus (e.g. by application or administration) with an effective amount of a compound of general formula (I), or a pesticidally acceptable salt thereof. For the avoidance of doubt, references herein to "treatment* as used herein includes references to curative, palliative and prophylactic treatment, references to "control" (of parasites and / or pests etc.) include kill, repel, expel, incapacitate, deter, eliminate, alleviate, minimise, eradicate. The compounds of the invention have utility In the control of arthropod pests. They may, in particular, be used in the fields of veterinary medicine, livestock husbandry and the maintenance of public health: against arthropods which are parasitic internally or externally upon vertebrates, particularly warm-blooded vertebrates, including man and domestic animals such as dogs, cats, cattle, sheep, goats, equines, swine, poultry and fish for example Acarina, including ticks (e.g. Ixodes spp., Boophllus 3pp. e.g. Boophilus microplus, Amblyomma spp., Hyalommaspp., Rhipicephalus spp. e.g. Rhlpicephalus appendicu/atus, Haemaphysalis spp., Dermacentorspp., Ornithodorus spp. (e.g. Omfthodorus moubata), mites (e.g, Damalinia spp., Dermanyssus gailinae, Sarcoptes spp. e.g. Sarcoptes scabiei, Psoroptes spp., Chorloptes spp., Demodex spp., Eutromblcula spp.), specific further arthropod pests include those described in International Patent Application Mo WO 2005/090313; Diptera (e.g. Aedes spp,, Anopheles spp.r Muscidae spp. e.g. Stomoxys palcltrans and Haematobla Irritans, Hypoderima spp., Gastrophilus spp., Simulium spp.); Hemiptera (e.g. Triatoma spp.); Phthiraptera (e.g, DamaOnia spp., Linognathus spp.); Siphonaptera (e.g. Ctenocephalldes spp.); Dictyoptera (e.g. Periplaneta spp,, Blatella spp.) and Hymenoptera (e.g. Monomorium pharaonis). The compounds of the present invention also have utility in the field of control of plant pests, soil inhabiting pests and other environmental pests. The present invention is particularly useful In the control of arthropod pests in mammals, in particular humarts and animals. Preferably this invention is useful in the control of arthropod pests in animals which includes livestock such as cattle, sheep, goats, equines, swine and companion animals such as dogs and cats. The com pounds of the invention are of particular value in the control of arthropods which are Injurious to, or spread or act as vectors of diseases in, man and domestic animals, for example those hereinbefore mentioned, and more especially in the control of ticks, mites, lice, fleas, midges and biting, nuisance and myiasis flies. They are particularly useful in controlling arthropods which are present inside domestic host animals or which teed in or on the skin or suck the Wood of the animal, for which purpose they may be administered orally, parenterally, percutaneously or topically. The compounds of the invention are of value for the treatment and control of the various lifecycte stages of parasites including egg, nymph, larvae, juvenile and adult stages. According to another aspect of the present invention, there is provided a method for the control of arthropod pests of insects which comprises treatment of the insect with an effective amount of a compound of general formula (I), or a pesticidaily acceptable salt thereof. Compounds of the present invention may also be used for the treatment of infections caused by mites, and in particular varoaa mites. In particular compounds of the present invention may also be used for the treatment of varoaa mite infection in bees. According to another aspect of the present invention, there is provided a method for the control of arthropod pests of plants which comprises treatment of the plant with an effective amount of a compound of general formula (I), or a pestlddally acceptable salt thereof. The compounds of the Invention also have utility in the control of arthropod pests of plants. The active compound is generally applied to the locus at which the arthropod infestation is to be controlled at a rate of about 0.005 kg to about 25 kg of acSve compound per hectare (ha) of locus treated, preferably 0.02 to 2 kg/ha. Under ideal conditions, depending on the pest to be controlled, the lower rate may offer adequate protection. On the other hand, adverse weather conditions and other factors may require that the active ingredient be used In higher proportions. For foliar application, a rate of 0.01 to 1 kg/ha may be used. Preferably, the locu3t3 the plant surface, or the soil around the plant to be treated. According to another aspect of the present invention, there is provided a method Jor the protection of timber which comprises treatment of the timber with an effective amount of a compound of general formula (I), or a pesticidaHy acceptable salt thereof. Compounds of the present iiwenlfon are ateo valuable in the protection of timber (standing, felled, converted, stored or structural) from attack by sawf lies or beetles or termites. They have applications in the protection of stored products such as grains, fruits, nuts, spices and tobacco, whether whole, milled or compounded into products, from moth, beetle and mite attack. Also protected are stored animal products such as skins, hair, wool and feathers in natural or converted form {e.g. as carpets or textiles) from moth and beetle attack; ateo stored meat and fish from beetle, mite and fly attack. Solid or liquid compositions for application topically to timber, stored products or household goods usually contain from about 0.00005% to about 90%, more particularly from about 0.001 % to about 10%, by weight of one or more compounds of formula 0) or pesticidaHy acceptable salts thereof. The liquid compositions of this invention may, in addition to normal agricultural use applications be used for example to treat substrates or sites Infested or liable to infestation by arthropods (or other pests controlled by compounds of this Invention) Including premises, outdoor or indoor storage or processing areas, containers or equipment or standing or running water. The present invention also relates to a method of cleaning animals in good health comprising the application to the animal of compound of formula (I) or a veterinary acceptable salt The purpose of such cleaning Is to reduce or eliminate the infestation of humans with parasites carried by the animal and to improve the environment in which humans inhabit The biological activity of the compounds was tested using one or more of the test methods outlined below. In vitro tick assay Application of octopamine agonists to acarids for example, ticks, causes distinct behavioural changes compared to untreated control ticks. Treated ticks become agitated and move constantly, this prevents ticks attaching and feeding on a host animal to which the compound has been applied. Normal behaviour of ticks is to go into stasis whBn all other external stimuli are removed. Agitation and movement can be measured in vitro in the laboratory to predict efficacy and potency in vivo. The assay was run using unfed Rhipioephalus sanguineus (brown dog tick) and preooated glass vials with an inner surface area of 34.5cm2. Each compound was tested in duplicate. Compound (345µg) was dissolved in isopropyl alcohol (500ul) and delivered to each vial. The vials were placed on a tilting roller In a fume hood for 2 hours to allow the isopropyl alcohol to evaporate giving a compound concentration for each vial of 10µg/cma. Five R.sanguineus (male and female) were added to each coated vial and the vial sealed with a firm wad of cotton wool. Vials were then kept, undisturbed, on the bench at room temperature. Observation and recordings of activity were taken at 24, 48 and 72 hours after addition of ticks to the vials. The ED100 value was determined as the lowest dose at which all five ticks were seen moving around inside the vial. Octopamine activity One skilled in the art could determine agonist activity of compounds against insect octopamine receptors expressed in CHO cells by adapting the methods described in B. Maguetra, H. Chatwin, P. D. Evans, J. Neurochemistry, 2005, 94,2,547. Compound activity can be measured as an increase in cAMP by various methods known to a skilled person and can be recorded as %Vrnax (Vmax=maximal octopamine response) and EC50. Adrenergic activity Methods from literature procedures were simply adapted, as could be readily performed by one skilled In the art, in order to determine cc2 adrenergic activity of the compounds. Suitable procedures Include those described in J J. Meana, F. Barturen, J. A. Garcia-Sevffla, Journal of Neurochemistry, 1989,1210; and D. J. Loftus, J. M. Stolk, D. C. U'Pritchard, Life Sciences, 1984,35,610. EXAMPLES The following Examples illustrate the preparation of compounds of the formula (I). In the following Examples, structures are depicted as follows: (Formula Removed) Unless; specified otherwise, the wedge and dashed bonds indicate absolute stereochemistry as drawn at this chiral centre, a wiggly bond indicates that the absolute stereochemistry is unknown but the compound is a single stereoisomer at this chiral centre. Straight bonds emanating from a chiral centre indicate that the stereoisomers are not resolved and a mixture of stereoisomers is present When the source of a simple precursor is unspecified these compounds may be obtained from commercial suppliers or according to literature procedures. The following is a list of commercial suppliers for such compounds: Sigma-Aldrich, P O Box 14508, St. Louis, MO, 63178, USA Lancaster Synthesis Ltd., Newgate, White Lund, Morecambe, Lancashire, LA3 3BN, UK Maybridge, Treviltett, Tintagei, Cornwall, PL34 0HW, UK Fluorochem Ltd., Wesley Street, Old Glossop, Derbyshire, SK13 7RY, UK ASDI Inc. 601 Interchange Blvd., Newark, DE, 19711, USA Alfa Aesar, 26 Parkridge Road, Ward Hill, MA, 01835, USA Blonet Research Ltd., Highfield Industrial Estate, Camelford, Cornwall, PL32 9QZ, UK Acros Organics, Janssens Pharmaceuticalaan 3A, Geet, 2440, Belgium Apin Chemicals Ltd., 3D Milton Park, Abingdon, Oxfordshire, 0X14 4RU, UK Pfaltz & Bauer, Inc., 172 East Aurora Street, Waterbury, CT 06708, USA Trans World Chemicals, Inc., 14674 Southlawn Lane, Rockville, MD 20BS0, USA Peakdale Molecular Ltd., Peakdale Science Park, Sheffield Road, Chapel-en-le-Frith, High Peak, SK23 OPG, UK TCI America, 9211 N. Harborgate Street, Portland, OR 97203, USA Fluka Chemle GmbH, Industriestrasse 25, P.O. Box 260, CH-9471 Buchs, Switzerland JRD Fluorochemicals Ltd., Unit 11, Mote Business Park, Leatherhead, Surrey, KT22 7BA, UK Instruments used In the following experimental details, nuclear magnetic resonance spectral data were obtained using Variari Inova 300, Varian Inova 400. Varian Mercury 400, Varian UnHyplus 400, Bruker AC 300MHz, Bruker AM 250MHz or Varian T60 MHz spectrometers, the observed chemical shifts being consistent with the proposed structures. N.m.r chemical shifts are quoted in p.p.m dowrtfield from tetramethylsilane. Mass spectral data were obtained on a Rnnigan ThermoQuest Aqa, a Waters micromass ZQ, Bruker APEX: IIFT-MS or a Hewlett Packard GCMS System Model 5971 spectrometer. The calculated and observed ions quoted refer to the isotopic composition of lowest mass. HPLC means high performance liquid chromatography. Analytical HPLC data was collected on a HP1100 Series HPLC system. Preparative HPLC data was collected using a Gllson Preparative HPCL system. CHN microanalysfs data were collected using Exeter Analytical CE 440 Instruments by Warwick Analytical Service, (University ot Warwick Science Park, Barclays Venture Centre, Sir WilGam Lyons Road, Coventry, CV4 7EZ). Optical rotation data was collected using a Perkh Elmer Polarimeter341 by Warwick analytical Service, (University of Warwick Science Park, Barclays Venture Centre, Sir William Lyons Road, Coventry, CV4 7EZ). Example 1 2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol (Formula Removed) A solution of the compound of Preparation 194 (11.0 g, 38.1 mmol) and palladium(ll) hydroxide (1.10 g, 7.83 mmol) in methanol (100 ml) was heated to 60°C at a pressure of 300 psi under a hydrogen atmosphere for 18 h. The reaction mixture was then filtered and concentrated in vacuo and the residue was re-crystallised from hotacetonitrile (50 mi) to give the title compound (3.27 g). Experimental MH+ 201.3; expected 201.1 1H-NMR (CD3OD): 1.50 -1.55 (3H), 2.15 - 2.20 (3H), 2.20 - 2.25 (3H), 4.40 - 4.50 (1H), 6,80 - 6.85 (1H), 6.90 - S.92 (2H), 6.95 - 7.00 (2H) Rhip. F:unct. ED100 mg/cmz= 0.1 .-' Alternative synthesis A solution of the compound of Preparation 1 (72 mg, 0.36 mmol) in methanol (5 mL) was hydrogenated at 100 psi and 60C using palladium (10 wt % on carbon, 10 mg), overnight The mixture was filtered and the filtrate concentrated in vacuo. The residue was dissolved in methanol (1 ml) and diethyiamlne (2-3 drops, 1 mi) and purified by automated preparative liquid chromatography (Gllson system, 150 mm x 30 mm LUNA C18(2) 10µm column, 40 ml / mln) using an acetonitrtte : water gradient [30:70 to 98:2]. Trie appropriate fractions were concentrated in vacuo to give the title compound (26 mg). Experimental MH+ 201.2; expected 201.1 1H-NMR (d6-DMSO): 1.65-1.72(3H), 2.13-2.18(3H),2.24-2.31 (3H), 4.43-4.52(1H), 6.89-6.92 (2H), 7.00 - 7.03 (1H), 7.03 - 7.11 (2H) Alternative synthesis To a mixture of the compound of Preparation 1 (1.0 g, 3.26 mmol) and ammonium formate (1.0 g, 15.9 mmol) in formic acid (20 mi) was added palladium (10% wt % on carbon, 1.0 g). The reaction mixture was heated at 100°C for 72 h, filtered and concentrated in vacuo. The residue was triturated with methanol: ethyl acetate [1:9] to give the title compound (200 rng). Experimental MH+ 201.3; expected 201.1 'H-NMR (CD3OD): 1.65 -1.70(3H), 2.20-255 (3H), 255 - 2.30 (3H), 4.80- 4.90 (1H), 6.80- 6.85 (1H), 7.00 - 7.10 (2H), 7.35 - 7.40 (2H) Alternative synthesis A mixture of the crude compound of Preparation 13 (500 mg, 2.3 mmol) and palladium (10wt %on carbon, 223 mg) in formic acid (10 mi) was heated at reflux for 36 h. The reaction mixture was tittered and the filtrate was concentrated in vacuo to give the crude title compound Experimental MH+ 201.3; expected 201.1 Example 2 2-[1-[2-Methyl-3-(trifluoromethtl)phenyl]ethyl}-1H-imidazol (Formula Removed) A mixture of the compound of Preparation 148 (2.0 g, 5.8 mmol) and palladium (10 wt % on carbon, 500 mg) in methanol (25 ml) was heated at 60°C under a hydrogen atmosphere (150 psi) for 24 h. The mixture was filtered through Arbocel® and the fiitrate was concentrated in vacuo. The residue was purified by flash chromatography (silica), eluting with methanol. The appropriate fractions were combined and concentrated to give the title compound (11 mg}. 1H-NMR (CD3OD): 1,58 -1.62 (3H), 2.40 - 2.43 (3H), 4.56 - 4.62 (1H), 6.90 - 6.94 (2H), 7.21 - 7.29 (2H), 7.47-7.51 (1H) Experimental MH+ 255.3; expected 255.1 Rhip. Funct ED100 mg/cma= >1 Example 3 2-[1-(1 H-imidazol-2-yl)ethyl-6-methylbenzonitrile (Formula Removed) To a solution of the compound of Preparation 167 (50 mg, 0.17 mrnol) in 2-propanol (2 ml) was added ammonium formate (105 mg, 1.67 mmol) and palladium (10 wt % on carbon, 36 mg). The reaction mixture was heated at 80°C, under nitrogen, for 2 h and men cooled. The mixture was filtered through Arbocel®, washing through with 2-propanol, and the filtrate was concentrated in vacuo. The residue was dissolved in acetonttrile: water (9:1,4 ml) and purified by automated preparative liquid chromatography (Giteon system, 150 mm x 30 mm LUNA C18(2) 10 \im column, 40 ml/min) using an acetonttrile: water gradient [30:70 (20 min) to 95:5 (21 min)]. The appropriate fractions were combined and concentrated to give the title compound (8 mg). Experimental MH+ 212.1; expected 212.1 1H-NMR (de-Acetone): 1.64 -1.66 (3H), 2.50 - 2.51 (3H), 4.59 - 4.61 {1H), 6.90 - 7.05 (2H), 7.19 - 7.21 (1H), 7.23 - 7.25 (1H), 7.42 - 7.45 (1H) Rhip. Funct. ED100 mg/cm2= 0.3 Similarly prepared were: (Table Removed) Example 4 1H-MMR (CDCI3): 1.14 -1.21 (3H), 1.62 -1.70 (3H), 2.53 - 2.62 (2H), 4.15 - 4.22 (1H), 6.80 - 6.85 (2H). 6.97 - 7.02 (2H), 7.02 - 7.07 (1H), 7.15 - 7.21 (1H) Example 5 1H-NMR (d6-DMSO): 0.58- 0.62 (2H),0.83-0.87(2H), 1.50-1.54 (3H), 1.80-1.84 (1H), 4.03-4.05 (1H), 6.80 - 6.88 (3H), 6.95 - 6.98 (3H), 7.10 - 7.14 (1H) Exampte6 1H-NMR (CD3OD): 1.68 -1.74 (3H), 4.25 - 4.34 (1H), 6.95 - 6.97 7.55 - 7,59 (2H) Example 7 1H-NMH (dB-DMSO): 1.42 -1.50(3H), 2.15 - 2.20 (3H), 4.37 - 4.41 (1H), 6.71 - 6.75 (IH), 6.89 - 6.98 (3H), 7.03-7.06 (1H) Example 8 1H-NMR (C03OD): 1.61 -1.65 (3H), 2.39 - 2.42 (3H), 4.51 - 4.58 (1H), 6.94 - 6,98 (2H). 7.32 - 7.36 (2H), 7.37-7.41 (1H) Examples 1H-NMR (d6-Acetore): 1.11 -1.19(3H), 1.55-1.59(3H), 2.26-2.28(3H), 2.60 - 2.68 (2H), 4.45 - 4.52 (1H), 6.89 - 6.93 (2H), 6.97 - 7.01 (3H) Example 10 1H-NMR (CDCl3): 1.65 -1.71 (3H), 2.35 - 2.38 (3H), 4.19 - 4.24 {1H), 6.98 - 7.00 (2H), 7.28 - 7.34 (3H) Example 11 1H-NMR (d6-Acetone): 1.60 -1.63 (3H), 2.58 - 2.59 (3H), 4.55 - 4.50 (1H), 6.90 - 6.95 (2H), 7.29 - 7.33 (1H), 7.50-7.60 (2H) Example 12 1H-NMR (CDC!3): 1.70 -1.75 (3H), 2.32 - 2.34 (3H), 4.54-4.60 (1H), 6.91 - 6.93 (2H), 7.21 - 7.25 (3H) Example 13 1 -Benzyl-2-(1-[3-difluroromethyl)phewnyl]ethyl-1H-imidazol (Formula Removed) To a solution of the compound of Preparation 142 (100 mg, 0.32 mmol) in 2-propanoJ (4 ml) was added ammonium formate (406 mg, 6.44 mmol) and palladium (10 wt % on carbon, 137 mg). The reaction mixture was heated at 80°C, under nitrogen, for 18 h and then cooled. The mixture was filtered through Arbocei®, washing through with 2-propanol, and the filtrate was concentrated in vacuo. The residue was dissolved in acetonitrile: water (9:1, 4 ml) and purified by automated preparative liquid chromatography (Gilson system, 100mm x 30 mm LUNA C18(2) 5 urn column, 40 ml /min) using an acetonitrile: water gradient [40:60 (20 min) Jo 95:5 (25 minJJ, The appropriate fractions were combined and concentrated to give the title compound (8 mg). Experimental MH+ 313.4; expected 313.2 1H-NMR (d6-Acetone): 1.58 -1.61 (3H), 4.25 - 431 (1H), 4.99 - 5.03 (1H), 5.10 - 5.14 (1H), 6.80 - 6.82 (1H), 6.94 - 6.98 (3H), 7.00 -7.02 (1H), 7.20 - 7.25 (3H), 7.38 - 7.41 (4H) Rhip. Funct. ED100 mg/cma= >1 Similarly prepared was: (Table Removed) Example 14 1H-NMR (CD3OD): 1.59 -1.62 (3H), 2.30 - 2.31 (3H), 4.54 - 4.59 (1H), 6.80 - 6.83 (3H), 6.88 - 6.90 (1H), 7.00 ■ 7.02 (2H), 7.15 - 7.17 (1H), 7.18 - 7.20 (2H), 7.26 - 757 (1H) Example 15 2-[1-(2-Methyl-3-propylphenyl)ethyl]-1H-imidazol (Formula Removed) To a solution of the compound of Preparation 136 (720 mg, 2.3 mmol) In 2-propanol (20 ml) was added ammonium formate (1.0 g, 20 mmol) and palladium (10 wt % on carbon, 300 mg). The reaction mixture was heated at 80°C, under nitrogen, for 72 h and then cooled. The mixture was filtered through' Arbocel®, washing through with 2-propanol, and the filtrate was concentrated in vacuo. The residue was dissolved in acetonitril© (2 ml) and diethylamine (2-3 drops) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 50 mm LUNA C18(2) AX 5 urn column, 40 ml / mln) using an acetonitrlle: water gradient [40:60 (15 min) to 95:5 (15.5 mln)]. The appropriate fractions were combined and concentrated to give the title compound (74 mg). Experimental MH* 229.3; expected 229.2 1H-NMR (d6-Acetone): 0.95 -1.00 (3H), 1.51 -1.60 (5H), 2.13-2.15 (3HJ, 2.58 - 2.61 (2H), 4.47-4.52 (1H), 6.85 - 6.90 (2H), 6.96 - 7.00 (3H) Rhip. Funct. ED100 mg/cm2= Example 16 2-{1-[2-(Trifluoromethylphenyl]ethyl]-1H-imidazol (Formula Removed) A mixture of the compound of Preparation 51 (212 mg, 0.86 mmol) and palladium (10 wt % on carbon, 500 mg) in methanol (10 ml) was heated at 60°C under a hydrogen atmosphere (150 psi) for 60 h. The mixture was filtered through Arbocel® and the filtrate was concentrated in vacuo. The residue was dissolved In methanol (2 mi) diethylamine (2-3 drops) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x50mm LUNA C13(2) 10um column, 40 ml/ min) using an acetonitrile: water gradient [35:65 to 95:5]. The appropriate fractions were concentrated in vacuo to gJve the title compound (58 mg). Experimental MH+241.3; expected 241.1 1H-NMR (CD3OD): 1.60-1.66 (3H), 4.53 - 4.61 (1H), 6.88 - 6.95 (2H), 7.31 - 7.39 (2H), 7.48 - 7.53 (1H), 7.62-7.68 (1H) Rhip. Funct. ED100 mg/cm2= 3 Similarly prepared were: (Table Removed) Example 17 1H-NMR (d6-Acetone): 1.60-1.70(3H), 2.08-2.15 (3H), 2.21 -2.30(3H), 4.40-4.50 (1H), 6.81-6.92 (2H), 6.93 - 6.99 (1H), 7.00 - 7.08 (2H) Example 18 1 H-NMR (CDCI3): 1.68 -1.72 (3H), 2.04-2.12 Example 19 1 H-NMR (CD3OD): 1.55 - 1.60 (3H), 2.19 - 2.21 (6H), 4.05 - 4.15 (1H), 6.75 - 7.80 (3H), 6.85 - 6.90 (2H) Example 20 1H-NMR (CDCI3): 1.67 -1.71 (3H), 2.28 - 2.30 (3H), 4.12 - 4.18 (1H), 6.90 - 6.93 (2H), 7.00 - 7.06 (2H), 7.17- 7.23 (2H) Example 21 1H-NMR (CDCI3): 1.67 -1.72 (3H), 4.14 - 4.21 (1H), 6.89 - 6.94 (2H), 7.18 - 7.25 (3H), 7.26 - 7.33 (2H) Example 22 1H-NMR (CDCI3): 1.67 -1.70 (3H), 2.29 - 2.31 (3H), 4.12 - 4.18 (1H), 6.89 - 6.92 (2H), 7.10 - 7.12 (4H) Example 23 1 H-NMR (CD30D): 1.55 -1.65 (3H), 2.00-2.10 (3H), 2.14-2.17 (3H), 2.18 - 2.20 (3H), 4.40 - 4.50 (1H), 6.80 - 6.90 {1H), 6.90 - 6.95 (3H) Example 24 1H-NMR (CDCI3): 1.69 -1.73 (3H), 4.23 - 4.30 (1H), 6.92 - 6.97 (2H), 7.31 - 7.35 (2H), 7.52 - 7.56 (2H) Example 25 1H-NMR (CDCI3): 1.69 - 1.74 Example 26 'H-NMR (CDCI3): 1.64 -1.68 6.87 - 6.89 (2H), 7.09 - 7.15 (1H) Example 27 1H-NMR (CDgOD): 1.03 - 1.09 (3H), 1.58-1.63 (3H), 2.29 - 2.31 (3H), 2.65 - 2.75 (2H), 4.42 - 4.48 (1H), 6.82 - 6.85 (2H), 6.92 - 7.00 (3H) Example 28 1H-NMR (CD3OD): 1.60 -1.65 (3H), 4.20 - 4.26 (1H), 6.90 ■ 6.93 (2H), 7.03 - 7.06 Example 29 1 H-NMR (CDCI3): 1.68 -1.72 (3H), 2.17 - 2.20 (3H), 4.60 - 4.65 (1H), 6.70 - 6.75 (1H), 6.90 - 6.93 (2H), 6.95- 7.00 (1H) Example 32 2-[1-(2.3.5-Trimethylphenyl)ethyl]-1H-imidazol (Formula Removed) A mixture of the compound of Preparation 64 (150 mg, 0.52 mmol) and palladium (10 wt % on carbon, 15 mg) in 2-propanol (5 ml) was heated at 60°C under a hydrogen atmosphere (200 psi) for 18 h. The mixture was littered through Arbocel® and the filtrate was concentrated In vacuo. The residue was dissolved in acetonitrile (1.22 ml) and diethyfamine (2-3 drops) and purified by automated preparative liquid chromatography (Giteort system, 150 mm x 50 mm LUNA C18(2) 5 pm column, 40 ml / min) using an acetonitrile: water gradient [32:68 (20 min) to 95:5 (21 min)]. The appropriate fractions were combined and concentrated to give the title compound (30 mg). Experimental MH+215.4; expected 215.2 1H-NMR (CD3OD): 1.57-1.60 (3H), 2.15 - 2.19 (6H), 2.20 - 2.22 (3H), 4.35 - 4.39 (1H>, 6.80 - 6.82 (1H), 6.87 -6.90 (3H) Rhip. Fund. ED100 mg/cms= >1 Example 33 2-[1-(2.3-Dimethylphenyl)propyl]-1H-imidazol (Formula Removed) A mixture of the compound of Preparation 47 (255 mg, 1.2 mmoi) and palladium (10 wt % on carbon, 50 mg) In 2-propanol (50 ml) was heated at 40°C under a hydrogen atmosphere (200 psi) for 18 h. The mixture was filtered through Arbocel® and the ftftrate was concentrated in vacuo. The residue was re-crystallised from warm diethyl ether {5 ml) and the solid was triturated with further diethyl ether (5 ml) to give the title compound (175 mg). Experimental MH+ 215.3; expected 215.2 1H-NMR (CDCIa): 0.87 - 0.95 (3H), 1.80 - 2.03 (1H), 2.11 -2.16 (3H), 2.23 - 2.27 (3H), 2.28 - 2.38 (1H), 4.19 - 4.25 (1H), 6.85 - 6.90 (2H), 7.01 - 7.07 (3H) Rhip. Funct. ED100 mg/cm2= 1 Example 34 2-[1-(2-Chloro-3-methylphenyl)ethyl]-1H-imidazol (Formula Removed) A mixture of the compound of Preparation 67 {1.51 g, 6.8 mmoi) and palladium hydroxide {20 wt % Pd on carbon, 500 mg) in 2-propanol (100 ml) was heated at 50°C under a hydrogen atmosphere (200 psi) for 18 h. The mixture was filtered through Arbocel® and the filtrate was concentrated in vacuo. The residue was dissolved in acetonitrlle (1 ml) and diethyfamrne (2-3 drops) and purified by automated preparative liquid chromatography (Gilson system, 100 mm x 30 mm LUNA CI 8(2) 10 urn column, 40 ml / min) using an acetonitrlle : water gradient [35:65 (15 rnin) to 95:5 (15.5 min)]. The appropriate fractions were combined and concentrated to give the title compound (21 mg). Experimental MH+ 221.3; expected 221.1 1H-NMR (d6-DMSO): 1.49 -1.53 (3H), 2.34 - 2.37 (3H), 4.58 - 4.62 (1H), 6.79 - 6.81 (1H), 6.95 - 7.00 (2H), 7.10 - 7.13 (1H), 7.18-7.20 (1H) Rhip. Funct. ED100 mg/cms= 0.1 Similarly prepared were: (Table Removed) Example 36 1 H-NMR (CD3OD): 1.53 -1.62 (3H), 2.20 - 258 (3H), 4.10 - 4.20 (1H), 6.83 - 6.92 Example 38 1 H-NMR (CD3OD): 1.60 -1.65 (3H), 4.20 - 4.30 (1H), 6.90 - 7.00 Example 39 1H-NMR (CD3OD): 1.60-1.63 (3H), 4.20 -4.24(1H), 6.95 - 6.97 (2H), 7.14- 7.16 (1H), 7.19-7.27 (3H) Example 40 'H-NMR (de-Acetone): 1.55 -1.65 (3H), 3.75 - 3.81 (3H), 5.18 - 5.25 (1H), 6.80 - 6.85 (1H), 6.95 - 6.9S (1H), 7.10-7.20 (2H), 7.35-7.40 (1H) Example 43 'H-NMR (CD3OD): 1.58 -1.61 (3H), 4.60 - 4.64 (1H), 6.95 - 6.97 (2H), 7.07 - 7.08 {1 H)r 7.18 - 750 Example 44 'H-NMR (CD3OD): 1.58 -1.61 (3H), 2.24 - 2.26 (3H), 4.15 - 4.20 (1H), &89- 6.91 {2H>, 7.00 - 7.02 Example 46 H-NMR (CD3OD): 1.57 -1.60 (3H), 3.62 - 3.63 (3H), 4.60 - 4.65 (1H), 6.60 - 6.61 (1H), 6.72 - 6.75 (1H), &91 - 6.93 (2H), 7.21 - 7.24 (1H) Example 48 2-[1-(2,3-Difluorophenyl)ethyl]-1H-imidazol (Formula Removed) To a solution of the compound of Preparation 2 (320 mg, 155 mmoi) in 2-propanol (20 ml) was added ammonium formate (1.47 g, 23.3 mmoi) and palfadfcim (10 wt % on carbon, 495 mg). The reaction mixture was heated at 80°C for 18 h and then cooled. The mixture was filtered through Arbocel®, washing through with 2-propanol (10 mO, and the filtrate was concentrated in vacuo. The residue was dissolved in acetonitrile (2 ml) and purified by automated preparative liquid chromatography (Giison system, 150 mm x 50 mm LUNA C18(2) 10 urn column, 40 ml / min) using an acetonitrile: water gradient [30:70 (20 min) to 95:5 (21 min)]. The appropriate fractions were combined and concentrated to give the title compound (10 mg). Experimental MH+209.4; expected 209.1 1H-NMR (CD3OD): 1.62 -1.65 (3H), 4.54 - 4.61 (1H), 6.90 - 6.96 (2H), 7.02 - 7.25 (3H) Rhip. FuncL ED100 mg/cm2=3 Similarly prepared were: (Table Removed) Example 49 1H-MMR (d6-DMSO): 1.45-1.49 (3H), 2.00 - 2.02 (3H)P 2.19 - 2.21 (3H), 3.60 - 3.61 (3H), 4.23 - 4.27 (1H), 6.70 - 6.72 (1H), 6.77 - 6.79 (1H), 6.83 - 6.85 (1H), 6.92 - 6.95 (1H) Example SO 1H-NMR (CDCI3): 1.62 -1.67 (3H>, 2.15 - 2.20 (3H), 4.19 - 4.24 (1H), 6.82 - 6.87 (3H), &97 - 7.01 (2H> Example 51 1H-NMR (CDCI3): 1.75 -1.80 (3H), 4.68 - 4.73 (1H), 6.82 - 6.87 Example 52 TH-NMR (CDCI3): 1.63 -1.66 (3H), 2.18 - 2.20 (3H), 4.39 - 4.44 (1H), 6.90 - 7.00 (4H), 7.10 - 7.15 (1H) Example 53 'H-NMR (CDCfe): 1.70 -1.74 (3H), 4.18 - 4.23 (1H), 6.90 - 7.00 (4H), 7.00 - 7.02 Example 54 1H-NMR (CDCI3): 1.69-1.74 (3H), 4.79 - 4.85 {1H), 6.94 - 6.98 (2H), 7.26 - 7.31 (1H), 7.41 - 7.44 (1H). 7.55-7.58 Example 55 1H-NMR (d6-Acetone): 1.60 -1.64 (3H), 2.25 - 2.27 (3H), 4.19 - 4.24 (1H), 6.75 - 6.82(2H), 6.85 - 6.98 (3H) Example 56 1H-NMR (CD3OD}: 1.60 -1.64 (3H), 2.50 - 2.54 (3H), 4.63 - 4.67 (1H), 6.90 - &93 (2H), 7.07 - 7.10 (1H), 7.18 - 7.20 (1H), 7.30 - 7.34 (1H) Example 57 2-[1-(2-Fluoro-5-methylphenyl)ethyl]-1H-imidazol (Formula Removed) A mixture oJ the compound of Preparation 3(74 mg, 0.31 mmol), palladium (10 wt % on carbon, 140 mg) and ammonium formate (394 mg, 6.4 mmol) in 2-propanol (20 ml) was heated at 80°C for 24 h. The mixture was tittered through Aroocef® and the filtrate was concentrated in vacuo. The residue was dissolved In aoetonittfle: methanol (1 ml) and purified by automated preparative liquid chromatography (Gifeon system, 150 mm x 30 mm LUNA C18(2) 10 um column, 40 ml / min) usmg an acetonitrlle: water gradient [50:50 (20 min) to 98:2 (20.5 min)]. The appropriate fractions were combined and concentrated to give the title compound (49 mg). Experimental MH+ 205.1; expected 205.1 1H-NMR (de-Acetone): 1,60 -1.63 (3H), 2.20 - 2.22 (3H), 4.43 - 4.47 (1H), 6.84 - 6.86 (1H), 6.90-7.00 (2H), 7.00 - 7.07 (2H) Rhip. Funct. ED100 mg/cm2= >1 Example 58 2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 1 (750 mg, 3.75 mmo!) was dissolved in ethanol (4 ml) and the enanttomers were separated by automated preparative liquid chromatography (Grteon system, 50 x 50 mm ID Chirateel OD, 20 |jm column, 50 ml /min) using ethanol: hexane [10:90] as the mobile phase. The appropriate fractions were combined and concentrated to give the title compound (370 mg). Retention time = 5.79 min Chiraloet OD-H, 250 x 4.6 mm ID, 5 um column, ethanol: hexane [10:90], 1 ml /min experimental MH+ 201.3; expected 201.1 1H-NMR (CD3OD): 1.56 -1.60 (3H), 2.18 - 2.20 (3H), 2.22 - 2.24 (3H), 4.45 - 4.50 (1H), 6.80 - 6.86 (3H), 6.95 - 6.99 (2H) Optical rotation, (25DC, methanol, 5.035 mgfrnl, path length f 00 mm): 365 nm = +266.93, 546 nm = +88.43,589 nm = + 73.58 Rhfp. Funct ED100 mg/cm2= 0.1 Alternative synthesis To a solution of the compound of Preparation 1 {600 g, 3 mol) in methanol (6.0 I) was added bis(norbornadiene)rhodium (I) tBftafluoroborate (1.50 g) and S(+)-1-[(fl)-2-dlphenyl phosphtnaferrocenyT] ethytdltert.butylphosphlne (2.61 g) and the reaction mixture was heated at 25°C, under a hydrogen atmosphere (45-60 psf), lor 10 h. The reaction wasmonitored by HPLC, (upon completion: startfng material Example 59 2-[(1R)-1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 1 (750 mg, 3.75 mmol) was dissolved in elhanol (4 mi) and the enantiomers were separated by automated preparative flquid chromatography (Gilson system, 50 x 50 mm ID Chiralcel OD, 20 um column, 50 ml /min) using ethanol: hexane {10:90] as the mobile phase. The appropriate fractions were combined and concentrated to give the title compound (370 mg). Retention time = 7.84 min Chiralcel OD-H, 250 x 4.6 mm ID, 5 µm cxalumn, ethanol: hexane [10:90], 1 ml /min Experimental MH+ 201.3; expected 201.1 1H-NMR (CD3OD): 1.56 -1.60 (3H), 2.18 - 2.20 (3H), 2.22 - 2.24 (3H), 4.43 - 4.48 (1H), 6.80 - 6.86 (3H), 6.95 - 6.99 (2H) Optical rotation, (25°C, methanol, 5.24 mg/ml, path fength 100 mm): 365 nm = -262.79, 546 nm = -86.26, 589 nm = -72.23 Rhip. Funct ED100, mg/cma=>10 Example 60 2-[(1IR*)-1 -(3-Methylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 20 (40 mg, 0J22 mmol) was dissolved in ethanol (1 mi) and the enantiomers were separated by automated preparative liquid chromatography (Gfison system, 250 x 20 mm ID Chiralpak AD-H, 5 µm column, 15 ml / min) using ethanol: hexane [5:951 as the moble phase. The appropriate fractions were combined and concentrated to give the title compound (16 mg). Retention time = 7.93 min Chiralpak AD-H, 260 x 4.6 mm ID, 5 µm column, ethanol: hexane [10:9011 mi / min Experimental MH+ 187.2; expected 187.1 1H-MMR (CD3OD): 1.58 -1.62 (3H), 223 - 2.27 (3H), 4.12 - 4.18 (1H), 687 - 6.89 (2H), 6.94 - 7.01 (3H), 7.09- 7.14 (1H) Rhlp. Fund EDiao mg/cm2= 0.3 Example 61 2-[(1R*)-1-(3-Methylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 20 (40 mg, 0.22 mmol) was dissolved in ethanol (1 ml) and the enanttbmers were separated by automated preparative liquid chromatography (Gilson system, 250 x 20 mm ID Chiralpak AD-H, 5 µm column, 15 ml / min) using ethanol: hexane 15:95] as the mobile phase. The appropriate fractions were combined and concentrated to give the title compound (15 mg). Retention time = 6.06 min Chiralpak AD-H, 250 x 4.6 mm ID, 5 µm column, ethanol: hexane [10:90], 1ml / min Experimental MH+187.2; expected 187.1 1H-NMR (CD3OD): 1.58 -1.62 (3H), 2.23 - 2.27 (3H), 4.12 - 4.18 (1H), 6.87 - 6.90 7.09- 7.14 (1H) Rhlp. Funct. ED100 mg/cma= 0.1 Example 62 1-Benzyl-2-[(1R*)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 76 (540 mg, 1.8 mmd) was dissolved In ethand (2 ml) and hexane (2 ml) and the enarrtlomers were separated by automated preparative liquid chromatography (Gilson system, 50 x 50 mm ID Chiralcel OD, 20µm column, 40 ml / mln) using ethanol: hexane 15:95] as the mobile phase. The appropriate fractions were combined and concentrated to give the title compound {240 mg). Retention time = 5.82 min Chlraloel OD-H, 350 x4.6 mm ID, 5 µrn column, ethanol: hexane [10:90], 1ml/ mln Experimental MH+ 291.3; expected 291.1 1H-NMR (d6-Acetone): 1.50 - 1.53 (3H), 2.19 - 2.26 (6H), 4.31 - 4.38 (1H), 4.68 - 4.72 (1H), 4.90 - 4.94 (1H), (3.70 - 6.72 (1H), 6.90 - 7.00 (6H), 750 - 7.25 Rhip. Funct. ED100 mg/cm2= 0.3 Example 63 1-Benzyl-2-[1-(1R*)2.3-dimethylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Exampe 76 (540 mg, 1.8 mmol) was dissolved in ethanol (2 ml) and hexane (2 ml) and the enantiomers were separated by automated preparative liquid chromatography (Gilson system, 50 x 50 mm ID Chiralcel OD, 20 µmn column, 40 ml /ruin) using ethanol: hexane [5:95] as the mobile phase. The appropriate fractions were combined and concentrated to give the title compound (260 mg). Retention time = 8.80 min Chlralcel OD-H, 250 x 4.6 mm ID, 5 µm column, ethanol: hexane [10:90], 1 ml /min Experimental MH+ 291.3; expected 291.1 Rhip. Funct. ED100 mg/cma= >3 Example 64 2-[(1R*)-1-( 2-FIuoro-3-methylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 7 (18 mg, 0.09 mmol) was dissolved in ethanol: hexane (1:1,2 ml) and the enantiomers were separated by automated preparative liquid chromatography (Gllson system, 250 x 20 mm ID Chiralcel OD-H, 5µm column, 15 ml/min) using ethanol: hexane [5:95] as the mobile phase. The appropriate fractions were combined and concentrated to give the title compound (6 mg). RetenUon time = 3.15 mm Chiralcel OD-H, 250 x 4.6 mm ID, 5 µm column, ethanol: hexane [10:30], 1 ml / min Rhip. Fund. ED100 mg/cma= 0.3 Example 65 2-[(1R*)-1-( 2-FIuoro-3-methylphenyl)ethyl]-1H-imidazol (Formula Removed) The compound of Example 7 (18 mg, 0.09 mmol) was dissolved In ethanol: hexane (1:1,2 ml) and the enanllomers were separated by automated preparative liquid chromatography (Gilson system, 250 x 20 mm ID Chiralcel OD-H, 5 urn column, 15 ml/min) using ethanol: hexane [5:95J as Ihe mobile phase. The appropriate fractions were combined and concentrated to give the title compound (7 mg). Retention time =6.90 min Chiralcel OD-H, 250x 4.6 mm ID 5 urn column, ethanol: hexane [10:90], 1ml/ min Rhip. Funct. EDioo mg/cma= 1 Example 66 {2-[(1R*)1-(2,3-Dimethylmethylphenyl)ethyl]-1H-imidazol-1-yl]methyl pivalate (Formula Removed) To a suspension of the compound of Example 1 (120 mg, 0.6 mmol) and potassium carbonate (246 mg, 1.8 mmol) in dimethylformamide (4 ml) was added chforomethyl pivalate (215 µI, 1.5 mmol) and the reaction mixture stirred at room temperature overnight. Water (10 ml) was added and the mixture then extracted with ethyl acetate (2 x 10 ml). The organic layers were combined, washed with water (10 ml) and brine (10 ml), dried (MgS04) and concentrated In vacuo. The residue was dissolved In acetonitrite chromatography (Gilson system, 150 mm x 21.2 mm LUNA C1B(2) 5µm column) using an acetonftrfle: water gradient [50:50 to 95:5]. The appropriate fractions were concentrated in vacuo to give the title compound (136 mg). Experimental MH+ 315.4; expected 315.2 1H-MMR (CD3OD): 0.96 - 0.99 (9H), 1.58 -1.61 (3H), 2J28 - 2.30 (1H), 5.53 - 5.66 (2H), 6.60 - 6.64 (1H), 6.90 - 7.00 (3H), 7.18 - 7.19 (1H) Rhip. Fund ED100 mg/cm2=0.03 Example 67 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl pivalate (Formula Removed) To a suspension of the compound of Example 1 (120 mg, 0.6 mmol) and caesium carbonate (731 mg, 1.8 mmol) In acetone (4 ml), under nitrogen, was added chloromelhyl propionate {Eur. J. Ptiarm. Sci; 24; 5; 2005; 433-440, f83mg, 1.5 mmol) and the reaction mixture was stirred at room temperature fori 8 h. The mixture was filtered and the filtrate was concentrated In vacuo. The residue was dissolved in acetonitrite (1.5 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 21.2 mm LUNA C18(2) 5mm column) using an acetonitrile: water gradient [50:50 to 95:5]. The appropriate fractions were concentrated to give the title compound (137 mg). Experimental MH+ 287.4; expected 287.2 1H-MMR (CD3OD);0.84-0.11 {3H)r 1.53-1.59(3H), 1.82-2.02 (2H),2.22-2.30(3H),2.31 -2.38 (3H), 4.60-4.68 (1H), 5.41 -5.48 (1H), 5.64-5.69(1H), 6.50-6.56 (1H), 6.83 - 6.99 (3H), 7.13 -7.16 (1H) Rhip. Funct. ED100 mg/cm2* 0.01 Similarly prepared from Example 1 were: (Table Removed) Ref. 1 : Acta Crtem. Scand. Ser. B; EN; 36; 7; 1982; 467-474. Ref. 2: J. Am. Chem. SOC; 43; 1921; 665 Ref. 3: EP-79782, Example 6 Example 68 {2-[1-(2,3-Dimethylphenyl)nethyl]-1 H-imidazol-1-yl]-methyl 3-methylbutanoate 1H-NMR (CD3OD): 0.75 - 0.80 (6H), 1\-1.58 (3H), 1.70 -1.80 (1H), 1.80 -1.84 (2H), 2.23 - 2.30 (3H), 2.31 - 2.34 (3H), 4.60-4.68 (1H), 5.48-5.55 {1H), 5.61 -5.68 (1H), 6.51 -6.58 (1H), 6.83-6.95 (2H), 6.95 - 6.99 (1H), 7.12 - 7.18 (1H) Example 69 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CD3OD): 0.82 - 0.89 (3H), 1.08 -1.3 (6H), 1.3 -1.4 (2H), 1.52 -1.59 (3H), 1.88 -1.98 (2H), 2.24 - 2.30 (3H), 2.30 - 2.35 (3H), 4.60 - 4.69 (1H), 5.42 - 5.51 (1H), 5.62 - 6.71 (1H), 650 - 6.56 (1H), 6.86- 6.99 (3H), 7.12-7.16 (1H) Example 70 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl butyrate 1H-NMR (CD3OD): 0.78 - 0.83 (3H), 1.35 -1.47 (2H), 1,55 -1.61 (3H), 1.90 -1.98 (2H), 2.28-2.32 (3H), 2.33 - 2.37 (3H), 4.61 - 4.70 {1H), 5.48 - 5.55 {1H), 5.64 - 5.72 (1 H)t 6.53 - 659 (1H), 6.90 - 6.96 (2H), 6.97 - 7,01 (1H), 7.16 - 7.20 (1H) Example 71 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl 3-cyclopntylpropanoate 1H-NMR (CD3OD): 0.92-1.06(2H), 1.35-1.45(2H), 1.47-1.55{2H)r 1.56-1,63 (6H), 1.63-1.73 (2H), 1.91 - 2.00 (2H), 2.28 - 2.33 (3H), 2.33 - £38 (3H), 4.62 - 4.71 (1H), 5.48 - 5.55 (1H), 5.68 - 5.73 (1H), 6.52-6.59 (1H), 6.88-7.01 (3H), 7.18-7.19(1H> Example 72 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl pentanoate 1 H-NMR (CD3OD): 0.82 - 0.86 (3H), 1.13 -1.24 (2H), 1.31 -1.40 (2H), 1.56 -1.61 (3H), 1.87 - 2.00 (2H), 2.26 - 2.31 (3H), 2.32 - 2.36 (2H), 4.61 - 4.69 (1H), 5.46 - 5.52 (1H), 5.66 - 5.72 (1H), 6.52 - 6.58 (1H), 6.88-7.00 (3H), 7.15-7.17 (1H) Example 73 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl 3,3-dimethylbutanoate 1H-NMR (d6-Acetone): 0.89 - 0.92 (9H), 1.58 -1.60 (3H), 1.96 -1.97 (2H), 2.29 - 2.31 (3H), 2.38 - 2.40 (3H), 4.60 - 4.64 (1H), 5.50 - 5.54 (1H), 5.70 - 5.74 (1H), 6.67 - 6.69 (1H), 6.90 - 6.96 (2H), 6.99 - 7.01 (1H), 7.12-7.14 (1H) Example 74 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl 2-methylpropanoate 1 H-NMR (d6-Acetone): 0.91 - 0.94 (6H), 1.58 -1.60 (3H), 2.20 - 2.24 (1H), 2.24 - 2.26 (3H), 2.36 - 2.38 (3H), 4.60 - 4.64 (1H), 5.66 - 5.70 (1H), 5.68 - 5.70 (1H), 6.90 - 6.95 (2H), 6,98 - 7.00 (1H). 7.12 - 7.14 (1H) Similarly prepared from Example 58 was: (Table Removed) Ref. 4: J. An. Chem. Soc; 43; 1921; 660 Example 75 {2-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl propionate 1H-NMR (d6-Acetone): 0.89 - 0.95 (3H)r 1.57 - 1.60 (3H), 2.03 - 2.0S (2H), 2.27 - 2J29 (3H), 2.32 - 2.35 (3H), 4.60 - 4.65 (1H), 5.44 - 5.50 (1HJ, 5.71 - 5.76 (1H), 6.62 - 6.64 (1H), &90 - 7.00 (3H), 7.14 - 7.16 (1H) Example 76 1-Benzyl-2-[1-(2.3-dimethylphenyl)ethyll-1H-imidazol (Formula Removed) To a Buspension of the compound of Example 1 (100 mg, 0.50 mmol) and caesium carbonate (407 mg, 1.25 mmol) in acetone (4 ml) was added benzyl bromide (171 mg, 1.00 mmol). The reaction mixture was stirred at room temperature, under nitrogen, for 18 h and then concentrated in vacuo. The residue was partitioned between water (10 ml) and ethyl acetate (10 ml) and the two layers were separated. The aqueous layer was extracted with ethyl acetate (10 ml) and the combined organic phases were dried (MgSO4) and concentrated in vacuo. The residue was dissolved in methanol: water (9:1,2 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 30 mm LUNA C18(2) lOum column, 40 ml/min) using an acetonitrile: water gradient [60:40 to 95:5]. The appropriate fractions were concentrated in vacuo to give the title compound (100 mg). Experimental MH+ 291.0; expected 291.2 1H-NMR (d6-Acetone): 1.45 -1.55 (3H), 2.15 - 2.20 (3H), 2.20 - 2.24 (3H), 4.26 - 4.35 (1H), 4.65 - 4.70 (1H), 4.85 - 4.93 (1H), 6.66 - 6.70 (1H), 6.82 - 7.00 (6H), 7.17 - 7.28 (3H) Rhlp. Funct. ED100mg/cm2= 0.01 Similarly prepared from Example 1 were: (Table Removed) Example 77 {2-[1-(2,3-Dimethylphenyl)ethyl]-1-(3-methoxybenzyl)-1H-imidazol 1 H-NMR (d6-Acetone): 1.50 -1.56 (3H), 2.19-258 (6H), &66 - 3.72 (3H), 4.30 - 4.39 (1 H), 4.66 - 4.71 {1H), 4.86 - 4.94 (1H), &40 - 6.44 (1H), 6.48 - 6.52 (1H), 6.71 - 6.80 (2H), 6.90 - 6.99 (3H), 7.00 - 7.02 (1H), 7.14-7.20 (1H) Example 78 2-[1-(2,3-Dimethylphenyl)ethyl]-1-(1-phenylethyl)-1H-imidazol 1 H-NMR (d6-Acetone): 1.72-1.79 (SH), 1.80- 1.90 (3H), 2.23-2.31 (6H), 5.05-5.11 (1H), 5.48-5.58 (1H), 6.64 - 6.70 (1H), 6.70 - 6.80 (2H), 6.88 - 6.95 (1H), 6.95 - 7.00 (1H), 7.04 - 7.20 (4H), 7.66 - 7.70 (1H) Example 79 1-[4-([2-[(1S)-1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl]methyl)phenyl]-1H-1,2,4-triazole (Formula Removed) To a mixture of the compound of Example 58 (90 mg, 0.45 mmol) and caesium carbonate (244 mg, 0.75 mmol) in 1-methyl-2-pyrrolidinone (1 ml) was added 1-[4-(bromomethyl}phenyl]-1 H-1,2,4-triazole (83µl, 0.5 rnmoE). The reaction mixture was stirred at room temperature for 18 h and then concentrated in vacuo. The residue was dissolved in 1 -mamyl-2-pyrrolldlnone (0.8 ml) and purified by automated preparative liquid chromatography (GBson system, 150 mm x 22.4 mm LUNA C18(2) 5 um column, 20 ml / min) using an acetonitrile: water gradient [15:85 (3 min) to 982 (11 min)]. The appropriate fractions were combined and concentrated to give the titte compound {57 mg). Experimental MH+ 358.5; expected 358.2 1H-MMR(CDCy: 1.61 -1.66(3H),2.13-2.21 (6H), 4.20-4.26(1H),4.60-4.80(2H).6.63-6.66(1H), 6.80 - 632 (1H), 6.87 - 6.98 (4H), 7.11-7.13 (1H), 7.47 - 7.51 (2H), 8.04 - 8.06 (1H), 8.43 - 8.45 (1H) Rhip. Funct. ED1D0 mg/cm2 Example 80 1-l3-(Benzyloxy)benzyl-2-[(1 S)-1-(2.3-dimethylphenyl)ethyl]-1 H-imidazol (Formula Removed) To a mixture of the compound of Example 58 {90 mg, 0.45 mmol) and caesium carbonate (244 mg, 0.75 mmol) in 1-methyl-2-pyrrol5dinone {1 ml) was added 1-(benzylc)-3-(bromomethyr)benzen9{139 mg, 0.50 mmol). The reaction mixture was stirred at room temperature for 48 h and then filtered through a Whatman PTFE filter tube (5 µm). The filtrate was purified by automated preparative liquid chromatography (GBson system, 150 mm x 22.4 mm LUNA C18(2) 5 µm column, 20 ml /min) using an acetonitrile: water gradient {50:50 (15 min) to 98:2 (20 min)J. The appropriate fractions were combined and cxwicentrated to give the title compound (31 mg}. Experimental MH+ 397.5; expected 397.2 1H-NMR (d6-Acetone); 1.50 -1.54 (3H), 2.19 - 2.25 (6H), 4.33 - 4.38 (1H), 4.65 - 4.70 (1H), 4.90 - 4.95 (1H), 4.98 - 5.00 (2H), 6.46 - 6.51 (2H), 6.74-6.76 (1H), 6.84 - 6.9S (4H), 7.00 - 7.01 (1H), 7.15 - 7.20 (1H), 7.31 - 7.42 (5H) Rhip. Funct. ED100 mg/cm2 Similarly prepared from Example 58 were: (Table Removed) Example 81 2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1-[4-(methylsulfonylbenzyl-1ZH-imidazol 1H-NMR (CDC3): 1.60 -1.64 (3H), 2.09-2.11 (3H), 2.18- 2.20 (3H), 2.97 - 3.00 (3H), 4.19 - 4.23 (1H), 4.70 -4.76 (1H)t 4.79-4.85 (1H), 6.61 - 6.65 (1H), 6.80 - 6.81 (1H), 6.84-6.95 (4H), 7.14-7.17 (1H), 7.72-7.78 (2H) Example 82 [4-([2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol-1 yl]methyl)phenyl]phenyl)methanone 1H-NMR (CDCI3): 1.64 -1.70 (3H), 2.17 - 2.19 (3H), 2.22 - 2.24 (3H), 4.23-4.29 (1H), 4.70 - 4.77 (IH), 4.80 •• 4.86 (1H), 6.80 - 6.84 (1H), 6.85 - 6.92 (3H), 6.94 - 7.00 (2H), 7.18 - 7.20 (1H), 7.45 - 7.52 (2H), 7.59 - 7.62 (1H), 7.68 - 7.72 (2H), 7.75 - 7.79 (2H) Example 83 Methyl 4-([2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol-1-yl]methylbenzoale 1 H-NMR (6-Acetone): 1.53 -1.61 (3H), 2.15 - 2.22 (6H), 3.83 - 3.85 (3H), 4.28 - 4.35 (1H), 4.80 - 4.86 (1H), 5.02 - 5.10 (1H), 6.70 - 6.74 Example 84 [4-([2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazoll-1-yl]methyl)pyridine 1H-NMR (CDCI3): 1.61 -1.64 (3H), 2.10 - 2.12 (3H), 2.21 - 2.23 (3H), 4.12 - 4.20 (1H), 4.60 - 4.66 (1H), 4.75 - 4.80 (1H), 6.65 - 6.71 (3H), 6.82 - 6.83 (1H), 6.89 - 6.96 (2H), 7.12-7.13 (1H), 8.40 - 8.44 (2H) Example 85 3-([2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol-1-yl]methyl)benzonitrile 1H-NMR (d6-Acetone): 1.55 -1.58 (3H), 2.17-2.20 (SH), 4.38 - 4.41 (IH), 4.93 - 4.98 (1H), 5.05 - 5.09 (1H), 6.63 - 6.65 (1H), 6.80 - 6.87 (2H), 6.97-7.00 (2H), 7.12 - 7.13 (1H), 7.18 - 7.20 (1H), 7.37- 7.40 (1H), 7.52-7.54 (1H) Example 86 2-([2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol-1-yl]methyl)benzonitrile 1H-NMR(d6-Acetone): 1.55-1.58(3H),2.16-2.20(6H),4.29-4.33(IH), 4.93-4.98(IH), 5.10-5.14 (1H), 6.66-6.68 (1H), 6.80 - 6.86 (2H), 6.95 - 7.00(3H), 7.10 - 7.11 (1H), 7.57 -7.59 (2H> Example 87 3-([2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazoll-1-yl]methyl)-4-fluorobenzonitrile 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.16 - 2.18 (3H), 2.20 - 2.22 (3H), 4.42 - 4.46 (1H), 5.01 - 5.05 (1H), 5.06- 5.11 (1H), 6.60-6.68 (2H), 6.80 - 6.82 (2H), 7.00 - 7.01 (1H), 7.15 -7.16 (1H), 7.21 • 7.25 (1H), 7.60- 7.62 (1H) Example 88 1-(3.5-Dimethoxybenzyl)-2-[(2-[(1S)-1(2.3-dimethylphenyl)ethyl]-1H-imidazol 1H-NMR (d6-Acetone): 1.50 - 1.53 (3H), 2.20 - 255 (6H), 3.62 - 3.66 (6H), 4.33 - 4.38 (IH), 4.60 - 4.64 (1H), 4.81 - 4.85 (1H), 6.02 - 6.05 (2H), 6.36 - 6.38 (1H), 6.76 - 6.79 (1H), 6.90 - 6.98 (3H), 7.00 - 7.01 (1H) Example 89 2-[(1S)-1-(2.3-Dimethylphenyl)ethyl)-1-(4-methoxybenzyl)-1H-imidazol 1H-NMR (de-Acetone): 1.51 -1.54 (3H), 2.20 - 2.25 (6H), 3.76 - 3.78 (3H), 4.36 - 4.40 (1H), 4.60 ■ 4.64 (1H), 4.80- 4.84 (1H), 6.68 - 6.70 (1H), 6.79-6.85 (4H), 6.90 - 7.00 (4H) Example 90 2-[(1S)-1-(2.3-Dimethylphenyl)ethyl)-1-(4-methoxybenzyl)-1H-imidazol 1 H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.20-2.25 (6H), 3.65 - 3.67 (3H), 4.36 - 4.40 (1H), 4.62 - 4.66 (1H), 4.90 - 4.94 (1H), 6.40 - 6.42 (1H), 6.48 - 6.50 (1H), 6.72 - 6.74 (1H), 6.79 - 6.81 (1H), 6.95 - 7.00 (3H), 7.00 - 7.01 (1H). 7.17 - 7.20 (1H) Example 91 Methyl 4-([2-[(1S)-1-(2.3-Dimethylphenyl)ethyl)-1H-imidazol-1-yl}methyl-3-methoxybenzoate 1H-NMR(d6-Acetone): 1.51 -1.54(3H), 2.16-2.18(3H),2.20-2.22(3H), 3.84-3.90(6H),4.32-4.36 (1H), 4.81 - 4.86 (2H), 6.46 - 6.48 (1H), 6.71 - 6.73 (1H), 6.85 - 6.90 (2H), 6.97 - 6.98 (1H), 7.01 - 7.02 (1H), 7.39-7.41 (IH), 7.50 - 7.51 (1H) Example 92 1-[4-([2-[(1S)-1-(2.3-Dimethylphenyl)ethyl)-1H-imidazol-1-yl]methyl)phenyl]-1 H-pyrazole 1H-NMR (d6-Acetone): 1.52 -1.55 (3H), 2.20 - 2.24 (6H), 4.36 - 4.40 (1H), 4.78 - 4.82 (1H), 4.96 - 5.00 (1H), 6.44 - 6.46 (1H), 6.70 - 6.72 (1H), 6.90 - 7.00 (5H), 7,04 - 7.06 (1H), 7.63 - 7.69 (3H), 8.21 - 8.23 (1H) Example 93 2-[(1S)-1-(2.3-Dimethylphenyl)ethyl)-1-(4-fluorobenzyl)-1H-imidazol 1H-NMR (d6-Acetone): 1.53 -1.56 (3H), 2.19 - 2.24 (6H), 4.32 - 4.36 (1H), 4.71 - 4,75 (1H), 4.90 - 4.94 (1H), 6.65 - 6.67 (1H), 6.89 - 6.95 (3H), 6.95 - 7.00 (4H), 7.00 - 7.01 (1H) Example 94 1-(3,4-Difluorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol 1H-NMR (d6-Acetone): 1.55-1.58 (3H), 220-223 (6H), 4.36 - 4,40 (1H), 4.80 - 4.84 (1H), 4.97 - 5.01 (1H}, 6.62 - 6.70 (3H), 6.82 - 6.90 (2H), &96 - 6.98 (1H), 7.04 - 7.05 (1H), 7.06 - 7.10 (1H) Example 95 2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1-(2-fluorobenzyl)-1 H-imidazol 'H-NMR (drAcetone): 1.56 -1.59 (3H), 2.20 - 2.24 (6H), 4.38 - 4.42 (1H), 4.80 - 4.90 (2H), 6.60 - 6.63 {1H), 6.64 - 6.66 (1H), 6.88 - 6.95 (3H), 7.00 - 7.03 (2H), 7.06 - 7.09 (1H), 7.25 - 7.28 (1H) Example 96 1 -[3-(Difluoromethoxy)benzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.19 - 2.23 (6H), 4.32 - 4.38 (1H), 4.79- 4.83 (1H),4.97-5.01 (1H), 6.61 - 6.63 (1H), 6.70 - 6.79 (2H), 6.81 - 6.82 (1H), 6.83 - 6.99 (2H), 7.00- 7.05 (2H), 7.25 - 7.30 (1H) Example 97 1-(2.3-Dmuorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyll-1 H-imidazol 1H-NMR (d6-Acetone): 1.56 -1.59 (3H), 2.20 - 2.24 (6H), 4.39 - 4.43 (1H), 4.89 - 4.93 (1H), 5.00 - 5.04 (1H), 6.39-6.41 (1H), 6.61 - 6.63 (1H), 6.81 - 6.90 (2H), 6.95 - 7.00 (2H). 7.06 - 7.07 (1H), 7.14-7.19 (1H) Example 98 2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1-(3-fluorobenzyl)-1 H-imidazoll 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.19 - 2.23 (6H), 4.32 - 4.36 (1H), 4.76 - 4.80 (1H), 4.96 - 5.00 (1H), 6.53 - 6.55 (1H), 6.70 - 6.75 (2H), 6.89 - 6.99 (4H), 7.02 - 7.04 (1H), 7.22 - 7.25 (1H) Example 99 1 -(2,4-Difluorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.56 -1.59 (3H), 250 - 224 (6H), 4.39 - 4.43 (1H), 4.81 - 4.91 (2H), 6.60 - 6.65 (2H), 6.77 - 6.80 (1H), 6.83 - 6.86 (1H), 6.89 - 6.99 (3H), 7.01 - 7.03 (1H) Example 100 1-(3,5-Difluorobenzyl-2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.56 - 1.59 (3H), 2.19 - 2.23 (6H), 4.36 - 4.40 (1H), 4.81 - 4.85 (1H), 5,00 - 5.04 (1H), 6.40 - 6.44 (2H), 6.69 - 6.71 (1H), 6.78 - 6.82 (f H), 6.83 - 6.90 (2H), 6.98 - 6.99 (1H), 7.09 -7.10 (1H) Example 101 1-(2.6-Difluorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.26 - 2.28 (3H), 2.37 - 2.39 (3H), 4.60 - 4.64 (1H), 4.72 - 4.77 (1H), 5.05 - 5.10 (1H), 6.57 - 6.59 (1H), 6.85 - 6.84 (3H), 6.97 - 7.05 (3H), 7.39 - 7.43 (1H) Example 102 1-(2-Chloro-4-fluorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H- imidazol 1 H-NMR (d6-Acetone): 1.56 -1 .59 (3H), 2.16 - 2.20 (6H), 4.32 - 4.37 (1 H), 4.81 - 4.85 (1H), 4.96 - 5.00 (1H):, 659 - 6.32 (1H), 6.69 - 6.71 (1H), &82 - 6.88 (3H), &99 - 7.03 (2H), 7.20 - 7.22 (W) Example 103 1-(2.5-Difluorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.57 - 1.60 (3H), 2.19 - 2.24 (6H), 4.40 - 4.44 (1H), 4.87 - 4.91 (1H), 4.96 - 5.00 (1H), 6.16 - 6.20 (1H), 6.67 - 6.70 (1H), 6.82 - 6.88 (2H), 6.96 - 7.00 (2H), 7.06 - 7.09 (2H) Example 104 1-[4-Chloro-2-fluorobenzyl)-2-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.56 - 1.59 (3H), 2.19 - 2.23 (6H), 4.39 - 4.44 (1H), 4.82 - 4.86 (1H), 4.96 - 5.00 (1H)„ 6.49 -6.53 (1H), 6.65 - 6.68 (1H), 6.80 - 6.90 (2H), 6.96 - 6.99 (2H), 7.07 - 7.08 (1H), 7.16 - 7.19 (1H) Example 105 2-[(1S)- 1,2,3-Dimethylphenylethyl)-1-(2,3,6-trifluorobenzyl-1 H-imidazol 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.21 - 253 (3H), 2.36 - 2.38 (3H), 4.57 - 4.61 (1 H), 4.85- 4.89 (1H), 4.97 - 5.01 (1H), 6.47 - 6.50 (1H), 6.81 - 6.89 (2H), 6.90 - 7.01 (3H), 753 - 7.28 (1H) Example 106 2-[(1S)- 1,2,3-Dimethylphenylethyl)-1-(2,3,6-trifluorobenzyl-1 H-imidazol 1H-NMR (d6-Acetone); 1.57 -1.60 (3H), 2.18 - 2.20 (3H), 2.21 - 253 (3H), 4.40 - 4.45 (1H), 4.90 - 4.94 (1H), 4.95 - 5.01 (1H), 6.27 - 6.32 (1H), 6.61 - 6.63 (1H), 6.80 - 6.88 (2H), 6.99-7.00 (1H), 7.10 - 7.11 (1H),7.11-7.15(1H) Example 107 2-[(1S)- 1,2,3-Dimethylphenylethyl)-1-(4-methylbenzyl-1 H-imidazol 1H-NMR (d6-Acetone): 1.51 -1.55 (3H), 2.20 - 2.22 (3H), 2.22 - 2.26 (6H), 4.30 - 4.36 (1H), 4.61 ■ 4.65 (1H), 4.80 - 4.85 (1H), 6.70 - 6.72 (1H), 6.78 - 6.81 {2H), 6.90 - 6.99 (4H), 7.03 - 7.06 (2H) Example 108 2-[(1S)- 1,2,3-Dimethylphenylethyl)-1-(2,4,6-trifluorobenzyl-1 H-imidazol 1H-NIWR (d6-Acetone): 1.57 -1.60 (3H), 2.21 - 2.23 (3H), 2.30 -2.32 (3H), 4.57 - 4.61 (!H), 4.76 - 4.80 (1H), 4.84 - 4.88 (1H), 6.47 - 6.49 (1H), 6.81 - 6.92 (5H), 6.97 - 6.99 (1H) Example 109 2-[(1S)- 1,2,3-Dimethylphenylethyl)-1-(2-methylbenzyl-1 H-imidazol 1H-NMR (d6-Acetone): 1.55-1.58 (3H), 2.02 - 2.04 (3H), 2.10-2.12 (3H), 251 - 2.23 (3H), 4.21 - 4.36 (1H), 4.65 - 4.69 (1H), 4.78 - 4.82 (1H), 6.47 - 6.49 (1H), 6.75 - 6.77 (1H), 6.80 - 6.82 (1H), 6.95 - 7.00 (3H), 7.04 - 7.07 (1H), 7.18 - 7.20 (2H) Example 110 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-[4-fluoro-2-[trifluoromethyl)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.07 - 2.09 (3H), 2.15 - 2.17 (3H), 458 - 4.32 (1H)r 5.00 - 5.04 (1H), 5.16 - 5.20 (1H), 6.38 - 6.41 (1H)> 6.78 - 6.80 example 111 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-{2-fluoro-3-methyl)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.57 -1.59 (3H), 2.20 - 2.25 (9H), 4.38 - 4.42 (1H), 4.80 - 4.86 (2H), 6.44 - 6.48 (1H), 6.64-6.66 (1H), 6.87- 6.97 (4H), 7.00- 7.01 (1H), 7.10 - 7.14(1H) Example 112 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-[3-[trifluoromethyl)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.52 -1.56 (3H), 2.18 - 251 (6H), 4.36 - 4.40 (1H), 4,90 - 4.95 (1H), 5,08 - 5.12 (1H), 6.67-6.70 (1H), 6.81 - 6.90 (2H), 6.98 - 6.99 (1H), 7.10 - 7.16 (3H), 7.40-7.44 (1H), 7.50 - 7.52 (1H) Example 113 1-(4-Chlorobenzyl)-2-[(1S)- 1-(2,3-dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.51 -1.54(3H), 2.18-2.22 (6H), 4.31 -4.38 (IH), 4.86 -4.91 (IH). 4.95-4.99 (1H), 6.67 - 6.70 (1H), 6.61 - 6.97 (5H), 7.03 - 7.04 {1H), 750 - 753 (1H) Example 114 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-[4-[trifluoromethyl)benzyl]-1H- imidazol 1H-NMR (de-Acetone): 1.52 -1.58 (3H), 2.17 - 250 (8H), 4.31 - 4.39 (1H). 4.90 - 4.96 (1H), 5,07 - 5.12 (1H}, 6.67 - 6.70 (1H), 6.83 - 6.89 (2H), 6.99 - 7.04 (3H), 7.09 - 7.10 (1H), 7.49 - 7.53 (2H) Example 115 1 -(3-Chlorobenzyl-2-[(1S)- 1-(2,3-dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.56 -1.58 (3H), 2.00 - 2.05 (6H), 4.34 - 4.39 (1H), 4.78 - 4,82 (1H), 4.98 - 5.02 (1H), 6.69 - 6.71 (1H), 6.79 - 6.83 (2H), 6.87-6.97 (3H), 7.04 - 7.05 (1H), 7.19 - 7.23 (2H) Example 116 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1 [2-[trifluoromethyl)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.56-1.58 (3H), 2.01 -2.03 (3H), 2.16-2.18 (3H),4.22 - 4.28 (1H), 4.99 - 5.03 (IH), 5.15 - 5.20 (1H), 6.40- 6.42 (1H), 6.78 - 6.80 (1H), 6.89 - 6.92 (2H), 7.01 - 7.04 (2H), 7.40 - 7.44 (2H), 7.70-7.72 (1H) Example 117 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-[3-fluoro-4-[trifluoromethyl)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.54 -1.58 (3H), 2.10 -2.17 (6H), 4.33 - 4.42 (1H), 5.00 - 5.05 (1H), 5.12 - 5.18 (1H), 6.60 - 6.70 (2H), 6.80 - 6.85 (3H), 7.00 - 7.01 (1H), 7.16-7.17 (1H), 7.45 - 7.52 (1H) Example 118 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-[5-fluoro-2-[trifluoromethyl)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.09 - 2.15 (6H), 4.31 - 4.38 (1H), 5.02 - 5.07 (1H), 5.10-5.15 (1H), 5.95 - 5.98 (1H), 6.78 - 6.80 (IH), 6.81 - 6.88 (2H), 7.04 - 7.05 Example 119 1 -(3-Chloro-2-f luorobenzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1,55 -1.58 (3H), 250 -2.23 (6H), 4.39-4.44 (1H), 4.90 - 4.95 (1H), 5.00- 5.05 (1H), 6.50 - 6.54 (1H), 6.61 - 6.63 (1H), 6.80 - 6.90 (2H), 6.95 - 7.00 (2H), 7.09 - 7.10 (IH), 7.30 - 7.35 (1H) Example 120 1-(3,.5-Dimethylbenzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.52 -1,55 (3H), 2.17 - 2.19 (6H), 2.21 - 2.25 (6H), 4.35 - 4.40 (1H), 4.60 - 4.65 (1H), 4.80-4.85 (1H), 6.42 - 6.45 (2H), 6.71 -6.73 (1H), 6.81 - 6.82 (1H), 6.90 - 7.00 (4H) Example 121 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-(2-ethylbenzyl)-1H- imidazol 1H-NMR (d6-Acetone): 0.98 -1.02 (3H), 1.56 -1.59 (3H), 2.16 - 2.17 (3H), 2.21 - 2.22 (3H), 2.30 - 2.38 (2H), 455 - 4,34 (1H), 4.71 -4.77 (IH), 4.80 - 4.85 (1H), 6.57 - 6.59 (1H), 6.73 - 6.80 (2H), 6.94-7.00 (3H), 7.05 - 7.09 (1H), 750 - 7.23 (2H) Example 122 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-(2-trifluoromethoxy)benzyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.55- 1.59 (3H), 2.16-2.22 (6H),4.31 -4.38(1H), 4.82-4.87 (1H)? 4.99-5.02 (1H), 6.58 - 6.60 (1H), 6.67 - 6.70 (1H), 6.84 - 6.91 (2H), 6.97 - 6.99 (1H), 7.01 - 7.02 (1H), 7.16 - 7.20 (1H), 7.30-7.40 (2H) Example 123 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-(3-trifluoromethoxy)benzyl)-1H- imidazol 1 H-NMR (d6-Acetone): 1.56 -1.59 (3H), 2.19- 2.22 (6H), 4.36 - 4.40 (1H), 4.80 - 4.85 (1H), 5.00 - 5.05 (1H), 6.70 - 6,72 (1H), 6,78 - 6.80 (IH), 6,82 - 6.94 (3H), 6.99 - 7.00 (1H), 7.06 - 7.08 (1H), 7.16 - 7.19 (1H), 7.35-7.38 (1H) Example 124 4-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol-yl]methylbiphenyl-2-carbonitriIe 1H-NMR (d6-Acetone): 1.57 - 1.60 (3H), 2.20 - 2.21 (6H), 4.38 - 4.42 (1H), 4.81 - 4.85 (1H)r 5.00 - 5.05 (1H), 6.76 - 6.78 (1H), 6.90 - 7.02 (5H), 7.07 - 7.08 (1H), 7.42 - 7.45 (2H), 7.58-7.61 (2H), 7.78 - 7.80 (1H), 7.82-7,84 (1H) Example 125 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-(4-iodobenzyl)-1H- imidazol 1H-NMR (d6- Acetone): 1.50 -1.53 (3H),1.97 -1.99 (3H), 2.00 - 2.02 (3H), 4.30 - 4.35 (1H), 4.75 - 480 (1H), 4.96 - 5.00 (1H), 6.61 - 6.64 , 6.86 - 6.95 (3H), 7.01 - 7.02 (1H), 7.58 - 7.60 (2H) Example 126 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-(4-[(trifluoromeyl)thio]benzyl]-1H- imidazol 1H-NMR (d6-Acetona): 1.53 -1.56 (3H), 2.17 - 2.20 (6H), 4.31 - 4.38 (1H), 4.83 - 4.88 (1H), 5.03 - 5.08 (1H), 6.67 - 6.69 (1H), 6.82 -6.88 (2H), 6.95 - 7.00 (3H), 7.07 - 7.08 (1H), 7.50 - 7.54 (2H) Example 127 2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1-[3-(4-fluorophenoxy)benzyl]-1H- imidazol 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.19 - 2.23 (6H), 4.33 - 4.38 (1H), 4.67 - 4.71 (1H), 4.89 - 4.93 (1H), 6.50 - 6.52 (1H), 6.64 - 6.68 (2H), 6.80 - 6.82 (1H), 6.86 - 7.00 (6H), 7.14 - 7.19 (2H), 7.22 - 7.25 (1H) Example 128 1-(4-tert-butyl(benzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.13 -1.15 (9H), 1.51 -1.53 (3H), 2.20 - 2.26 (6H), 4.36 - 4.40 (1H), 4.66 - 4.70 (1H), 4.82 - 4.87 (1H), 6.70 - 6.73 (1H), 6.80 - 6.82 (2H). 6.90 - 7.00 (4H), 7.25 - 723(2H) Example 129 1-(2,,5-Dichlorobenzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.55 -1.59 (3H), 2.11- 2.20 (6H), 4.37 - 4.41 (1H), 4.89 - 4.93 (1H), 5.02 - 5.06 (1H), 6.19 - 6.21 (1H), 6.76 - 6.79 (1H), 6.80 - 6.82 (1H), 6.82 - 6.84 (1H), 7.00 - 7.01 (1H), 7.09 - 7.10 (1H), 7.19 - 722 (1H), 7.37 - 7.39 (1H) Example 130 1-[2-Chloro-5-(trifluoromethylbenzyl]-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone}: 1.56 - 1.60 (3H), 2.10 - 2.12 (3H), 2.18 - 2.20 (3H), 4.39 - 4.44 (1H), 4.99 - 5.05 (1H), 5.12 - 5.18 (1H), 6.57 - 6.59 (1H), 6.71 - 6.80 (3H), 7.01 - 7.03 (1H), 7.10-7.12 (1H), 7.50-7.53 (1H), 7.58-7.60 (1H) Example 131 1 -(5-Chloro-2-methylbenzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.56-1.60 (3H)t 2.02 - 2.04 (3H), 2.10 - 2.12 (3H), 2.20 - 2.21 (3H), 4.24 - 4.28 (1H), 4.71 - 4.78 (1H), 4.88 - 4.93 (1H), 6.32 - 6.34 (1H), 6.78 - 6.80 (1H), 6.90 - 7.00 (4H), 7.13-7.17 (1H) Example 132 2-[(1S)- 1-(2,3-Dimethylphenylethyl)1-(-naphthylmethyl)--1H- imidazol 1H-NMR (d6-Acetone): 1J51 -1.54 (3H), 2.17 - 2.21 (6H), 4.38 - 4.41 (1H), 4.87 - 4.91 (1H). 5.10 - 5.14 (1H), 6.74-6.78 (1H), 6.90-6.93 (2H), 6.98 - 6.99 (1H), 7.01 - 7.08(2H), 758 -7.29 Example 133 1-(3.4-Dichlorobenzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.62 -1.55 (3H), 2.19 - 222 (6H), 4.35 -4.40 (1H), 4.85 - 4.90 (1H), 5.00 - 5.06 (1H), 4.98 - 5.00 (2H), 6.63 - 6.66 (1H), 6.78 - 6.80 (1H), 6.81 - 6.87 (3H), 6.99 - 7.00 (1H), 7.10 - 7.11 (1H), 7.30-7.33 (1H) Example 134 1 -(2.6-Dichlorobenzyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.60 -1.63 (3H), 2.30 - 2.32 (3H), 2.40 - 2.42 (3H), 4.66 - 4.72 (2H), 5.05 - 5.09 {1H). 6.41 - 6.43 (1H), 6.67 - 6.70 (1H), 6.81 - 6.82 (1 H)t 6.96 - 7.01 (2H), 7.40 - 7.46 (3H) Example 135 1-(Biphenyl-4-ylmethyl)-2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol 1H-NMR (d6-Acetone): 1.54 -1.56 (3H), 2.20 - 2.22 (6H), 4.36 - 4.40 (1H), 4.80 - 4.84 (1H), 4.97 - 5.00 (1 H)„ 6.71 - 6.73 (1H), 6.93 - 6.99 (4H), 7.06 - 7.07 (1 H), 7.36 - 7.37 (1H), 7.42 - 7.46 (3H), 7.55 - 7.58 (2H), 7.60-7.63 (2H) Example 136 Cvclopropylmethyl {2-[(1S)- 1-(2,3-Dimethylphenylethyl)-1H- imidazol-1-yl)methyl carbonate (Formula Removed) To a mixture of the compound of Example 1 (100 mg, 0.50 mmol) and caesium carbonate (407 mg, 1.25 mmol) in acetone (5 ml) and under nitrogen was added Preparation 119 (205 mg, 155 mmol). The reaction mixture was stirred at room temperature for 60 h and then concentrated In vacuo. To the residue was added water (10 ml) and ethyl acetate (20 ml) and the two layers were separated. The organic phase was then dried (MgSO4) and concentrated in vacuo. The residue was dissolved in acetonitrile (0.8 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x30mm LUNAC18(2) 10 urn column, 40 ml /min) using an acetonitrile: water gradient [55:45 (20 min) to 98:2 (20.1 min)]. The appropriate fractions were combined and concentrated to give the title compound (74 mg). Experimental MH+ 329.4; expected 329.2 1H-NMR (d6-Acetone): 0.20- 0.30 (2H), 0.50 - 0.60 (2H), 1.05 -1.15 (1H), 1.55 -1.60 (3H)r 2.30 - 2.40 (6H), 3.80 - 3.95 (2H), 4.60 - 4,70 (1H), 5.40 - 5.45 (1H), 5.70 - 5.80 (1 H), 6.65 - 6.70 (1 H),6.90 - 6.95 (2H), 6.95 - 7.00 (1H), 7.17-7.20 (1H) Rhip. Funct ED100 mg/cm2= 0.01 Similarly prepared from Example 1 were: (Table Removed) Example 137 {2-[1-(2,3-Dimethylphenylethyl)-1H- imidazol-1-yl]methyl 4-methoxybenzyl carbonate 1H-NMR (d6-Acetone): 1.50 -1.60 (3H), 2.25 - 2.35 (6H), 3.80 - 3.85 (3H), 4.60 - 4.65 (1H), 4.95 - 5.10 (2H), 5.40 - 5.50 (1H), 5.70 - 5.80 (1H), 6.60 - 6.65 (1H), 6.90 - 7.00 (5H), 7.15 - 7.18 {1H), 7.25 - 7.35 (2H) Example 13S {2-[1-(2,3-Dimethylphenylethyl)-1H- imidazolI-1-yl}methyl 2.2.2-trifluoroethyl carbonate 1H-NMR (d6-Acetone): 1.50- 1.60 (3H), 2.20-2.30 (6H), 4.50-4.70 (3H), 5.50-5.56 (1H), 5.80-5.85 (1H), 6.60- 6.64 (1H), 6.85-7.00 (3H), 7.14- 7.18 Example 139 {2-[1-(2,3-Dimethylphenylethyl)-1H- imidazolI-1-yl}methyl3-methylbutyl carbonate 1H-NMR (d6-Acetone): 0.B0 - 0.90 (6H), 1.40 -1.50 (2H), 1.55 -1.60 (3H), 1.60 -1JB5 (1 H)r 2.20 - 2.30 (6H),4.00-4.10 (2H), 4.60-4.65 (1H), 5.40-5.45 (1H), 5.70-5.75(1H), 6.60-a65 (1H). a8S-6.90 (2H), 6.95-7.00 (1H), 7.10-7.15 (1H) Example 140 {2-[1-(2,3-Dimethylphenylethyl)-1H- imidazolI-1-yl}methyl isooropyl carbonate 1H-NMR (d6-Acetone): 1.10- 1.20 (6H), 1.50-1.60 (3H), 2.20-2.30(6H),4.60-4.65(1H), 4,70-4.75 (1 H), 5.38 - 5.42 (1 H), 5.65 - 5.70 (1H), 6.60 - 6.64 (1H), 6.85 - 6.90 (2H), 6.95 - 7.00 (1H), 7.10 - 7.14 (1H) Example 141 Cyclobutyl {2-[1-(2.3-dimethylphenyl)ethyl]-1 H-imidazol-1 -ylmethyl carbonate 1H-NMR (d6-Acetone): 1.50 -1.60 (3H), 1.60 -1.75 (2H), 1.90 - 2.00 (2H), 2.20 - 2.24 (2H), 2.25 - 2.30 (6H), 4.55 - 4.60 (1H), 4.70 - 4.80 (1H), 5.38 - 5.41 (1H), 5.65 - 5.70 (1H), 6.60 - 6.64 (1H), a85 - 6.90 (2H), 6.95 - 7.00 (1H), 7.10 - 7.13 (1H) Example 142 {2-[1-(2,3-Dimethylphenylethyl)-1H- imidazol-1-yl}methyl (2.4-dichlorobenzylcarbamate (Formula Removed) To a mixture of the compound of Example 1 {100 mg, 0.5 mmol) and caesium carbonate (163 mg, 0.5 mmoi) in anhydrous acetone (2 ml) was added dropwise the compound of Preparation 125 (134 mg, 0.5 mmof) in anhydrous acetone (1 ml). The reaction mixture was stirred at room temperature for 4 days and then ethyl acetate (5 ml) and water (5 ml) was added. The two layers were separated and the aqueous layer was extracted with ethyl acetate (2x5 ml). The combined organic layers were dried (MgSO4) and concentrated In vacuo. The residue was dissolved In methanol {1.5 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x30 mm LUNA C18(2) 10 µm column, 40 ml/ min) using an acetonitrile: water gradient 155:45 (20 min) to 95:5 (21 min)]. The appropriate fractions were combined and concentrated to give the title compound (106 mg). Experimental MH+ 432.3; expected 432.1 1H-NMR d6-Acetone): 1.48-1.55 (3H). 2.23 - 2.27 (3H), 2.29-2.33 (3H), 4.22 - 4.30 (2H), 4.60 - 4.65 (1H). 5.38 - 5.41 (1H), 5.59 - 5.62 (1H), 6.60 - 6.63 (1H), 6.8 - 6.95 (3H), 7.08 - 7.10 (1H), 7.20 - 7.26 (1H), 7.41- 7.50 (1H) Rhip. Fund ED100 mg/cm2= 1 Example 143 1-[2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)ethyl methyl [2-(methylsulfonyl)ethyl]carbamate (Formula Removed) To a mixture of the compound of Example 1 (100 mg„ 0.5 mmol) and caesium carbonate (163 mg, 0.5 mmol) in anhydrous acetone (2 ml) was added dropwlse Preparation 133 (230 mg, 0.5 mmol) in anhydrous acetone (1 ml). The reaction mixture was stirred at room temperature for 14 days and ttien dichloromethane (5 ml) and water (5 ml) was added. The two layers ware separated and the aqueous layer was extracted with dichloromethane (2x5 ml). The combined organic layers were dried (MgS04) and concentrated In vacuo. The residue was dissolved in methanol (1.5 ml) and purified by automated preparative liquid chromatography (Gilsort system, 150 mm x 21.4 mm LUNAC18(2}5 µm column, 20 ml/ min) using an acetonitrile: water gradient {20:80 (3 min) to 98:2 (16 min)]. The appropriate fractions were combined and concentrated to give the titte compound (7 mg). Experimental MH+ 408.4; expected 408.2 Rhip. Fund. ED100 mg/cma= 0.3 Similarly prepared from Example 1 were: (Table Removed) 1H-NMR (d6-Acetone): 1.48-1.55 (3H), 2.23 - 2.27 (3H), 2.29- 2.33 (3H), 4.22 - 4.30 (2H), 4.60 - 4.65 (1H). 5.38 - 5.41 (1H), 5.59 - 5.63 {1H), 6.60 - 6.63 (1H), 6.81 - 6.95 (3H), 7.08 - 7.10 (1 Hi), 7.20 - 7.26 (1H), 7.41-7.50 (1H) Rhip. Funct ED100 mg/cma= 1 Example 143 1 -[2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)ethyl methyl [2-(methylsulfonyl)ethyl]carbamate (Formula Removed) To a mixture of the compound of Example 1 (100 mg, 0.5 mmol) and caesium carbonate (163 mg, 0.5 mmol) in anhydrous acetone (2 ml) was added dropwlse Preparation 133 (230 mg, 0.5 mmol) in anhydrous acetone (1 ml). The reaction mixture was stirred at room temperature for 14 days and then dichloromethane (5 ml) and water (5 ml) was added. The two layers were separated and the aqueous layer was extracted with dichloromethane (2x5 ml). The combined organic layers were dried (MgS04) and concentrated In vacuo. The residue was dissolved in methanol (1.5 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm X21.4 mm LUNA G18(2) 5 urn coJumn, 20 ml/min) using an acetonitrile: water gradient [20:80 (3 min) to 982 (16 min)]. The appropriate fractions were combined and concentrated to give the title compound (7 mg). Experimental MH+408.4; expected 408.2 Rhip. Funct. ED100 mg/cma= 0.3 Similarly prepared from Example 1 were: (Table Removed) Example 145 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl thiomorpholine-4-carboxylate 1,1-dioxide 1H-NMR {d6-Acetone): 1.52 - 1.S5 (3H), 2.25 - 2-27 (3H), 2.37 -2.39 (3H), 2.75 - 2.85 (2H), 2.90 - 3.00 (2H), 3.35 - 3.42 (2H)r 3.76 - 3.80 (ZH), 4.61 - 4.65 [i H), 5.68 - 5.69 (2H), 6.62 - 6.64 (1 H), 6.89 - &95 (2H)„ 6.98 - 7.01 (1H), 7.09-7.10 (1H) Example 146 1-[2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl 2-methyl (2S)-pyrrolidine-1.2- dicarboxylate 1H-NMR (d6-Acetone): 1.50 - 1.55 (3H), 1.78 -1.89 (3H), 2.10 - 250 (1H), 2.22 - 2.27 (3H), 2.34 - 2.39 (3H), 3.58 - 3.63 (3H), 4.59 - 4.64 (1H), 6.59 - 6.61 f1 H), 6.82 - 6.90 (3H), 7.01 - 7.06 (1H) Example 147 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl cyclohexylcarbamate 1H-NMR (d6-Acetone): 1.02 -1.50 (3H), 1.20 -1.30 {2H)( 1.51 -1.54 (3H}, 1.54 -1.57 (1H), 1.61 -1.68 (2H), 1.75 -1.82 (2H), 252 - 2.24 (3H), 2.30 - 2.33 (3H), 3.22 - 3.30 (1H), 4.60 - 4.64 (1H), 5.31 - 5,34 (1H), 5.54 - 5.57 (1H), 6.60 - 662 {1H), 6.82 - 6,83 (1H), 8.83 - 6.87 (1H}, 6.95 - 6.98 (1H), 7.03 - 7.04 Example 148 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl [2-(2.4-dichlorophenyl}ethylcarbamate 1H-MMR (d6-Acetone): 1.50 -1.56 (3H), 252 - 2,24 (3H), 2.30 - 2.32 (3H), 2.85 - 2.90 (2H), 3.30 - 3.35 (2H), 4.60 - 4.64 (1H), 5.30 - 5.33 (1H), 5.55 - 5.58 Example 149 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl cyclohexyl(methyl)carbamate 1H-NMR (d6-Acetone): 1.00-1.10 (1H), 1.20 -1.40 Example 150 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl benzyl(methylcarbamate 1H-NMR (d6-Acetone): 1.41 -1.59 (3H), 2.18 - 2.26 (3H), 2.30 - 2.40 (3H), 2.70 - 2.80 (3H), 4.00 - 4.05 (1H), 4.25 - 4.38 (1H), 4.60 - 4.73 (1H), 5.59 - 5.69 (2H), 660 - 6.70 (1H), 6.80 - 7.00 (3H), 7.01 - 7.06 (1H}, 7.10 - 7.19 (2H), 750 - 7.33 (3H) Example 151 [2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl)methyl methyl(2-phenylethyl)carbamate 1H-NMR (dB-Acetone): 1.33 -1.41 (3H), 1.50 -1.56 (3H), 2.17 - 2.20 f1H), 2.20 - 252 {3H), 2.22 - 2.26 (2H), 2.36 - 2.39 (3H}, 2.45 - 2.55 (1H), 4.62 - 4.70 (1H), 5.60 - 5.70 (2H), 6.67 - 6.70 (1H), 6.82 - 6.92 (3H), 7.10 - 7.18 (2H), 7.18 - 7.24 (2H), 7.24 - 7.27 (2H) Example 152 1-(1-[2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazol-1yl) 2-methyl (2S)-pyrrolidine-1.2- dicarboxylate 1H-NMR (CD3OD): 1.10-1.13 (3H), 1.56 -1.60 (3H), 1.85 -1.90 (3H), 2.20 - 2.24 (1H), 2-30 - 2.32 (3H), 2.39 - 2.41 (3H), 3.40 - 3.50 (2H), 3.60 - 3.63 (1H), 3.70 - 3.75 (2H), 4.29 - 4.33 (1H), 4.79 - 4.83 (1H), 6.10 - 6.13 (1H), 6.37 - 6.40 (1H), 6.90 - 9.93 (1H), 7.00 - 7.03 (1H), 7.20 - 7.23 (1H) Example 153 2-[(1S)-1 -(2.3-Dimethylphenylethyl-1-methyl-1H-imidazole (Formula Removed) To a mixture of the compound of Example 58 (100 ma. 0.5 mmol) and caesium carbonate (407 mg, 125 mmol) in acetone (4 ml) was added iodomelhane (78 µl, 125 mmol). The reaction mixture was stirred at room temperature, under nitrogen, for 4 h and then concentrated fn vacuo, to the residue was added water (10 ml) and the solution was extracted with ethyl acetate (2x10 ml). The oombrrted extracts were dried (MgS04) and concentrated in vacua The residue was dissolved In methanol (1 ml) and purified by automated preparative Iquld chromatography (Gilson system, 150 mm x 21.4 mm LUNA C18(2) 5 urn column, 20 ml /mil] using an acetonitrile: water gradient [20:80 (3 min) to 98:2 (16 min)]. The appropriate fractions were combined and concentrated to give the title compound (40 mg). Experimental MH+ 215.3; expected 215.1 1H-NMR (d6-Acetone): 1.45-1.50 (3H), 2-20-2.30 (6H), 3.10-3.15 (3H), 4.35-4.45 (1H), 6,55 - 6.60 (1H), 6.80 - 6.85 (1H), 6.85 - 6.90 (2H), 6.90 - 6.95 (1H) Rhip. Funct. ED100 mg/cm2 = 0.3 Similarly prepared from Example 1 was: (Table Removed) Example 154 1-(Cyclopropylmethyl)-[2-[1-(2.3-Dimethylphenyl)ethyl]-1H-imidazole 1H-NMR (d6-Acetone)r 0.00 - 0.05 (1H), 0.10 - 0.20 (1H), 0.30 - 0.45 (2H), 0.80 - 0.90 (1H). 1.50 -1.60 (3H), 2.20-2.30 (6H), 3.30-3.50 (2H), 4.40-4.50 (1H), 6.60- 6.65 {1H), 6.80-6.90 (2H), 6.90-6.95 (1H),7.05-7.10 (1H) Similarly prepared from Example 58 was : (Table Removed) Example 155 2-[(1S)-1-(2.3-Dimethylphenyl)ethyl]-1H-imidazole 1H-NMR (d6-Acetone): 0.90 -1.00 (3H), 1.50-1.60 (3H), 2.20-2.35 (6H), 3.50-3.70 (2H), 4.40-4.50 (1H), 6.60-6.63 (1H), 6.80-6.90 (2H), 6.90-7.00 (2H) Example 156 {2-[1-(2,5-Dimethylphenyl)ethyl-1 H-imidazol-1-yl}methyl pivalate (Formula Removed) To a mixture of the compound of Example 17 (58 mg, 0.29 mmol) and caesium carbonate (236 mg, 0.72 mmol) in acetone (5 ml) was added chloromethyl pivalate (87 mg, 0.58 mmol). The reaction mixlure was stirred at room temperature and under nitrogen for 18 h and then concentrated in vacuo. To the residue was added diethyl ether and the solution was passed through a silica plug (10 g), eluting with diethyl ether. The appropriate fractions were combined and concentrated to give tie title compound (78 mg). 1H-NMR (CDCI3): 1.01 -1.05 (9H), 1.61 -1.65(3H), 2.13 - 2.16 (3H), 2.35- 2.37(3H), 4,38-4.44 (1H), 5.34 - 5.38 (1H), 5.47 - 5.51 {1H), 6.65 - 6.67 Experimental MH4 315.4; expected 315.2 Rhip. Fund ED100 mg/cm2 Similarly prepared by alkylatlon with chloromethyl pivafate were: (Table Removed) Example 157 [2-[1-(3-Methoxy-2-methylphenylethyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CDCI3): 1.01 -1.05 (9H), 1.61 -1.65 (3H), 2.23 - 2.25 (3H), &?9 - 3.81 (3H), 4.45 - 4.55 Example 158 (2-{1 -[2-(Trifluoromethyl)phen yl]ethyl]-1H-imidazol-1-yl]methyl pivalate 1 H-NMR (CDCI3): 0.93 - 0.96 (9H), 1.69 -1.73 (3H), 4.61 - 4.68 (1H), 5.51 - 5.60 (2Hfc 6.98 - 7.01 (2H), 7.24 - 7.31 (2H), 7.37 - 7.42 (1H), 7.61 - 7.64 {1H) Example 159 (2-{1-[3-(Trifluoromethyl)phen yl]ethyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CDCI3): 0.96 - 0.99 (9H), 1.68 -1.72 (3H), 4.30 - 4.36 (1H), 5.52 - 5.56 (1H), 5.65 - 5.69 (1H), 6.98 - 7.01 (2H), 7.36 - 7.38 (2H), 7.42 • 7.45 (2H) Example 160 {2-[1-(3-Methylphenyl)ethyl-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CDCI3): 1.02 -1.05 (9H), 1.68-1.71 (3H), 2.25 -2.27 (3H), 4.19-4.25 (1Hfc 5.51 - 5.62 (2H>, 6.93 - 7.01 (4H), 7.11 - 7.16 (1H) Example 161 [2.[1-(2.6-Dimethylphenyl)ethyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CDCl3): 1.03 -1.06 (9H). 1-72 - 1-76 (3H), 2.00' -2.10 (6H), 4.54 - 4.60 (1H)r 5.13 - 5.17 (1H>, 5.32 - 5.36 (1H), 6.92 - 7.02 (5H) Example 162 {2-[1-(3-Chlorophenyl)athyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CDCI3): 1.00 -1.03 (9H), 1.66 -1.70 (3H), 4.20 - 457 {1H), 551 - 5.66 {2H), 6.97 - 7.01 Example 164 {2-[1 -(2-Ethyl-3-methylphenyl]ethyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CD3OD): 0.98 -1.00 (9H), 1.20 -1.24 (3H). 1.60 -1.63 (3H)r 2.37 - 2.36 (3H), 2.80 - 2.B6 (2H). 4.60 - 4.65 (1H), 5.53 - 5.56 (1H), 5.66 - 5.70 (1H), 6.61 - 6.63 (1H), 6.90-6.95 (2H), 6.99 - 7.01 (1H), 7.18-7.19 (1H) Example 166 (2-{1-[2-Chloro-3-(trifluoromethyl)phenyl]ethyl]-1H-imidazol-1-yl]methyl pivalate 1H-NMR (CDCl3): 0.96 - 0.99 (9H), 1.69-1.72 (3H), 4.94 - 5.01 (1H), 5.60 - 5.64 (1H)r 5.72 - 5.76 (1B), 7.03 - 7.05 (2H), 756 - 7.30 (1H), 7.40 - 7.43 (1H). 7.55 - 7.59 (1H) Example 167 Experimental MH+ 198.1; expected 198.1 1H-NMR (CDCl3): 1.63-1.72 (3H), 4.22 - 4.26 (1H), 6.97 - 7.00 (2H), 7,40 - 7.43 {1H), 7.50 • 7.55 (3H) Rhip. Funct. ED100mg/cmz= >1 Example 169 1-Benzyl-2-[1-(3-methylphenyl]ethyl]-1H-imidazole (Formula Removed) To a mixture of the compound of Exampie 20 (500 mg, 2.68 mmo!) and caesium carbonate (2.19 g, 6.71 mmol) in acetone (20 mI) was added benzyl bromide (0.64 ml 5.37 mmol). The reaction mixture was stirred at room temperature for 18 h, filtered through Celite® and then concentrated in vacuo. The residue was dissolved in acetonitrile (2 ml) and purified by automated preparative liquid . chromatography (Gilson system, 150 mm x 50 mm LUNA C18(2) 10 µm column, 40 ml / min) using an-acetonitrile: water gradient [50:50 (20 mln) to 95:5 (21 min)]. The appropriate fractions were combined and concentrated to give the title compound (272 mg). Experimental MH+ 277.4; expected 277.2 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.11 - 2.12 (3H), 4.08 - 4.13 (1H), 4.90 - 4.95 (1H). 5.01 - 5.06 (1H), 6.90-6.91 (1H), 6.91 - 7.00 (6H), 7.10-7.14 (1H), 7.21 - 7.25 (3H) Rhip. Funct ED100 mg/cm2= >1 Example 170 1-Methyl-2-[1-(3-methylphenyl)ethyH-1H-imidazole (Formula Removed) To a mixture of the compound of Example 20 (500 mg, 2.68 mmol) and caesium carbonate (2.19 g, 6.71 mmol) in acetone (20 ml) was added methyl iodide (0.33 ml, 5.37 mmol). The reaction mixture was stirred at room temperature for 2 h, filtered through Celite® and then concentrated in vacuo. The residue was dissolved in acetonitrile (2 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 50 mm LUNA C18(2) 10 µm column, 40 ml /min) using an acetonitrile: water gradient [50:50 (20 min) to 95:5 (21 min)]. The appropriate fractions were combined and concentrated to give the title compound (230 mg). Experimental MH+ 201.4; expected 201.1 1H-NMR (d6-Acetone): 1.59 -1.62 (3H), 2.12 - 2.14 (3H), 4.17 - 4.21 (1H)r 6.80 - 6.81 (1H), 6.89 - 6.90 {1H), 6.96 - 7.02 (3H), 7.14 - 7.17 (1H) Rhip. Funct ED100 mg/cm2= >1 Example 171 1-[2-[1-(2,3-Dimethylphenyl)ethyl-1H-imidazol-1-yl}ethyl morpholine-4-carboxylate (Formula Removed) To a mixture of the compound of Example 1 (100 mg, 0.5 mmol) and caesium carbonate {163 mg. 0.5 mmoi) in anhydrous acetone (2 mi) was added Preparation 134 (96 mg, 0.50 mmol) in anhydrous acetone (1 ml). The reaction mixture was stirred at room temperature for 14 days and then diluted with water (5 ml) and ethyl acetate (5 mi). The two layers were separated and the aqueous phase was extracted with ethyl acetate (2x6 ml). The combined organic phases were dried (MgS04) and concentrated in vacuo. The residue was dissolved in acstonitrite (1.5 ml) and purified by .automated preparative liquid chromatography (Giisonsystem, 150mm x21.4 mm LUNAC18(2)5µm column, 20 ml/mln)using an acetonJtrile: water gradient [20:80 (3 mln) to 985 (16 min)]. The appropriate fractions were combined and concentrated to give the title compound {6 mg). Retention time 6.13 min (Gilson system, 150 mm x 46 mm LUNA C18(2) 5 µm column, 15 ml/ min) using a 0.1% trifluoroacetic acid: acetonitrile gradient [95:5 (5 min) to 2:98 (9 min)]. Experimental MH* 358.5; expected 358.2 1H-NMR (CD3OD): 1.55 -1.60 (3H), 1.62 -1.65 (3H), 2.27 - 2.30 (3H), 2.30 - 2.33 (3H), 2.90 - 3.00 (2H), 3.39 - 3.49 (2H), 4.61 - 4.65 (1H), 6.50 - 6.56 (2H), 6.85 - 6.89 (1H), 6.99 - 7.03 (1H), 7.17 - 7.18 (1H) Rhip. Funct. ED100 mg/cm2= 1 Example 172 {2-[(1S)-1-(2.3-Dimethylphenyllethyl-1H-imidazol-1-yl]methyl pivalate (Formula Removed) To a mixture of the compound of Example 58 (500 mg, 2.5 mmoi) and caesium carbonate {1.79 g, 5.5 mmof) in anhydrous acetone (10 ml) was added chtoromethyl pivalate (0.43 ml, 3.0 mmoi). The reaction m ixture was stirred at room tem perature for 18 h. To the mixture was added dichioromethane (10 ml) and water (10 ml) and the two layers were separated. The aqueous phase was extracted with dichloromelhane (2 x 10ml) and the the combined organic phases were dried (MgSO4) and concentrated in vacuo. The residue was dissolved in acetonitrle (2 ml) and purified by automated preparative liquid chromatography (Gilsort system, 250 mm x 50 mm LUNA C18(2) 10 urn column, 120 ml/min) using an acetonitrile: water gradient [55:45 (£0 min) to 95:5 (20.5 min)l. The appropriate fractions were combined and concentrated to give the title compound (410 mg). Experimental MH+ 315.2; expected 315.2 1H-NMR {d6-Acetone): 0.07 - 1.00 (9H), 1.57-1.60 (3H), 2.28 - 2.30 (3H), 2.37 - 2.39 (3H), 460 - 4.65 (1H),5.56-5.60 (1H), 5.65-5.69(1H), 6.75 -6.78 (1H), 6.90-7.00(3H), 7.12- 7.13 (1H) Example 173 (Formula Removed) To a mixture of the preparation of Example 58 (50 mg, 0.25 mmol) and caesium carbonate (203 mg, 0.62 mmol) in acetonitrife (2.5 ml) was added l.l.l-trffluoro-3-lodopropane (73 µl, 0.62 mmol). The reaction mixture was heated at 100°C in a microwave(200vV) for 45 mln and then concentrated in vacua Tothe residue was added water (10 ml) and the mixture was extracted with ethyl acetate (2 x 10 ml). The combined extracts were dried (MgS04) and concentrated in vacuo, The residue was dissolved In acetonitrils (1 ml) and diethylamine (2-3 drops) and purified by automated preparative Bquid chromatography (Grlson system, 150 m m x 30 mm LUNA C18(2) 10 µm column, 40 ml / min) using an acetonitrile: water gradient [50:50 (20 mm) to 98:2 (20.1 mln)]. The appropriate fractions were combined and concentrated to give the title compound (20 mg). Experimental MH+ 297.3; expected 297.2 1H-NMR (d6-Acetone): 1.55 -1.60 (3H), 1.79 -1.90 (1H), 2.23 - 2.25 (3H), 2.43 - 2.62 (4H), 3.81 - 3.89 (2H), 4.46 - 4.53 (1H), 6.58 - 6.61 (1H), 6.85 - 6.92 (2H), 6.96 - 6.99 (1H), 7.06 - 7.08 (1H) Rhip. Funct. ED100 mg/cm2 Similarly prepared from Example 58 was: (Table Removed) Example 174 2- [( 1 S)-1-(2.3-Dimethylphenyl)eth yl]-1-isopropyl-1 H-imidazole 1H-NMR (d6-Acetone): 0.80 - 0.83 (SH). 1.29-1.32 (3H), 1.57 -1.59 (3H), 2.25 - 2.27 (3H), 2.30 - 2.32 (3H), 4.00 - 4.06 (1H), 4.41 - 4.45 (1H), 6.58 - 6.60 (1H), 6.85 - 6.88 (2H), 6.95 - 6.97 (1H), 7.06 - 7.07 (1H) Example 175 2- [( 1 S)-1-(2.3-Dimethylphenyl)eth yl]-1-[4-methoxypenzyl)-1H-imid azole (Formula Removed) To a solution of the compound of EKample 1 (100 mg, 0.5 mmol) andN,N-dlisopropytethylaniine (77 mgt 0.6 mmol) In dichloromethane, under nitrogen, was added 4-methoxybenzvl bromide (151 mg, 0.75 mmol). The reaction mixture was stirred at room temperature for 90 min and water (10 ml) was added. The layers were separated, and the aqueous layer washed With dichloromethane (15 ml). The combined orgaru'cs were dried (MgS04) and concentrated In vacuo. The residue was dissolved in methanol: water (9:1,3 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 4.6 mm LUNA C18(2) 10pm column, 20 ml /min) using an acetonitrile: water gradient [60:40 to 95:5]. The appropriate fractions were concentrated in vacuo to give the title compound (10 mg). Experimental MH+ 321.5; expected 321.2 1H-NMR (d6-Acetone): 1.48 -1.53 (3H), 2.16 - 2.21 (3H), 2.21 - 2.24 (3H), 3.70 - 3.75 (3H), 4.31 - 4.36 {1H), 4.58 - 4.64 (1H), 4.74 - 4.81 (1H), 6.62 - 6.69 (1H), 6.72 - 6.82 (4H), 6.35 - 6.98 (4H) Rhip. Funct. ED100mo/cm2=0.3 Similarly prepared from Example 1 were: (Table Removed) Example 176 2- [( 1 S)-1-(2.3-Dimethylphenyl)eth yl]-1-[4-{trifluoromethyl)benzyl]-1H-imidiazole 1H-NMR (d6-Acetone}: 1.51 - 1.58 (3H), 2.12- 2.21 (6H), 4.32-4.40 (1H), 4.91 - 4.99 (1H), 5.08-5.16 (1H). 6.68-6.78 (1H), 6.84-6.92 (2H). 6.96-7.06 (3H), 7,07 - 7.12 (1H), 7.48-7.56 (2H) Example 177 2-[1-(2.3-Dimethylphenyl)eth yl]-1-(rmethoxymethyl)-1 H-imidazol 1H-NMR (d6-Acetone): 1.64 -1.60 (3H), 2.28-2.32 (3H), 2.33 -2.37 (3H), 3.04 -3.09 (3H), 4.54-4.61 (1 H)„ 4.82-4.90 (1H), 4.92-4.99(1H),6.72-6.78(1H), 6.88-7.00(3H),7.08-7.12 (1H) Example 178 2- [1-(2.3-Dimethylphenyl)eth yl]-1-(2-methoxybenzyl]-1H-imidazole (Formula Removed) 1 -(Bromomemyf)-2-metroxybenzene (J. Indian Chem. Soc.,- 28,1951,277; 150 mg, 0.75 mmot) was added to a suspension of the compound of Example 1 (100 mg, 0.5 mmof) and caesium carbonate (406 mg, 12 mmof) in acetone (4 mJ), under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 18 h. The mixture was filtered and the ffltrate was concentrated in vacua To the residue was added water (10 ml) and ethyl acelate (10 ml) and the two layers were separated. The aqueous layer was washed with a further portion of ethyl acetate (10 ml) and the combined organic layers were dried (WlgS04) and concentrated In vacuo. The residue was dissolved in methanol: water (9:1,2 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 30 mm LUNA C18(2) I0µm column, 40 ml/mln) using an acetonitrile: water gradient [20:80 to 98:2]. The appropriate fractions were concentrated in vacuo to give the title compound (24 mg). Experimental MH+ 321.5; expected 321.2 1H-NMR (d6-Acetone): 1.48 -1.53 (3H), 2.14-2.19 (3H), 2.20 - 2.26 (3H), 3.78-3.82 (3H), 4.32 - 4.40 (1H), 4.64 - 4.78 (2H), 6.49 - 6.54 (1H), 6.68 - 6.72 (1H), 6.73 - 6.80 (1H), 6.86 - 6.98 (5H), 7.19 - 7.24 (1H) Rhip. Funct. ED100 mg/cm8 Example 179 1-Benzyl-2-[1-(2-fluoro-3-methylphenyl)ethyl]-1H-imidazole (Formula Removed) To a solution of the compound of Example 7 (69 mg, 0.34 mmol) and triethylam Ine (57 uJ, 0.41 mmol) in anhydrous tetrahydrofuran (3 ml), under nitrogen, was added benzyl bromide (B1µl, 0.68 mmol). The reaction mixture was stirred at room temperature for 11 days and then concentrated in vacua To the residue was added saturated aqueous sodium hydrogen carbonate solution (10 ml) and Ihe mixture was extracted with ethyl acetate (2x10 ml). The combined extracts were dried (MgSO4), filtered through silica and the filtrate was concentrated in vacuo to give the title compound (56 mg). Experimental MH+295.2; expected 296.2 1H-NMR (d6-Acetone): 1.56 - 1.60 (3H). 2.19 - 2.22 (3H), 4.43 - 4.50 (1H), 4.95 - 5.00 (1H), 5.04 - 5.10 {1H), 6.90- 6.99 (5H), 7.00 - 7.04 (2H), 7.10 - 7.17 (3H) Rhip. Fund. ED100 mg/cm2 = 1 Example 180 4-Fluorophenyl 2-[1-(2,3-dimethylphenyl)ethyll-1 H-imidazol-1-carboxvlate (Formula Removed) To a solution of the compound of Example 1 (100 mg, 0.5 mmol) in anhydrous tetrahydrofuran (2 ml) was added irlethylamlne (0.08 ml, 0.6 mmol), followed by 4-fluorophenyl chloToformate {0.28 ml, 2.0 rnmol). The reaction mixture was then stirred at room temperature, under nitrogen, for 1 h. To the mixture was added ethyl acetate (10 ml) and water (10 ml) and the two iayers were separated. The aqueous layer was washed with ethyl acetate (10 ml) and the combined organic phases were dried (MgSO4) and concentrated in vacua The residue was dissolved in acetonitrile (1 ml) and purified fay automated preparative liquid chromatography (Gilson system, 150 mm x30 mm LUNA C18{2) 10 µm column, 40 ml / min) using an acetonitrile: water gradient [55:45 (20 min) to 98:2 (20.1 min}]. The appropriate fractions were concentrated in vacuo to give the title compound (60 mg). Experimental MH+339.3; expected 339.1 1H-NMR (d6-Acetone): 1.50 -1.60 (3H), 2.15 - 2.25 (6H), 4.40 - 4.50 (1H), 6.80 - 6.85 (1H), 6.90 - 7.00 (3H), 7.00-7.05 (1H), 7.15 - 7.25 (2H), 7.35 - 7.40 (1H) Rhip. Funct. ED100 mg/cm2= 0.03 Example 181 Benzyl 2-[(1S)-1-(2.3-dimethylphenyl)ethyl-1H--imidazole-1-carboxylate (Formula Removed) To a solution of the compound of Example 58 (7.50 g, 37.4 mmol) and triethyiamine (5.74 ml, 41.2 mmol) in dichloromethane (100 ml), cooled in an ice bath, was added dropwise benzyf chforoformate (21.4 ml, 150 mmol). The reaction mixture was afkiwed to warm to room temperature and stirred under nitrogen for 3 h. The mixture was cooled, before addition of aqueous sodium hydrogen carbonate solution and dichloromethane and tiie two layers were separated. The aqueous phase was extracted with dichloromethane and the combined organic phases were dried (MgSO4) and concentrated in vacuo. To the residue was added cyclohexane and the solution was filtered and concentrated in vacuo. The residue was purified by flash chromatography (silica) with gradient edition, ethyl acetate: cyclohexane [10:90 to 100:0]. The appropriate fractions were combined and concentrated to give the titie compound (9.98 g). Experimental MH+ 335.2; expected 335.2 1H-NMR (d6-Acetone): 1.50-1.53 (3H), 2.22 - 2.29 (6H), 5.05 - 5.10 (1H), 5.23 - 5.25 (2H), 6.50 - 6.52 (1H), 6.83 - 6.87 (1H), 6.97 - 7.00 (2H), 7.28 - 7.31 (2H), 7.35 - 7.38 (3H), 7.50 - 7.51 (1H) Rhip. Fund. ED100 mg/cm2= >0.03 Similarly prepared from Example 1 was: (Table Removed) Example 182 Isopropyl 2-[1-[2.3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.10 -1.20 (6H), 1.45 -1.55 (3H), 2.20 - 2.35 (6H), 4.90 - 5.00 (1H), 5.00 - 5.10 (1H), 6.40 - 6.45 (1H), 6.80 - 6.85 (1H), 6.90 - 7.00 (2H), 7.40 - 7.45 (1H) Example 1S3 Isobutyl 2-[1-[2.3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate (Formula Removed) To a solution ol the compound of Example 58 (1.00 g, 5.0 mmol) and triethyfamine {0.77 ml, 5.5 mmol) in anhydrous dichforomefhane {10 ml) was added dropwfse isobutyl chtoroformate {2.60 ml, 20 mmol). The reaction mixture was stirred at room temperature for 18 h and then concentrated in vacuo. The residue was partitioned between waler {10 ml) and ethyl acetate (10 ml) and the two layers were separated. The aqueous layer was extracted with ethyl acetate (10 mi) and the combined organic layers were dried (MgSO+) and concentrated in vacuo. The residue was dissolved in acetonitrile: water (9:1, 4 ml) and purified by automated preparative liquid chromatography (Gilson system, i50mm x 30 mm LUNA C18(2) 5 urn column, 40 ml /min) using an acetonitrile: water gradient [65:35 to 95:5]. The appropriate fractions were combined and concentrated to give the title compound (150 mg). Experimental MH+301.4; expected 301.2 1H-NMR (CDCI3): 0.89 - 0.95 (6H), 1.60 -1.63 (3H), 1.91 - 2.00 (1H), 2.28- 2.39 (6H), 3.95 - 4.04 {2H), 5.05 - 5.11 (1H), 6.62 - 6.65 1H), 6.90 - 7.01 (3H), 7.40 - 7.41 (1H) Rhip. Funct. EDt0O mg/cm2= 0.03 Similarly prepared by acylation with isobutyl chlorocarbonate were: (Table Removed) Example 184 Isobutyl 2-[1 -(3-fluoro-2-methylphenyl)elthyl]-1h-imidiazol-1-carboxylate 1H-NMR (CDCI3): 0.83 - 0.95 (6H), 1.60 -1.64 (3H), 1.91 -1.99 (1 H) 2.35 - 2.38 (3H), 3.97 -4.02 (2H), 5.00 - 5.03 (1H), 6.59 - 6.61 (1H), 8.80 - 6.85 (1H), 6.98 - 7.03 (2H), 7.39 - 7.40 (1H) Example 185 Isobutyl 2-[1-(2.6-difluoro-3-methylphenyl)ethyl]-1 H-imidazole-1-carbxylate 1H-NMR (CDCI6): 0.85 - 0.96 (6H), 1.74 -1.78 (3H), 1.95 - 2.00 (1H), 2.17 - 2.20 (3H), 3.98 - 4.04 (2H), 4.99 - 5.03 (1H), 6.65 - 6.71 (1H), 6.90 - 6.97 (2H), 7.39 - 7.41 (1H) Example 186 Isobutyl 2-[1-(2.3-dimethylphenvl)ethyl-1H-imidazole-1-carbxylate 1H-NMR (d6-Acetone): 0.80 - 0.90 (6H), 1.40 -1.50 (3H), 1.80 -1.90 (1H), 2.20 - 2.30 (6H), 3.90 - 4.00 (2H), 5.00 - 5.10 (1H), 6.45 - 6.50 (1H), 6.80 - R85 (1H), 6.90 - 6.95 (2H), 7.45 - 7.50 (1H) Example 187 2-[1-(2.3-Dimethylphenyl)ethyl-N,N-dimethyl-1 H-imidazol-1 -sulfonamide (Formula Removed) To a solution of the compound of Example 1 (100 mg, 0.5 mmol) and triethylamine (77 µl, 0.55 mmol) in anhydrous tetrahydrofuran (4 ml), was added dimethylsulphamoyl chloride (59 µl, 0.55 mmol). The. reaction mixture was stirred at 60°C, under nitrogen, for 36 h and then concentrated in vacuo. The residue was partitioned between water (10 ml) and ethy! acetate (10 ml) and the two layers were separated. The aqueous layer was extracted with ethyl acetate (10 ml) and the combined organic layers were dried (MgS04) and concentrated in vacuo. The residue was dissolved in methanol (1.5 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 50 mm LUNA C18 (2) 10 µm column, 120 ml / min) using an acetonitrile: water gradient [20:80 to 96:5]. The appropriate fractions were combined and concentrated to give the title compound (49 mg). Experimental MH* 308.2; expected 308.1 1H-NMR (d6-Acetone): 1.50 -1.56 (3H), 2.22 - 2.26 (3H), 2.31 - 2.36 (3H), 2.50 - 2.57 (6H), 4.95 - 5.01 (1H), 6.70 6.74 (1H), 6.85 - 6.95 (2H), 7.00 • 7.04 (1H), 7.40 - 7.41 (1H) Rhip. Funct. ED100 mg/cm2 Example 188 2-Ethoxy-1-[ethoxycolumntethyl 2-[(1S)-1-(2,3-dlcolumnpheml)ethyl]-1H-lmldazole-1-carboxytate (Formula Removed) To a mixture of Example 58 (500 mg, 2.5 mmol) and pyridine (0.44 ml, 5.5 mmol) in anhydrous dichloromethane (5 ml), at 0°C and under nitrogen, was added phosgene {20% in toluene, 1.44 ml, 2.75 mmoi). The mixture was stirred at 0°C for 20 min, before addition of 1,3-diethoxypropan-2-ol (407 mg, 2.75 mmol). The reaction mixture was stirred at room temperature for 30 min and then poured into ice: water (10 ml). The mixture was adjusted to pH 7 by addition of solid sodium hydrogen carbonate and the two layers were separated. The aqueous phase was extracted with dichloromethane (2x10 ml) and the combined extracts were dried (MgSO4) and concentrated in vacuo. The residue was dissolved in methanol (1.5 ml) and purified by automated preparative liquid chromatography (Gilson system, 150 mm x 50 mm Sunfire C1810 µn column, 120 ml / min) using an acetonitrile: water gradient [60:40 (20 min) to 982 (20.5 min)]. The appropriate fractions were combined and concentrated to give the title compound (435 mg). Experimental MH+ 375.2; expected 375.2 1H-NMR (d6-Acetone): 0.97 -1.02 (3H), 1.05-1.10 (3H), 1.55 -1.59 (3H), 2.25 - 2.28 (3H), 2.32 - 2.35 (3H), 3.32 - 3.50 (5H), 3.52 - 3.58 (3H), 5.05 - 5.12 (1H), 6.54 - 6.57 (1H), 6.84 - 6.89 (1H), 6.96 - 6.99 (2H), 7.49-7.50(1 H) Rhip. Fund. ED100 mg/cm2 = 0.03 Example 189 Cycopropylmethyl 2-[(1S)-1-(2,3-dblmethylphenyl]ethyl]-1H-lmldazole-1-carboxytate (Formula Removed) To a mixture of the compound of Exampfe 58 (100 mg, 0.5 mmol) and pyridine (90 µl, 1.1 mmol) in anhydrous acetonitrfle (1 ml), at 0°C and under nitrogen, was added diphosgene (33 µl, 0.28 mmoJ). The mixture was stirred at 0°C for 30 min, before addition of cyclopropylmethanQl (43 µl, 0.55 mmof). The reaction mixture was stirred at room temperature for 1 to and then tittered. The filtrate was purified by automated preparative liquid chromatography (Gilson system, 150 mm x 22.4 mm LUNA C18(2) 5 Mm column, 20 m I /min) using an acetomtrile: water gradient [15:65 (3 min) to 98:2 (16 mm)]. The appropriate fractions were combined and concentrated to give the title compound (30 mg). Experimental MH* 299.4; expected 299.2 1H-NMR (CDCfe): 0.20 - 0.30 (2H), 0.50- 0.60(2H), 1.02 -1.10 (1H), 1.59-1.65 (3H), 2.30 - 2.29 (6H), 3.96 - 4.05 (2H), 5.03 - 5.10 (1H), 6.62 - 6.65 (1 H), &91 - 7.00 (3H), 7.40 - 7.41 (1H) Rhlp. Funct ED100 mg/cm2=0.03 Similarly prepared from Example 58 were: (Formula Removed) (Table Removed) Example 190 2-lsopropoxyethyl2_[(1S)-1_('2.3-dlmethyphenyl)ethyl]-1H-lmidazole-1-carboxylate 1H-NMR (de-Acetone): 1.00 -1.09 (6H), 1.51 -1.55 (3H), 2.25 - 2.27 (3H). 2.36 - 2.38 (3H), 3.50 - 3.63 (3H), 4.32 - 4.36 (2H), 5.08 - 5.12 (1 H)t 6.55 - 6.58 (1H), 6.82 - 6.87 (1H), 6.95 - 6.98 (2H), 7.45 - 7.47 (1H) Example 191 3-(3-Propoxypropoxy)propyl 2-[({1S)-1-(2,3-dimethylphenyl)methyl]-1H-imldazole-1 -carboxylate 1H-NMR (d6-Acetone): 0.81 - 0.92 (3H), 0.97 -1.13 (6H), 1.42-1.53 (2H), 1.57 -1.60 (3H), 2.25 - 2.40 (6H), 3.21 - 3.40 (4H), 3.50 - 3.61 (3H), 5.00 - 5.15 (2H), 6.50 - 6.58 (1H), 6.83 - 651 (1H), 6.95 - 6.98 (2H), 7.47- 7.50 (1H) Example 192 2-Ethoxyethyl 2-[(1S)-(2,3-dimethylphenyl]tethyl]-1H-lmidazote-1-carboxylate 'H-NMB (d6-Acetone): 1.02 -1.09 (3H), 1.52 -1.57 (3H), 2.24 - 2.26 (3H), 2.37 - 2.39 (3H), 3.40 - 3.48 (2H), 3.59 - 3.66 (2H), 4.30 - 4.37 (2H), 5.05 - 5.11 (1H), 6.55 - 6.58 (1H), 6.84 - 6.90 (1H), 6.95 - 6.99 (2H), 7.48- 7.49 (1H) Example 193 Cyclobutyl2-[(1S)-1-(2,3-dlmethylphenyl)ethyl]-1H-imldazole-1-carboxylate 'H-NMR (d6-Acetone): 1.53 -1.56 (3H), 1.60 -1.65 (1H), 1.70 -1.75 (1H), 1.98 - 2.08 (2H), 2.22 2.30 (5H), 2.36 - 2.39 (3H), 4.98 - 5.06 (2H), 6.48 - 6.50 (1H), 6.84 - 6.87 (1H), 6.95 - 6.98 (2H), 7.50 - 7.52 (1H) Example 194 Cyclobutyl2-[(1S)-1-(2,3-dlmethylphenyl)ethyl]-1H-imldazole-1-carboxylate 1H-NMR (de-Acetone): 0.81 - 0.97 (2H), 1.10-1.30 (4H), 1.42 -1.55 (5H), 1.59 -1.70 (5H), 2.27-2.29 (3H), 2.36 - 2.38 (3H), 4.20 - 4.30 (2H), 5.04 - 5.09 (1H), 6.50 - 6.53 (1H), 6.85 - 6.89 (1H), 6.95 - 6.99 (2H), 7.46-7.47 (1H) CHN Analysis Predicted: %C= 74.54, %H= 8.53, %N=7.90 Observed: %C= 74.31, %H= 8.50, %N= 7.95 Example 195 Tetrahydro-2H- 6.87 -4-ylmethyl 2-[( 1S)-1-2.3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylale 1H-NMR (de-Acetone): 1.17-1.24(2H), 1.40 - 1V4S (2H), 1.54 -1.57 (3H), 1.80 -1.90 (1H),257-2.29 (3H), 2.37 - 2.39 (3H), 350 - 3.30 (2H), &79 - 3.84 (2H), 4.01 - 4.15 (2H). 5.02 - 5.09 (1H), 6.51 - 6.54 (1H), 6.83 - 6.86 (1H), 6.95 - 6.98 (2H), 7.50 - 7.51 (1H) Example 196 3-(3-Methoxypropoxy)propyl 2-[( 1S)-1-2.3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylale 'H-NMR (de-Acetone): 0.95 -1.04 (4H), 1.18 -1.21 (3H), 1.51 1.56 (3H), 2.27 - 2.29 (3H), 2.37-2.39 (3H), 3.20 - 3.23 (2H), 354 - 3.40 (3H), 3.40 - 3.59 (2H), 5.04 - 5.10 (2H), 6.49 - 6,59 (1H), 6.82 - 6.88 . (1H), 6.96 - 6.99 (2H), 7.46 - 7.48 (1H) Example 197 (2-MethylCyc1opropyl)methyl 2-[(1S)-1-(2,3-dimethy|phenyl)methyl]-1H-midazole-1-carnoxylate 1H-NMR (d6-Acetone): 0.21 - 0.26 (1H), 0.40-0.48 (1H), 0.62 - 0.81 (2H), 0.92 - 0.97 (3H), 1.53-1.56 (3H), 2.26 - 2.28 (3H), 2.37 - 2.39 (3H), 4.00 - 4.12 (2H), 5.05 - 5.10 (1H), 6.56 - 6.59 (1H), 6.86 - 6.89 (1H), 6.95 - 6.98 (2H), 7.50 - 7.51 (1H) Example 198 3-r3-(3-Butoxypropoxy)propoxylpropyl 2-{( 1S)-[ -(2,3-dlmethylphenyl)methyl]-1H-imidazole-1- carboxylate 1H-NMR (de-Acetone): 1.15- 1.20 (3H), 1.30-1.40 (2H), 1.41 -1.50 (2H), 1.53 -1.56 (3H), 255- 259 (3H), 2.33-2.37 (3H), 3.20-3.25(1H),3.30-3.41 (4H),3.47-3.61 (5H), 5.00-5.05(1H), 5.10-5.17 (2H), 6.50 - 6.54 (1H), 6.82 - 6.86 (1H), 6.95 - 6.98 (2H), 7.50 -7.53 (1H) Example 199 2.25-Trtfluoroethyl 2-[(1S)-1-(2,3-dlmethylphenyl)ethyl]-1H-lmidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.53 -1.56 (3H), 2.26 - 2.28 (3H), 2.36 - 2.38 (3H), 4.80 - 4.91 (2H), 5.05 - 5.10 (1H), 6.56 - 6.59 (1H), 6.86 - 6,88 (1H), 6.96 - 6.98 (1H), 7.00 • 7.01 (1H), 7.50 - 7.51 (1H) Example 200 Cyclobutyl2-[(1S)-1-(2,3-dlmethylphenyl)ethyl]-1H-imldazole-1-carboxylate 'H-NMR (d6-Acetone): 1.50 - 1.55 (3H), 1.70 -180 (2H), 1.80 -1.90 (2H). 1.90 - 2.02 (2H), 2,25 - 2.27 (3H), 2.35 - 2.37 (3H), 4.12 - 4.21 (2H), 5.03 - 5.09 (1 H)t 6.53 - 6.57 (1H), 6.85 - 6.89 (1H), 6.95 - 6.98 (2H), 7.46- 7.47 (1H) Example 201 (1-MethylCyclopropyl)methyl 2-[(1 S)-1-[2.3-dimethylphenyl}ethyl]-1H-lmldazote-1-carboxylate 1H-NMR (d6-Acetone): 0.30 - 0.40 (2H)r 0.45 - 0.55 (2H), 1.02 -1.05 (3H), 1.53 -1.56 (3H), 2.23 - 2.25 (3H), 2.34 - 2.36 (3H)t 4.00 - 4.07 (2H), 5.10 - 5.15 (1H). 6.57 - 6.59 (1H), 6.84 - 6.86 (1H). 6.95 ■ 6.98 (2H).7.51-7.53(1H) Example 202 2-Cyclopropylethyl 2-{( 1 S)-1-(2,3-d]methyllphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 0.00 - 0.05 (2H), 0.35 - 0.40 (2H)4 0.60 - 6.68 (1H), 1.45 -1.56 (SH), 2.24 ■ 2.26 (3H), 2.35 - 2.38 (3H), 4.20 - 4.35 (2H), 5.05 - 5.13 (1H), 6.51 - 6.53 (1H), 6.84 - 6.88 (1H), 6.92 - 6.98 (2H), 7.49-7.50 (1H) Example 203 2-Methoxy-1 -(methoxymethyl]ethyl 2-[(1S)-1-(2,3-dimethylphenyl}ethyl]-1H-imidazole-1- carboxylate 'H-NMR {d6-Acetone): 1.50 -1.53 (3H), 2.29 - 2.31 (3H), 2.36 - 2.36 (3H), 3.29 - 3.35 (6H), 3.41 - 3.51 (4H), 5.05 -5.12 (2H), 6.53 - 6.55 (1H), 6.85 - 6.87 (1H), 6.95 - 6.98 (2H), 7.49 - 7,51 (1H) Example 204 (3-Methyloxetan-3-yl]methyl2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-lmidiazole-1-carboxylate 'H-NMR (d6-Acetone): 1.25 -1.26 (3H), 1.55-1.58 (3H),2.26-2.28 (3H), 2.36 - 2.33 (3H), 4.23 - 4.29 (3H), 4.39 - 4.44 (3H), 5.05 - 5.10 (1H), 6.58 - 6.60 (1H), 6.84 - 6.87 (1H), 6.95 - 6.98 (2H), 7.50 - 7.52 (1H) Example 205 S-Methylhexyl2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carpoxylate 'H-NMR (d6-Acetone): 0.80 - 0.84 (6H), 1.15 -1.20 (2H), 1.25 -1.30 (2H), 1.49 - 1.61 (5H), 2.26 • 2.28 (3H), 2.37 - 2.39 (3H), 4.19 - 4.25 (2H), 5.05 - 5.10 (1H), 6.56 - 6.58 (1H), 6.84 - 6.86 (1H), 6.95 - 6.98 (2H), 7.48- 7.50 (1H) Example 206 3-f4-Fluorophenoxy)propyl2-[(1S)-1-(2,3-dlmethhylphenvmethyl]-1H-imidazo[e-1-carboxylate 'H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.05 - 2.10 (2H), 2.24 - 2.2S (3H), 2.34 - 2.37 (3H), 3.97 - 4.01 (2H), 4.36 - 4.40 (1H), 4.01 - 4.05 (1H), 5.02 - 5.07 (1H), 6.50 - 6.53 (1H), 6.82 - 6.90 (3H), 6.91 - 6.96 (2H), 7.00 - 7.05 (2H), 7.51 - 7.52 (1H) CHN Analysis Predicted: %C= 69.68, %H= 6.36, %N= 7.07 Observed: %C= 69.70, %H=6.37r %N=7.Q7 Example 207 2,2.3,3,3-Pentafluoropropyl 2-[(1S)-[-(2,3-dimethylphenyl]ethyl]-1H-imidazofe-1 -carboxylate 'H-NMR (de-Acetone): 1.53 -1.57 (3H), 2.25 - 2,27 {3H)f 2.35 - 2.38 (3H), 4.85 - 4.99 (2H), 5.03 - 5.09 (1H), 6.55 - 6.58 (1H), 6.85 - 6.99 (2H), 7.00 - 7.01 (1H), 7.45 - 7.46 (1H) Example 208 2-[Methylthiot)ethyl 2-[(1S)-1-(2,3-dimethytphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.51 -1.54 (3H), 2.02-2.06 (3H), 2.24 - 2.26 (3H), 2.35- 2.38 (3H), 2.61 - 2.72 (2H), 4.30 - 4.41 (2H), 5.03 - 5.10 (1H), 6.52 - 6.56 (1H), 6.85 - 6.91 (1H), 6.95 - 6.99 (2H), 7.50 - 7.51 (1H) Example 209 Ethyl 2-([1S)-1-(2,3-dlmethylphenvnethyl]-1 imidazole-1 -carboxylate 1H-NMR (d6-Acetone): 1.17-151 (3H), 1.51 -1.53 (3H),2.26-258 (3H), 2.36-2.38(3H),4.19-4.26 (2H), 5.03 - 5.08 (1H), 6.51 - 6.53 (1H), 6.85 - 6.88 (1H), 6.96 - 6.99 (2H), 7.47 - 7.49 (1H) Example 210 3-Cyclohexylpropyl 2-K1 St-1-(2,3-dimethylphenyl)ethyl]-1H-tmidazoie-t-cartioxyIate 1H-NMR (de-Acetone): 0.79- 0.89 (2H), 1.10-155 (6H) 1,51 -1.54 (3H), 1.58 -1.70(7H), 2.25 - 2.27 (3H), 2.35 - 2.38 (3H), 4.12 - 4.25 (2H), 5.02 - 5.09 (1H), 6.50 - 6.53 (1H), 6.84 - 6.89 (1H), 6.95 - 6.98 (2H), 7.49-7.54 (1H) Example 211 3-Methylbutyl 2-([1 S)-1-(2,3-dlmethylprienyl}ethyl]-1H- irnidazole-1-carboxylate 1H-NMR (de-Acetone): 0.81 - 0.87 (6H), 1.43 -1.60 (6H), 2.27 - 2.29 (3H), 2.36 - 2.38 (3H), 4.19 - 4.27 (2H), 5.03 - 5.08 (1H), 6.51 - 6.53 (1 H), 6.86 - 6.88 (1H), 6.96 - 6.99 (2H), 7.47 - 7.49 (1H) Example 212 2-lsopropylCyclohexyl 2-[(1S)-[-(2,3-dfmethylphen ylmethyl]-1H-imldazole-1 -carboxylate 1H-NMR (de-Acetone): 0.50 - 0.54 (3H), 0.70 - 0.80 (3H), 1.00-150 (3H), 150-1.45 (3H), 1.50 -1.60 (3H), 1.61 -1.72 (3H), 1.80 -1.89 (1H), 2.24 - 258 (3H), 2.35 - 2.38 (3H), 4.60 - 4.65 (1H), 4.70 - 4.76 (1H), 5.00 - 5.08 (1H), 6.35 - 6.45 (1H), 6.82 - 6.90 (1H), 6.95 - 6.98 (2H)r 7.49 - 7.54 (1H) Example 213 2-Methoxyethyl2-[(1S)-1-(2,3-dirmethylphenvmethyl]-1H-imtdazole-1-carboxylate 1H-NMR (de-Acetone): 1.51 -1.54 (3H), 2.25 - 2.27 (3H), 2.31 - 2.33 (3H), 3.22 - 3.23 (3H), 3.45- 360 (2H), 4.30- 4.40 (2H), 5.04 - 5.11 (1H), 6.56 - 6.58 (1H), 6.84 - 6.86 (1H), 6.95 - 6.99 (2H), 7.44 - 7.45 (1H) 113 Example 214 Tetrahydro-2H-nyran-4-yl2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (d6-Acetcne): 1.50 -1.55 (3H), 1.90 -1.96 (1H), 2.09 - 2.11 (1H), 2.24 - 221 (3H), 2.32 - 2.34 (3H), 3.70 - 3.83 Example 215 3-cyclopentylpropyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (cfe-Acetone): 0.99 -1.05 (2H), 122-128 (2H), 1.48-1.62 (9H), 1.69 -1.74 {3H), 2.26 - 2.28 (3H), 2.36 - 2.38 {3H), 4.15 - 4.22 (2H), 5.03 - 5.08 (1H), 6.51 - 6.53 (1H), 6.85 - 6.37 (1H), 6.95 - 6.98 (2H), 7.47- 7.49(1 H) Example 216 1-Methylpiperldin-4-yl2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.54 (3H), 1.60 -1.71 (3H), 1.79 -1.88 (2H), 2.10 - 2.21 (4H), 2.27 ■ 2.29 (3H), 2.36 - 2.38 (3H), 2.50 - 2.60 (2H). 4.70 - 4.80 (1H), 5.03 - 5.10 (1H), 6.52 - 6.54 (1H), 6.82 - 6.88 (1H), 6.95 - 6.98 (2H), 7.49 - 7.50 (1H) Example 217 4,4,4-Trlfluorobutyl2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate ' H-NMR (de-AcBtone): 1.50 -1.55 (3H), 1.89 -1.96 (3H), 2.10-2,21 (4H), 2.37 - 2.39 (3H), 4.21 - 4.26 (1H), 4.35 - 4.40 (1H), 5.02 - 5.09 (1H), 6.50 - 6.53 (1H), 6.83 - 6.86 (1H), 6.96 - 6.99 (2H), 7.47 - 7.48 (1H) Example 218 cycloperrtyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.54 (3H), 1.55 -1.75 (6H), 1.80-1.90 (2H), 2.25 - 2.27 (3H), 2.35 - 2.37 (3H), 5.05 - 5.11 (1H), 5.18 - 5.20 (1H), 6.52 - 6.54 (1H), 6.83 - 6.98 (3H), 7.44 - 7.45 (1H) Example 21S (1-Methylcyclohexyl)methyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1 H-NMR (d6-Acetone): 0.92- 0.93 (3H), 1.20-1.40 (5H), 1.40- 1.49 (5H)t 1.53- 1.56 (3H), 2.26- 2.28 (3H), 2.36 - 2.38 (3H), 3.96 - 4.02 (2H), 5.10 - 5.15 (1H), 6.56 - 6.59 (1H), 6.85 - 6.87 (1H), 6.95 - 6.98 (2H), 7.48-7.50 (1H) Example 220 Cydopenlylmethyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (de-Acetone): 1.17 -1.25 (2H), 1.45 -1.70 (11 H)r 2.15-2,21 (1H), 2.25 - 2.26 (3H), 2.35 - 2.37 (3H), 4.04 - 4.19 (2H), 5.04 - 5.10 (1H), 6.52 - 6.55 (1H), 6.83 - 6.88 (1H), 6.95 - 6.98 (2H), 7.47 - 7.48 (1H) Example 221 4-Methy}pentyl2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (d6-Acetone): 0.80 - 0.85 (6H), 1.12-1.20 (2H), 1.50 -1.56 (4H), 1.58-1.61 (2H), 2.27 - 2.29 (3H), 2.35 - 2.37 (3H), 4.14 - 4.19 (1H), 4.20 - 4.24 (1H), 5.04 - 5.08 (1H)„ 6.52 - 6.55 (1H), 6.85 - 6.87 (1H), 6.93 - 6.97 (2H), 7.47 - 7.49 (1H) Example 222 (1-Propylcyclobutynmethyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR {d6-Acetone): 0.81 - 0.85 (3H), 1.20-1.26 {2H), 1.42 -1.46 (2H), 1.52-1.56 (3H), 1.75 -1.86 (6H), 2.26-2,28 (3H), 2.35 - 2.37 (3H), 4.15 - 4.22 (2H), 5.09 - 5.13 (1H), 6.58 - 6.60 (1H), 6.85 - 6.87 (1H), 6.95 - 6.98 (2H), 7.43 - 7.45 (1H) Example 223 2-[(4-Chlorophenyl)thiolethyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (d6-Acetone): 1.54 -1.56 (3H), 2.25 - 2.27 {3H), 2.35 - 2.37 (3H), 3.20 - 3.25 (2H), 4.36 - 4.40 (2H), 5.00 - 5.05 (1H), 6.51 -6.53 (1H), 6.85 - 6.87 (1H), 6.91 - 6.95 (2H), 7.30 - 7.40 (5H) Example 224 (2S)-2-methylbutyl2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (d6-Acetone): 0.90 - 0.95 (3H), 1.10 -1.20 (1H), 1.32 -1.41 (1H), 1.54 -1.56 (3H), 1.65 -1.71 (1H), 2.25 - 2.27 (3H), 2.34 - 2.36 (3H), 4.03 - 4.05 (2H), 5.04 - 5.08 (1H), 6.52 - 6.54 (1H), 6.83 - 6.86 (1H), 6.96 - 7.00 (2H), 7.48 - 7.50 (1H) Example 225 3-[Methylthio)propyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR {de-Acetone): 1.52 -1.54 (3H), 1.85 -1.92 (2H), 2.05 - 2.07 (3H), 2.27 - 2.29 (3H), 2.36 - 2.38 (3H), 2.42 - 2.46 (2H), 4.22 ■ 4.30 (2H), 4.23 - 4.29 (1H), 4.32 - 4.38 (1H)r 6.51 - 6.53 (1H), 6.83 - 6.86 (1H), 6.96 - 6.99 (2H), 7.51 - 7.53 (1H) Example 226 Cyclohexylmethyl 2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (de-Acetone): 0.82 - 0.99 (2H), 1.05 -1.23 (3H), 1.50-1.55 (3H), 1.56 -1.70 (6H), 2.25 - 2.27 (3H), 2.37 - 2.39 (3H), 3.98 - 4.08 (2H), 5.02 - 5.09 (1H), 6.49 - 6.52 (1H}, 6.83 - 6.86 (1H), 6.96 - 6.99 (2H), 7.48-7.49(1 H) CHN Analysis Predicted: %C= 74.08, %H= 8.29, %N= 8.23 Observed: %C= 74.09, %H= 8.27, %N= 8.27 Example 227 3-ethoxypropyi2-[(1S)-1-(2,3-dimeahylphanyllethyl)-1H-imldazols-1-carboxylate 1H-NMR (d6-Acetone): 1.02 -1.06 (3H), 1.54 -1.57 (3H), 1.80 -1.86 (2H), 2.26 - 2.28 (3H), 2.36 - 2.38 (3H), 3.35 - 3.40 (4H), 4.21 -4.30 (2H), 5.03 - 5.05 (1H), 6.52 - 6.54 (1H), 6.83 - 6.86 (1H), 6.96 - 6.99 (2H), 7.50-7.52 (1H) Example 228 2-Methylcyclohexyl2-[(1S)-1-2,3-dimethylphenyl)ethyl]-1H-imiazole-1-carboxylate 1H-NMR (d6-Acetone): 0.70 - 0.73 (3H), 1.00 1.10 (2H), 1.20 -1,30 (2H), 1.40 -1.45 , f .55 -1.58 (3H), 1.60 -1.64 , 1.65 - 1.75 (2H), 1,80 -1.85 , 226 - 2.28 (3H), 2.36 - 2,38 (3H), 4.30 - 4.36 , 5.00 - 5.05 , 6.40 - 6.44 , 6.82 - 6.85 , 6.98 - 6.99 (2H), 7.50 - 7.52 Example 229 2-(2.6-Dimethylmorpholin-4-yl]ethyl2-[(1S)1-(2,3-dinrethylphenyl)ethyl]-1H-imidazol-1- cafboxylale '1H-NMR {d6-Acetone): 0.98 -1.03 (3H), 1.53-1.56 (3H), 1.59 -1.65 , 221 - 224 , 227 - 2.28 (3H), 2.38 - 2.39 (3H), 2.42 - 2.58 (2H), 2.60 - 2.63 (1 H), 2.65 - 2.67 , 3.20 - 3.29 , 3.35 - 3.41 , 4.30 - 4.35 (2H), 5.04 - 5.09 , 6.54 - 6.56 , 6.62 - 6.87 , 6.95 - 7.00 (2H), 7.49 - 7.50 Example 230 Penlyl]2-{(1S)-1-(2,3-dimethylphenyl)ethyl)-1H-lmidazole-1-carboxylate 1H-NMR (d6-Acetone): 0.81 - 0.36 (3H), 1.20 -1.33 (4H), 1.53 -1.56 (3H), 1.59 -1.62 (2H). 226 - 2.27 (3H), 2.35 - 2.36 (3H), 4.17 - 425 (2H), 5.04 - 5.10 , 6.52 - 6.54 , 6.83 - 6.87 , 6.95 - 6.97 (2H), 7.49-7.50 Example 231 trans-4-Methylcyclohexyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 0.82 - 0.90 (3H), 1.00 -1.10 (1H), 120 -1.45 (4H), 1.52 -1.55 (3H), 1.65 -1.70 (2H), 1.85 - 1.95 (2H), 2.24 - 2.30 (6H), 4.60-4.66 , 5.02 - 5.10 6.52 - 6.55 {1H}, 6.82 - 6.98 (3H), 7.46- 7.49 Example 232 2-Propylpenlyl 2-[(1 S)-1-(2,3-dime1hylphenyi)ethyl)-1H-imidazole-1-carboxylate 1H-NMR (d8-Acetone): 0.90 - 0.97 (6H), 120 - 1.38 (8H), 1.54 - 1.58 (3H), 1.65 -1.72 , 2.27 - 2.29 (3H), 2.36 - 2.38 (3H), 4.10 - 4.19 (2H), 5.10 - 5.15 , 6.55 - 6.53 , 6.35 - 6.88 , 6.96 - 6.99 (2H), 7.44-7.46(1 H) Example 233 2-ethylbutyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-lmidazole-1-carboxylate 1 H-NMR (d6-Acetone): 0.90 - 0.96 (6H), 1.24 - 1.36 (4H), 1.54 -1.53 (4H), 2.27 - 2.29 (3H), 2.36 - 2.38 (3H), 4.10-4.15 , 4.16 - 4.20 , 5.07 - 5.11 , 5.57-5.59 , 6.83 - 6.87 , 6.95 -'6.98 (2H), 7.46-7.48 Example 234 2,2-Dimethylpropyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 0.95 - 0.98 (9H), 1.54 - 1.57 (3H), 226 - 2.28 (3H), 2.32 - 2.34 (3H), 3.90 - 3.94 , 3.96 - 4.00 , 5.09 - 5.13 (1H}, 6.57 - 6.59 , 6.84 - 6.88 , 6.94 - 6.98 (2H), 7.55 - 7.57 Example 235 Bicyclo[2,2,1]hept-2-ylmethyl 2-[(1S-1-{2,3-]lmethyIphenyl]ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 0.62 - 0.70 , 1.10 -1.16 (2H), 1.25 -1.35 (3H), 1.40-1.48 (2H), 1.52-1.57 (3H), 1.61 - 1.66 , 2.12 - 2.19 (2H}, 2.28 -2.30 (3H), 2.37 - 2.39 (3H), 4.19 - 4.27 (2H), 5.03 - 5.08 (1H), 6.51 - 6.53 (1H), 6.84 - 6.88 , 6.96-6.99 (2H), 7.46-7.48 Example 236 3.3-Dimethylbutyl 2-[(1S)-(2,3-dimethylpherryl)ethyl)-1H-imldazole-1-carboxylate 1H-NMR (de-Acetone): 0.89 - 0.92 (3H), 1.48-1.57 (5H), 2.28 - 2.30 (3H), 2.37 - 2.39 (3H), 4.20 - 4.25 , 4.30 - 4.35 (1H), 5.02 - 5.08 , 6.51 - 653 , 6.84 - 6.87 , 6.98 - 6.99 (2H), 7.45 - 7.47 Example 237 4-lsopropylcyclohexyl 2-[(1S)-1-(2f3-dimethylphenyl)ethyl]-1H-imdilazole-1-carboxylate 1H-NMR {d6-Acetone): 0.81 - 0.86 (6H), 1.03-1.20 (2H), 1.20 -1.29 (2H), 1.38-1.48 (2H), 1.54 -1.57 (3H), 1.75 -1.81 (2H), 1.90 - 2.00 (2H), 2.27 - 2.29 (3H), 2.37 - 2.39 (3H), 4.60 - 4.67 , 5.02 - 5.08 , 6.49 - 6.52 , 6.84 - 6.87 (1H), 6.96 - 6.99 (2H), 7.46 - 7.48 CHN Analysis Predicted: %C= 74.95, %H= 8.75, %N= 7.60 Observed: %C= 74.98, %H= 8.78, %N= 7.58 Example 238 3-{Ethylthio)propyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.15 - 1.20 (3H), 1.55-1.58 (3H), 1.83 -1.89 (2H), 2.28 - 2.30 (3H), 2.36 - 2.38 (3H), 2.42 - 2.50 (4H), 4.25 - 4.30 , 4.33 - 4.38 , 5.04 - 5.08 , 6.53 - 6.55 (1H}, 6.85 - 6.88 , 6.96 - 6.99 (2H), 7.50 - 7.52 Example 239 Propyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-1H-lmldazole-1-canboxylate 1H-NMR (d6-Acetone): 0.82 - 0.86 (3H), 1.55 -1.58 (3H), 1.60 -1.66 (2H), 227 - 2.29 (3H), 2.36 - 2.38 (3H), 4.10 - 4.20 (2H), 5.04 - 5.10 , &53 - 655 , 6.85 - 6.88 , 6.96 - 6.99 (2H), 7.49 - 7.51 Example 240 3-Methoxy-3-methylbutyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl|-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.10 -1.12 (6H), 1.53 -1,55 (3H), 1.70-1.80 (2H), 2.26 -2,28 (3H), 2.37-2.38 (3H), 3.09 - 3.10 (3H), 4.21-4.31 (2H), 5.03 - 5.07 , 6.51 - 6.53 (1H), 6.85 - 6.88 (1 H)r 6.97 - 6-99 (2H), 7.46-7.47 Example 241 3-( Dimethylamino)-2,2-dimethylpropyl 2-[(1 S)-1-(2,3-dimetriylpheny[)ethyl]-1H-imidazole-1- carboxylate 1H-NMR (de-Acetone): 0.83 - 0.90 (6H), 1.52-1.55 (3H), 2.15-2,20 (6H), 2.23 - 2.24 (3H), 2.35 - 2.36 (3H), 4.00 - 4.08 (2H), 5.10-5.16 , 6.52 - 6.55 , 6.83 - &87 , 6.95 - 6.99 (2H), 7.49 - 7.50 OH) Example 242 4-Methoxybutyl 2-[(1S)-1-(2,3-dirnethylphenyl]ethy1]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.47 -1.55 (5H), 1.61 -1.66 (2H), 2.28-2.30 (3H), 2.37 - 2.39 (3H), 3.21 - 3.22 (3H). 3.30 - 3.34 (2H), 4.20 - 4.26 (2H), 5.04 - 5.08 , 6.52 - 6.54 , 6.83 - 6.86 , 6.97 - 7.00 (2H), 7.48 -7.49(1 H) Example 243 2,2,4-Trlmethylpentyl 2-[(1S)-1-(23-dimetriylphenyr)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 0.82 - 0.90 (6H), 0.95-0.97 (6H), 1.20-1.22 (2H), 1.53 -1.57 (3H), 1.61 -1.71 , 2.25 - 2.27 (3H), 2.35 - 2.37 (3H), 3.95 - 4.01 (2H), 5.10 - 5.15 , 6.55 - 6.58 , 6.84 - 6.87 (1H), 6.95 - 7.00 (2H), 7.49 - 7.50 CHN Analysis Predicted: %C= 74.12, %H= 9.05, %N= 7.86 Observed: %C= 74.22, %H= 9.05, %N= 7.91 Example 244 Butyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 0.82 - 0.88 (3H), 1.21 -1.28 (2H), 1.54 -1.60 (5H), 2.28 - 2.30 (3H), 2.37 - 2.39 (3H), 4.17 - 4.25 (2H), 5.03 - 5.07 , 6.52-6.54 , 6.82 - 6.85 t 6.97 - 7.00 (2H), 7.47 - 7.49 Example 245 3-[luoro-3-methylbutyl 2-[(1S)-1-(2,3-dimethylphenyl)etthyi]-1-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.30 -1.33 (3H), 1,37 -1.39 (3H), 1.53 -1.56 (3H), 1.85 -1.95 (2H), 2.29 - 2.31 (3H), 2.36 - 2.38 (3H), 4.30 - 4.34 , 4.39 - 5.02 , 5.03 - 5.07 , 6.52 - 6.54 , 6.85 - 6.88 , 6.96 - 6.99 (2H), 7.45 - 7.46 Example 246 2-lsobutoxyethy] 2-[91S)-1-(2,3-dimethylphenyl)ethyl)-1H-lmtdazole-1-carboxylate 1H-NMR (d6-Acetone): 0.80 - 0.85 (6H), 1.53-1.57 (3H), 1.65 -1.79 , 2.26 - 2.28 (3H), 2.35 - 2.37 (3H), 3.15 - 3.20 (2H), 3.57 - 3.64 , 4.31 - 4.40 (2H), 5.06-5.15 , 6.57 - 6.60 , 6.84-6.87 , 6.95 - 6.99 (2H), 7.47 - 7.48 Example 247 4-cyclohexylbutyl 2-[(1S)-1-(2,3-dimie1hylphenyl)ethyl]-1H-imtdazole-1-carboxylale 1H-NMR (drAcetone): 0,80 - 0.90 (2H), 1.10-1.25 (8H), 1.50 -1.70 (10H), 2.27 - 2.29 (3H), 2.37 - 2.39 (3H), 4.15 - 4.26 (2H), 5.02 - 5.10 , 6.50-6.52 . 6.84 - 6.87 , 6.96 - 7.00 (2H), 7,47 - 7.43 Example 248 4-Methylpent-3-en-1-vl 2-[(1S)-1-[2,3-dimethylphenyl)ethyl)-1H-imldazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.60 (6H), 1.62 -1.64 (3H), 2.23 - 2.30 {3H), 2.25 - 2.35 (2H), £37 - 2.39 (3H), 4.11 - 4.21 (2H), 5.02 - 5.10 (2H), 6.53 - 6.57 , 6.84 - 6,89 , 6.96 - 6.99 (2H), 7.42 - 7.43 Example 249 1-ethylpropyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetcne}: 0.72 - 0.78 (3H), 1.44-1.53 (7H), 2.25 - 2.28 (3H), 2.32 - 2.35 (3H), 4.74 -4.79 , 5.01 - 5.06 , 6.42 - 6.44 , 6.82 - 6.S6 , 6.96 - 6.99 (2H), 7.50 - 7.52 Example 250 (1S)-1-Me1hylbutyl 2-H1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imldazole-1-carboxylate 1H-NMR (d6-Acetone): 0.39-0.93 (3H), 1.10-1.22 (5H), 1.41 -1.52 (5H), 2.25 - 2.28 (3H), 2.36 - 2.39 (3H), 4.89-4.95 , 5.01 - 5.06 , 6.41 - 6.46 , 6.85 - 6.90 , 6.96 - 6.99 (2H), 7.47 - 7.49 Example 251 (3S)-3,7-Dimethyloctyl 2-[(1S)-1-(2,3-didmethyhphenyl)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 0.91 - 0.96 (3H), 1.10-1.16 (3H), 1.20 -1.30 (3H), 1.38 -1.43 , 1.45-1.55 (5H), 1.60- 1.65 , 2.29 - 2.31 (3H), 2.36 - 2.38 (3H), 4.20 -4.30 (2H), 5.05 - 5.10 , 6.51 - 6.53 , 6.83 - 6.85 , 6.96 - 6.98 (2H), 7.46 ■ 7,48 Example 252 2-Propoxyethyl 2-1[(1S)-1-(2,3-dimethylphenyl)ethyl-1H-Imidazole-1-carboxylate 1H-NMF) (d6-Acetone}: 0.90 - 0.95 (3H), 1.42 -1.52 (5H), 2.27 -2,29 (3H), 2.36 - 2.33 (3H), 3.31 - 3.37 (2H), 3.59 - 3.64 (2H), 4.30 -4.36 (2H), 5.07 - 5.12 , 6.57 - 6.59 , 6.83 - 6.85 , 6.95 6.98 (2H), 7.46-7.48 Example 253 2,3-Dimethylpentyl 2-[(1S)-1-(2,3-dImethylphenyl)ethyl]-1H-imldazole-1-carboxylate 1H-NMR (d6-Acetone): 0.75 - 0.88 (6H), 1.10 -1.21 , 1.30 - 1.43 (2H), 1.52 -1.55 (3H). 1.79 - 1.88 , 2.25 - 2.27 (3H), 2.34 - 2.36 (3H), 4.00 - 4.25 (2H), 5,02 - 5,11 , 6.50 - 6.52 (1 H), 6.84 - 6.87 , 6.96 - 6.99 (2H), 7.44 - 7.46 Example 254 2,2-Dimethylbutyl2-[(1S)-1-(2,3-d]methylphenyl)ethyl)-1H-imldazole-1-carboxylate 1H-NMR (de-Acetone): 0.79 - 0.83 (3H), 0.90-0.92 (6H), 1.25 -1.33 (2H), 1.52 -1,55 (3H), 2.24 - 2.26 (3H), 2.33 - 2.35 (3H), 3.90 - 3.95 , 4.00 -4.04 , 5.10 - 5.15 , 6.57 - 6.59 , 6.85 - 6.88 , 6,94 - 6.97 (2H), 7.49 - 7.50 Example 255 3-Methoxy-2,2-dimethyl-3-oxopropyl 2-[(1S)-1-(2,3-dimethylphenyl}ethyl)-1H-imidazole-1- carboxylate 1H-NMR (d6-Acetone): 1.19-1-24 (6H), 1.51 -1.54 (3H), 2.23 - 2.26 (3H), 2.31 - 2.34 (3H), 3.59 - 3.60 (3H), 4.20 - 4.30 (2H), 5.05 - 5.11 6.57 - 6.60 , 6.82 - 6.86, 6.95 - 6.99 (2H), 7.19 - 7.20 Example 256 4-Butoxybenzyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-lH-imidazole-1-carboxylate (Formula Removed) To a mixture of the compound of Example 58 (200 mg, 1.0 mmol) and pyridine (177 µL1, 22. mmol) in anhydrous acetonitrl]e (3 ml). at 0°C ancf under nitrogen, was added diphosgene (132 jJ, 1.1 mmol). The mixture was al]owed to warm to room temperature and stirred for 10 min, before addition to (4- butoxyphenyl)methanol (198 mg, 1.1 mmol) via syringe. The reaction mixture was stirred at room temperature for 30 min and filtered. The Ultrate was purified by automated preparative liquid chromatography (Gilson system, 150 mm x 22.4 mm LUNA C18(2) 10 pm column, 24 ml/min) using an acetonitrile: water gradient [15:85 (3 min) to 98:2 (16 min)]. The appropriate fractions were combined and concentrated to give the title compound (6 mg). Experimental MH+ 364.0; expected 363.2 (compound de-carboxylates) 1H-NMR (de-Acetone): 0.92 - 0.98 (3H), 1.43 -1.55 (5H), 1.69 -1.78 (2H), 2.24 - 2.30 (6H), 3.97 - 4.01 (2H), 5.04 • 5.09 , 5.17 - 5.18 (2H), 6.48 - 6.50 , 6.83 - 6.88 (3H), 6.95 - 6.98 (2H), 7.10-7.13 (2H), 7.44-7.45(1 H) Rhip. Funct. ED-100 mg/cm2= 0.03 Similarly prepared from Example 53 were: (Formula Removed) (Formula Removed) Example 257 Biphenyl-4-ylmethyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.52 -1.55 (3H), 2.23 - 2.30 (6H), 5.09 - 5.13, 529 - 5.32 (2H), 6.50 - 6.52 , 6.84 - 6.86 , 6.96 - 6.99 (2H), 7.35 - 7.39 (3H), 7.42 - 7.46 (2H), 7.57 - 7.58 , 7.60 - 7.68 (4H) Example 258 2,2-Diphenylethyl 2-[(1 Sl-1-(2,3-dimethylphenyl]ethyl)-1H-imidazole-1-carboxylate 1H-NMR {de-Acetone): 1.48 -1.56 (3H), 2.25 - 2.35 (6H), 4.40 - 4.47 , 4.79 - 4.87 (2H), 5.00 - 5.05 , 6.55 - 6.58 , 6.82 - 6.88 (2H), 6.95 - 6.99 , 7.19- 7.21 , 7.21 - 7.24 (2H), 7.29 - 7,39 (8H) Example 259 3.5-Difluorobenzyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.52 -1.56 (3H), 2^2-2,24 (3H), 2.28 - 2.30 (3H), 5.02 - 5.10 , 5.22 - 5.25 5.32 - 5.37 , 6.48 - 6.50 , 6.84 - 7.00 (6H), 7.59 - 7.60 Example 260 4-Chlorobenzyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-1-carboxylale 1 H-NMR (de-Acetone): 1.53 -1.56 (3H), 2.22 - 2.28 (6H), 5.02 - 5.07 , 5.21 - 5.28 (2H), 6.48 - 6.51 , 6.84 - 6.87 , 6.97 - 6.99 {2H), 7.25 - 7.28 (2H), 7.36 - 7.39 (2H), 7.50 - 7.51 Example 261 4-[(4-[luorobenzyl)oxy1benzyl 2-[(1S)-1-(2,3-dimethylahenyl)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (de-Acetone): 1.52-1.55 (3H), 2,22 - 2.30 (6H), 5.04 - 5.13 (3H), 5.19 - 5.20 (2H), 6.51 - 6.53 , 6.82 - 6.86 , 6.95 - 7.00 (4H), 7.11 - 7.20 (2H), 7.22 - 7.25 (2H). 7.45 - 7.46 . 7.50 - 7.56 (2H) Example 262 2.4,5-Trimethylbenzyl 2-[(1S)-1-(2,3-dmethylphenyl)ethyl]-1H-imildazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51-1.54 (3H), 2.15-2.17 (3H), 2.19 - 2.23 (6H), 2.23 - 2.25 (3H), 5.02 - 5.06 , 5.17 - 520 , 5.21 - 5.24 , 6.48 - 6.51 , 6.84 - 6.86 , 6.96 - 6.99 (3H), 7.00-7.01 , 7.46-7.48 Example 263 2,4-dimethylpenzyl 2-[(1S)-(2,3-dimethylptienyl)ethyl)-1H-imidazole-1-carboxylate Example 264 1-Naphthylrnethyl2-[(1S)-1-(2,3-dimethylphenyl)athyl)-1H-imidazole-1-carboxylate 1 H-NMR (de-Acetone): 1.46 -1.51 (3H), 2.19 - 2.26 (6H), 5.04 - 5.10 , 5.75 - 5.79 (2H), 6.52 - 6.55 , 6.83 - 6.87 , 6.90 - 6.96 (2H), 7.42 - 7.50 (3H)r 7.53 - 7.53 (2H), 7.95 - 7.99 (2H), 8.00 - 8.03 Example 265 Mesity)methyl2-[(1S)-1-{2,3'dimethylpheny/)ethyl)-1H-iida2ole-1-carboxylate Example 266 4-(1H-1,2,4-Triazol-1-yl]benzyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-1H-lmldazole-1-carboxylate 1 H-NMR (d6-Acetone): 1.53 -1.56 (3H), 2.22 - 2.24 (3H), 2,30 - 2.32 (3H), 5.03 - 5.08 , 5,31 - 5.39 (2H), 6.49 - 6.52 (1H), 6.84 - 6.86 , 6.97 - 7,00 (2H), 7.41 - 7.44 (2H), 7,56 - 7.58 , 7.80 - 7.83 (2H), 8.13 - 8.14 r 9.02 - 9.04 (1H) Example 267 4-tert-Butylbenzyl 2-[(1S)-1-[ 2.3-dimethylphenyitethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.28 -1.33 (9H), 1.52 -1.55 (3H), 2.22 - 2.28 (6H), 5.02 - 5.07 , 5.20 - 5.22 (2H), 6.51 - 6.53 (1H), 6.84 - 6.86 , 6.95 - 6.98 (2H). 7.20 - 7.23 (2H), 7.38 - 7.41 (2H), 7.50 - 7.51 Example 268 2-Fluorobenzyl 2-[(1S)-1-(2,3-dImethylphanyl)ethyl]-1H-lmidazole-1-carboxylate 1 H-NMR (de-Acetone): 1.50 -1.54 (3H), 2J22 - 2.28 (6H), 5,02 - 5.07 , 5.28 - 5.31 , 5.37- 5.40 , 6.51 - 6.53 , 6.83 - 6.85 , 6.95 - 6.98 (2H), 7.16 - 7.20 (2H), 7.30 - 7.33 , 7.40 - 7,43 , 7.46-7.47 Example 269 4-[Benzyloxy)benryl 2-H1 SH-(2,3-dimethylphenyl)ethyl)-1H-imldazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.24 - 2.29 (6H), 5.02 - 5.07 , 5.11 - 5.13 (2H), 5,18-5.20 (2H), 6.48 - 6.50 , 6.81 - 6.84 , 6.94 - 7.00 (4H), 7.20-7.24 (2H), 7.33 - 7,41 (3H), 7.42 - 7.45 (3H) Example 270 Pentaffuorobenzyl 2-[(1S)-1-(2,3-dimethylphenyl)eihyl)-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 {3H)r 2.25 - 2.27 (3H), 2.29 - 2.31 (3H), 4.99 - 5.02 , 5.38 - 5.41 , 5.42 - 5.45 , 6.40 - 6.42 , 6.80 - 6.83 , 6.90 - 6.92 , 6.97 - 6.98 . 7.46 - 7.47 Example 271 Biphenyl-2-yimethyl 2-[(lS)-1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.53 (3H), 2.15 - 2.17 (3H), 2.19 - 2.21 (3H), 4.98 - 5.02 , 5.19 - 5,21 (2H), 6.48 - 6.50 , 6.85 - 6.95 (3H), 7.20 - 7.24 (2H), 7,30 - 7.38 (5H), 7.39 - 7.41 (2H), 7.41 - 7.44 Example 272 3-Phenoxybenzyl 2-[(1S)-1-(2,3-dimethylPhenyl)ethy1l-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.54 - 1.57(3H), 2.23 - 2.25 (3H), 2.28 - 2.30 (3H), 5.02 - 5.10 , 5.20 - 5.27 (2H), 6.51 - 6.54 , 6.83 - 6.85 , 6.91 - 7.04 (7H), 7.13-7.17(1H) 7.30 - 7.41 (3H), 7.49-7.50 Example 273 2,3,5-Trifluorobenzyl 2-[(1S)-1-(2,3-dimethylphenyL)ethyl)-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.53 -1.56 (3H), 2.22 - 2.25 (3H), 2.29 - 2.32 (3H), 5.00 - 5.05 , 5.30 - 5.33 (1 H), 5.40 - 5.43 , 6.48 - 6.50 , 6.82 - 6.35 , 6.93 - 6.98 (3H)r 7-25 - 7.29 , 7,57 - 7.59 (1H) Example 274 2-Chloro-4-[luorobenzyl 2-[(1S)-1-(2,3-dimethylphenyl]ethyl]-1 H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.21 - 2.27 (6JH), 5.02 - 5.06 , 5.30 - 5.34 , 5.36 - 5.40 , 6.49 - 6.51 , 6.84 - 6.86 , 6.95 6.98 (2H), 7.09-7.12 , 7.32 - 7.34 , 7.39 - 7.41 , 7.49 - 7.51 Example 275 4-Fluoro-3-methoxybenzyl 2-[(1S)-1-(2,3-diniethylphenyl]ethyl]-1H-imidazole-1-carboxylarte 1H-NMR (de-Acetone): 1.50 -1.53 (3H), 2.01 - 2.03 (3H), 251 - 2.26 (6H), 3.80 - 3-81 (3H), 5.05 - 5.10 , 5.20 - 5.23 (2H), 6.47 - 6.49 (f H), 6.84 - 6.87 (2H), 6.95 - 6.98 (2H), 7.09 - 7.16 (2H), 7.49 - 7.51 Example 276 2.6-Dlchlorobenzyl 2-[nSl-1-(2,3-dimethylphenyl]ethryl)-1H-iidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.50 - 2.26 (6H), 5.00 - 5.05 , 5.70 - 5.72 , 5.77 - 5.79 , 6.47 - 6.49 , 6.81 - 6.83 (1H), 6.95 - 6.98 (2H), 7.42 - 7.43 , 7.49 - 7.52 (3H) Example 277 2-[4-tert-Butylphenyl)ethyl2-[(1S)-1-(2,3-dimethylphenyl)ethyI]-1H-lmidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.23 -1.27 (9H), 1.50 - 1.53 (3H), 2.23 - 2.30 (6H), 2.85 - 2.93 (2H), 4.38 - 4.42 (2H), 5.00 - 5.05 , 6.54 - 6.56 (1H), 6.85 - 6.88 , 6.91 - 6.95 (2H), 7.16-7.19 (2H), 7.35 - 7.38 (2H), 7.42-7.43(1 H) Example 278 (2R)-2-Phenylpropyl 2-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-lmidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.22 -1.26 (3H), 1.50 -1.53 (3H), 2.25 - 2.27 (3H), 2.30-2.32 (3H), 3.12 - 3.18 , 4.24 - 4.30 (2H), 5.00 - 5.06 , 6.52 - 6.54 , 6.85 - 6.90 (2H), 6.90 - 6.94 , 7.20 - 7.25 (3H), 7.29 - 7.32 (2H), 7.37 - 7.39 Example 279 2-Mesitytethyl2-[(1S)-1-(2,3-dimethytphenyl)ethyl)-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.53 -1.55 (3H), 2.20 - 251 (3H), 254 - 2.26 (6H), 257 - 259 (3H), 2.36 - 2.38 (3H), 4.20 - 4.25 (2H), 5.01 - 5.06 , 6.51 - 6.53 (1H), 6.80 - 6.81 (2H), 6.85 - 6.87 , 6.95 - 6.99 (2H),7.46-7.48 Example 280 2-[4-Chlorophenyl)ethyl2-[(1S)-1-(2,3-dimethylphenyl]ethyl)-1H-lmidazole-1-carboxyiate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.24 - 2.26 (3H), 256-258 (3H), 2.90 - 2.96 (2H), 4.40- 4.50 (2H), 5.01 - 5.06 , 6.52 - 6.54 , 6.83 - 6.96 (3H), 750 - 753 (2H), 7.25 - 7.27 (2H), 7.39 - 7.40 (1H) Example 281 2-(4-lsopropyl-2-methylphenyl]ethyl2-[(1S)-1-(2,3-dimethylphBnyl)ethyI]-1H-imidazole-1- carboxylate 1H-NMR (d6-Acetone): 1.19 -1.26 (9H), 1.50 -1.55 (3H), 2.25 - 2.29 (6H), 2.S5 - 2.92 (1H), 3.04 - 3.15 , 4.22 - 4.31 (2H), 5.00 - 5.10 , 6.52 - 6.55 , 6.82 - 6.36 (3H), 7.15-7.21 (4H). 7.38 - 7.39 Example 282 2-(4-Methylphenyl)ethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.52 - 1.55 (3H), 2.25 - 2.28 (6H), 2.30 - 2.31 {3(H), 2.64 - 2.89 (2H), 4.35 - 4.42 (2H), 5.01 - 5.09 , 6.53 - 6.55 , 6.82 - 6.B7 , 6.95 - 6.98 (2H), 7.08 - 7.09 (4H), 7.40 - 7.41 (1H) Example 283 1-Phenylpropyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 0.89 - 0.93 (3H), 1.54 -1.57 (3H), 1.79 -1.84 , 1.90 - 2.00 , 2.30 - 2.36 (6H), 5.00 - 5.05 , 5.60 - 5.64 , 6.47 - 6.49 , 6.89 - 6.93 , 6.93 - 7.02 (2H), 7.19 - 7.21 (2H), 7.29 - 7.33 (3H), 7.60 - 7.61 Example 284 2-(2,5-dimethylphenyl)Bthyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.52 -1.56 (3H), 2.20 - 2.25 (6H), 2.29 - 2.36 (6H), 2.81 - 2.94 (2H), 4.31 - 4.41 (2H), 5.00 - 5.05 , 6.50 - 6.52 , 6.84 - 6.98 (5H), 7.00 - 7.02 (1H}, 7.42 - 7.43 Example 285 3-Phen ylpropyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 1.90 -1.98 (2H)r 2.23 - 2.25 (3H), 2.36 -2.3B (3H), 2.60 - 2.64 (2H), 4.20 - 4.26 (2H), 5.04 - 5.08 , 6.51 - 6.53 , 6.85 - 6.88 , 6.96 - 6.98 (2H), 7.16 - 7.19 (3H), 7.22 - 7.25 (2H), 7.46 - 7.48 Example 286 2-Phenylpropyl2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.20 -1.24 (3H), 1.51 -1.55 (3H), 2.25 - 2.27 (3H), 2.32 - 2.34 (3H), 3.05 - 3.09 , 4.25 - 4.39 (2H), 5.02 - 5.10 , 6.51 - 6.53 , 6.81 - 6.95 (3H), 7.19 - 7.22 , 7.27 - 7.30 (4H), 7.37- 7.38 CHN Analysis Predicted: %C= 76.21, %H= 7.23, %N= 7.73 Observed: %C= 76.07, %H= 7.24, %N= 7.63 Example 287 2-(3-Methylphenyl)etriyl2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50-1.53 (3H), 2.22 - 2.25 (6H). 2.32 - 2.35 (3H), 4.38 -4.42 (2H), 5.01 - 5.05 , 6.55 - 6.57 , 6.85 - 6.88 , 6.92 - 7.00 (3H), 7.00 - 7.05 (2H), 7.14 - 7.18 , 7.40 - 7.41 Example 288 2-Phenytethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.26 - 2.23 (3H), 2.31 - 2.33 (3H), 2.90 - 2.95 (2H), 4.39 - 4.44 (2H), 5.02 - 5.06 (1 H>, 6.52 - 6.55 (T H), 6.85 - 6.95 (3H), 7.20 - 7.30 (5H), 7.39 - 7.40 Example 289 2-(2-MethylphenyHethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-WMR (d6-Acetone): 1.50 -1.53 (3H), 2.27 - 2.30 (6H), 2.33 - 2.35 (3H), 2.65 ■ 2.99 (2H), 4.35 - 4.42 (2H), 5.02 - 5.09 , 6.50 - 6.52 , 6.84 - 6.87 (1H), 6.96 - 6.99 (2H), 7.10-7.19 (AH), 7.41 - 7.42 CHN Analysis Predicted: %C= 76.21, %H= 7.23, %N= 7.73 Observed: %C= 7&22, %H= 7.22, %N= 7.68 Example 290 2-[(2-Chloropyrimidin-4-yl]phenyl)ethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR {d6-Acetone): 1.50 -1.54 (3H), 2.21 - 2.29 (6H), 3.10 - 320 , 3.20 - 3.28 (1H), 4.40-4.50 (2H), 4.97 - 5.03 , 6.50 - 6.52 , 6.33 - 6.91 (3H)r 7.18 - 7.29 (4H), 7.35 - 7.38 , 7.40 - 7.42 , 8.75-8.77 Example 291 2,3.4-Trifluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMH (de-Acetone): 1.50 - 1.53 (3H), 2.22 - 2.30 (6H), 5.01 - 5.07 , 5.25 - 5.30 , 5-39 - 5.41 , 6.42 - 6.44 , 6.81 - 6.85 , 6.92 - 6.97 (2H), 7.16 - 7.20 (2H), 7.44 - 7.46 CHN Analysis Predicted: %C= 64.94, %H= 4.93, %N= 7.21 Observed: %C= 64.90, %H= 4.93, %N= 7.21 Example 292 2-(2-Phenylethyl)ben2yl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.53 (3H), 2.21 - 2.25 (6H), 2.80 - 2.95 (2H)r 2.90 - 2.95 (2H), 5.01 - 5.06 , 5.20 - 5.24 , 5.31 - 5.35 , 6.49 - 6.52 (1H), 6.82 - 6.B5 (1 H), 6.94 - 6.97 (2H), 7.12 - 7.20 (4H), 7.20 - 7.26 (3H), 7.30 - 7.34 (2H), 7.46 - 7.47 Example 293 5-Fluoro-2-methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 - 1.53 (3H), 2.20 - 2.29 (9H), 5.01 - 5.06 , 5.20 - 5.25 , 5.31 ■ 5.35 , 6.43 - 6.51 , 6.82 - 6.85 , 6.92 - 7.00 (2H), 7.00 - 7.05 (2H), 7.20 - 7.24 , 7.56 - 7.58 Example 294 Pentamethylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.45 -1.49 (3H), 2.00-2.02 {3H), 2.11-2.13 (6H), 2.18 - 2.22 (9H)a 2.22 - 2.23 (3H), 4.98 - 5.02 (1H), 5.31 - 5.35 , 5.40 - 5.43 , 6.40 - 6.43 , 6.31 - 6.84 , 6.90 - 6.94 (2H), 7.43-7.45 Example 295 4-[Benzyloxyl-3-methoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.21 - 2.27 (6H), 3.78-3.80 (3H), 5.04 - 5.11 (3H), 5.18- 5.20 (2H), 6.50 - 6.53 , 6.80 - 6.90 (2H), 6.90 - 7.00 (4H), 7.30 - 7.40 (3H), 7,43 - 7.46 (2H) Example 296 2-Chlorobenzyl 2-[(1S)-1-(2,3-dimethy1phenyt)ethyl)-1H-lmidazole-1-carboxy1ate 1H-NMR (d6-Acetone): 1.51 - 1.54 (3H), 2.20 - 2.26 (6H), 5.04 - 5.09 , 5.30 - 5.40 (2H), 6.50 - 6.53 , 6.83 - 6.35 , 6.96 - 7.00 (2H), 7.30 - 7.33 (2H), 7.39 - 7.41 , 7.43 - 7.45 , 7.54 - 7.55 OH) Example 297 2-Methoxy-5-methylbenzyl2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR(d6-Acetone): 1.50 -1.53 (3H), 2.20-2.30 (9H), 3.78-3.80(3H), 5.04-5.12 ,5.20-5.27 (2H), 6.52 - 6.54 , 6.85 - 6.90 (2H), 6.95 - 7.00 (2H), 7.00 - 7.02 (1H), 7.15-7.18 , 7.42 - 7.44 Example 298 3-Fluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.22 - 2.28 (6H), 5.02 - 5.07 , 5.12 - 5.19 (2H), 6.49-6.51 (1H), 6.82 - 6.84 , 6.96 - 7.00 (2H), 7.02 - 7.10 (3H), 7.36 - 7.40 , 7.57 - 7.58 Example 299 4-ethoxyber)zyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Aceton6): 1.37 -1.40 (3H), 1.50 -1.53 (3H), 2.23 - 2.28 (6H). 4.00 - 4.05 (2H), 5.03 - 5.07 , 5.17 - 5.20 (2H), 6.49 - 6.51 , 6.82 - 6.90(3H), 6.95 - 6.99 (2H), 7.10 - 7.14{2H), 7.44 - 7.46 Example 300 2.4-Difluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 - 1.53 (3H), 2.22 - 2.27 (6H), 5.01 - 5.05 , 5.21 - 5.24 , 5.35 - 5.39 , 6.43 - 6.45 , 6.91 - 6.93 , 6.95 - 7.00 (2H), 7.00 - 7.09 (2H), 7.37 - 7.40 , 7,44 - 7.46 Example 301 2,4-Dimethoxy-3-methylbenzyl2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.57 -1.60 (3H), 2.09 - 2.11 (3H), 2.22 - 2.27 (6H), 3.71 - 3.73 (3H), 3.79-3.81 (3H), 4.45 - 4.54 (3H), 6.69 - 6.72 , 6.89 - 6.91 (2H), 6.95 - 7.00 (3H), 7.10 - 7.12 Example 302 2-Fluoro-5-methoxybenzyl2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.22 - 2.27 (6H), 3.79-3.81 (3H), 5.02 - 5.07 , 5.21 - 5.24 , 5.26 - 5.29 , 6.51 - 6,54 , 6.83 - 6.86 , 6.90 - 6.96 (4H), 7.03 - 7.0S , 7.49 - 7.51 (1H Example 303 4-Fluoro-2-melhoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone}: 1.51 -1.54 (3H)r 2.22 - 2.26 (6H), 3.80 - 3.81 (3H), 5.02 - 5.07 , 5.19-5.22 , 5.23 - 5.26 , 6.49 - 6.52 , 6.62 - 6.66 (1H), 6.80 - 6.90 (2H), 6.95 6.98 (2H), 7.21 - 7.24 , 7.42- 7.44 (1H) Example 304 4-Chloro-2-Fluorohenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (dB-Acetone): 1.51 -1.54 (3H), 2.21 - 2.27 (6H), 5.01 - 5.05 , 5.21 - 5.25 (1H), 5.35- 5.39 , 6.47 - 6.50 , 6.82 - 6.86 , 6.92 - 6.96 (2H), 7.20 - 7.22 , 7.25 - 7.35 {2H), 7.47 - 7.49 Example 305 2.5-dimethoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.53 (3H), 2.21 - 2.25 (6H), 3.72 - 3.76 (6H), 5.05 - 5.09 , 5.20 - 5.24 (2H), 6.54 - 6.57 (1H), 6.82 - 6.93 (6H), 7.47 -7.49(1 H) Example 306 3-Ethoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.35 -1.39 (3H), 1.52 -1.55 (3H), 2.22-2,27 (6H), 4.00 - 4.04 (2H). 5.03 - 5.07 , 5.20 - 5.24 (2H), 6.51 - 6.53 , 6.30 - 6.89 (4H), 6.95 - 6.98 (2H), 7.20 - 7.24 , 7.50 - 7.52 Example 307 2.5-Dichlorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.21 - 2.27 (6H), 5.01 - 5.06 , 5.30 - 5.34 , 5.39 - 5.43 , 6.50 - 6.53 , 6.84 - 6.87 , 6.92 - 6.97 (2H), 7.40 - 7.47 (3H), 7.48 - 7.50 Example 308 2.6-Difluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.21 - 2.27 (6H), 5.01 - 5.06 , 5.32 - 5.36 , 5.40 - 5.44 , 6.50 - 6.53 , 6.82 - 6.85 , 6.90 - 6.95 (2H), 7.42 - 7.44 , 7.50 - 7.55 Example 309 3,5-Dlchlorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.22 - 2.24 (3H), 2.27 - 2.30 (3H), 5.01 - 5.06 , 5.20 - 5.24 , 5.31 - 5.35 , 6.50 - 6.53 , 6.85 - 6.88 , 6.95 - 6.99 (2H), 7.29 - 7.31 , 7.42 - 7.44 ,7.57-7.59 Example 310 5-Chloro-2-methoxylberzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.21 - 2.27 (6H), 3.79 - 3.31 (3H), 5.03 - 5.09 , 5,20 - 5.23 , 5.27 - 5.30 (1H), 6.51 - 6.53 , 6.84 - 6.86 , 6.90 - 6,94 (2H), 7.00 - 7.03 (1H), 7.21 - 7.23 , 7.35 - 7.38 , 7.50 - 7.51 (1H) Example 311 3,4-Dimethylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.51 -1.54 (3H), 2.20 - 2.25 (6H), 2.26 - 2.30 (6H), 5.05 - 5.10 , 5.17 - 5.21 (2H), 6.50 - 6.53 , 6.83 - 6.85 , 6.95 - 6.97 (2H), 6.9B - 7.03 (2H), 7.05 - 7.03 , 7.44 - 7.46 Example 312 4-Bromobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.22 - 2.29 (6H), 5.01 • 5.06 , 5.20 - 5.29 (2H), 6.43 - 6.45 , 6.83 - 6.86 , 6.95 - 6,99 (2H), 7.09 - 7.11 (2H), 7.49 - 7.53 {3H) Example 313 4-[cyclopentytoxy)-3-methoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51-1.54 (3H), 1.58 -1.62 (2H), 1.70 - 1.81 (4H), 1.82 -1.39 (2H), 2.22 - 2.29 (6H), 3.75 - 3.77 (3H), 4.80 - 4.83 , 5.06 - 5.10 , 5.17 - 5.19 (2H), 6.50 - 6.53 {1 H), 6.80 - 6,90 (3H), 6.93 - 5.98 (3H), 7.47 -7.48 Example 314 2,3.5.6-Tatrafluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d8-Acetone): 1.51 -1.54 (3H), 2.22 - 2.28 (6H), 5,00 - 5,05 , 5.39 - 5.43 , 5.45 - 5.48 , 6.42 - 6.45 , 6.80 - 6.83 , 6.89 - 6.91 , 6.95 - 6.97 , 7.47 - 7.48 , 7.59 - 7.63 Example 315 3-Methoxy-4-methylberizyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (dB-Acetone}: 1.51 -1.54 (3H), 2.07 - 2.09 (3H), 2.22 - 2.28 (6H), 3.78 - 3.80 (3H), 5.04 - 5.09 , 5.20 - 5.22 (2H), 6.50 - 6.53 , 6.78 - 6.80 , 6.82 - 6,88 (2H), 6.95 - 6.98 (2H), 7.18 - 7.20 , 7.50-7.51 Example 316 4-Methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.51 -1.55 (3H), 2.22 - 2.30 (9H), 5.02 - 5.06 , 5.20 - 5.23 (2H), 6.50 - 6.53 , 6.83 - 6.86 , 6.95 - 6.98 (2H), 7.15 - 7.19 (3H), 7.45 - 7.46 Example 317 4-Cyanobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 - 1.53 (3H), 2.21 - 2.28 (6H), 5.02 - 5.08 , 5,35 - 5,42 (2H), 6.49 - 6.52 , 6.88 - 6.92 , 6.97 - 7.00 (2H), 7.40 - 7.43 (2H), 7.58 - 7.59 (1H), 7.70 - 7.73 (2H} Example 318 2-ethoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1,20 -1.26 (3H), 1.50-1.53 (3H), 2.20 - 2,24 (6H), 3.97 - 4.03 (2H), 5,05 - 5.13 , 5.21 - 5.24 (1 H)r 5.33 - 5.36 , 6.53 - 6.55 , 6.82 - 6.89 (2H), 6.92 - 6.98 (3H), 7.19 - 7,21 , 7.30 - 7.33 , 7.46 - 7.47 Example 319 2-[luoro-5-methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.54 (3H), 2.22 -2.31 (9H), 5.02 - 5.10 , 5.20 - 5.23 t 5.31 - 5.34 , 6.50 - 6.52 t 6.82 - 6.86 , 6.94 - 6.98 (2H), 7.00 - 7.04 , 7.10 - 7.13 , 7.20 - 7.24 , 7.45- 7.46 Example 320 2.5-Difluoro-4-meihylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50-1,54 (3H), 2.22-2.31 (9H), 5.01 - 5.06 , 5.20 - 5.24 , 5.30 ■ 5.33 , 6.46 - 6.48 , 6.82 - 6.99 (3H), 7.00 - 7.10 (2H), 7.49 - 7.53 Examp/e 321 2.3.6-Tritluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.21 -2,28 (6H), 5.01 - 5.06 , 5.35 - 5.39 (1H}, 5.41 - 5.45 , 6.44 - 6.46 , 6.81 - 6.85 , 6.93 - 6.98 (2H), 7.05 - 7.08 , 7.40 - 7.45 (2H) Example 322 (2-Methylblphenyl-3-yl]ethyl) 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.54 (3H), 2.17-2.18 (3H), 2.21 - 2.26 (6H), 5.05 - 5.11 , 5.36 - 5,41 (2H), 6.50 - 6.52 , 6.85 - 6.88 , 6.93 - 6.98 (2H), 7.20 - 7.32 (5H), 7.38 - 7.40 , 7.41 - 7,45 (2H), 7.56 -7.57(1 H) Example 323 2-Methoxybenzyl) 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.54 (3H), 2.22 - 2.29 (6H), 3.79 - 3.80 (3H), 5.03 - 5.11 , 5.20 ■ 5.30 (2H), 6.51 - 6.53 , 6.82 - 6.99 (4H)t 7.00 - 7.02 , 7.18 - 7.20 (1 H)> 7.33 - 7.36 , 7.45 - 7.46 Example 324 4-Bromo-2-[luorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.55 (3H), 2.21 -2,27 (6H), 5.01 - 5.06 , 5.22 - 5.26 , 5.32 - 5.36 , 6.45 - 6.47 , 6.82 - 6.85 , 6.95 - 6.98 (2H), 7.20 - 7.23 , 7.35 - 7.38 , 7.40-7.43 , 7.51-7.53(1H) Example 325 2,3-Dimethoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.52 -1.55 (3H), 2.22 - 2.27 (6H), 3.69 - 3.70 (3H), 3.83 - 384 (3H), 5-04 - 5.09 (1H}, 5.24 - 5.27 (2H), 6.51 - 6.53 , 6.79 - 6.81 , 6.84 - 6.87 , 6.95 - 6.98 (2H), 7.00 - 7.06 (2H), 7.45-7.46 Example 326 2,3-Dichlorobdenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR {d6-Acetone): 1.54 -1.57 (3H), 2.21 - 2.2S (6H), 5.02 - 5.08 , 5,35 - 5.40 , 5.41 - 5.45 , 6.47 - 6.49 , 6.84 - 6.87 , 6.97-7.00 (2H), 7.21 - 7.23 (1H), 7.30 - 7.33 , 7.57 - 7.58 , 7.58-7.59 Example 327 4-Butylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 0.88 - 0.94 (3H), 1.30 -1.40 (2H), 1.50 -1.61 (5H), 2.23 - 2.26 (6H), 2.80 - 2.83 (2H}, 5.02 - 5.10 , 5.20 - 5.21 (2H), 6.50 - 6.52 , 6.83 - 6.86 , 6.95 6.99 (2H), 7.17 - 7.20 (4H}, 7.47- 7.48 Example 328 3-Methoxybenzyl 2- 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 - 1.54 (3H), 2.22 - 2.27 (6H), 3.88 - 4.00 (3H), 5.04 - 5.09 , 5-21 - 5.23 (2H), 6.52 - 6.54 , 6.81 - 6.90 (4H), 6.95 - 6.99 (2H), 7.21 - 7.25 , 7.46 - 7.47 Example 329 3,4-Dichlorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.53 -1.56 (3H), 2.23-2,28 (6H), 5.02 - 5.08 . 5.20 - 5.24 , 5.27 - 5.31 , 6.44 - 6,46 , 6.84 - 6.87 (1H), 6.96 ■ 6.99 (2H), 7.20 - 7.22 , 7.50 - 7.56 (3H) Example 330 3.4-Diethoxylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.31 -1.39 (6H), 1.50 -1.55 (3H), 2.22 - 2.28 (6H), 3.96 - 4.07 (4H), 5.03 - 5,09 , 5.17 - 5.18 (2H), 6.52 - 6.54 , 6.80 - 6.90 (3H), 6.95 - 7.00 (3H), 7.45 - 7.46 (1H} Example 331 3-Methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.53 -1.56 (3H), 2.23 - 2.30 (9H), 5.04 - 5.09 (1H), 5.20 - 5.24 (2H). 6.49 - 6.51 , 6.84 - 6.87 , 6.95 - 6.98 (2H), 7.05 - 7.10 (2H), 7.15 - 7.18 , 7.20 - 7J23 , 7.48 - 7.49 Example 332 4-lsopropylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.20 -1.24 (6H), 1.52 -1.55 (3H), 2.23 - 2.28 (6H), 5.03 - 5.08 , 5.20 - 5.22 (2H), 6.49 - 6.51 , 6.83 - 6.86 , 6.96 - 6.99 (2H), 7.20 - 7.24 (4H), 7.50 - 7.51 Example 333 3-Chlorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (d6-Acetone): 1.52-1.55 (3H), 252 - 2.24 (3H), 257 - 2.29 (3H), 5.02 - 5.07 , 5.21 - 5.30 (2H), 6.49 - 6.51 , 6.85 - 6.88 , 6.95 - 6.99 (2H), 7.20 - 7.22 , 7.35 - 7.39 (3H), 7.57- 7.58 (1H) Example 334 3,4-Dlfluorobenzyl 2 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.52 -1.55 (3H), 2.22 - 2.24 (3H)t 2.28 - 2.30 (3H), 5.02 - 5.07 , 5.20 - 5.24 , 5.25 - 559 (1H), 6.44- 6.46 (1H), 6.83 - 6.86 , 6.95 - 6.99 (2H), 7.09 - 7.12 , 7.21 - 7.23 (2H), 7.56-7.57(1 H) Example 335 2-Chloro-3.4-dimethoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (de-Acetone): 1.52 -1.55 (3H), 252 - 2.26 (6H), 3.80 - 3.81 (3H), 3.90 - 3.92 (3H), 5.02 - 5.06 , 5.21 - 5.29 (2H), 6.49 - 6.51 , 6.85 - 6.89 , 6.94 - 7.00 (3H), 7.09 - 7.12 (1H), 7.44 - 7.45 Example 336 2-Methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.20 - 2.29 (9H), 5.02 - 5.07 r 551 - 5.25 , 5.29 - 5.34 , 6.48 - 6.51 , 6.84 - 6.89 (2H), 6.90 - 6.96 (2H), 7.16 - 7.25 (3H), 7.50 - 7.51 Example 337 2-Chloro-6-fluofobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (d6-Acetone): 1.50-1.54 (3H), 251 - 255 (6H), 5.01 ■ 5.06 (1H), 5.39 - 5.67 (2H), 6.49 - 6.52 , 6.82 - 6.87 , 6.90 - 6.95 (2H), 7.19 - 7.24 , 7.35 - 7.38 , 7.43 - 7.44 , 7.50 - 7.56 Example 338 4-Methoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.54 (3H), 2.24-2,29 (6H), 3.80 - 3.81 (3H), 5.02 - 5.10 , 5.19-550 (2H), 6.50 - 6.53 , 6.83 - 6.90 (3H), 6.95 - 6.99 (2H), 7.20 - 753 (2H), 7.43 - 7.44 (1H) Example 339 2.3.5,6-Tetramethylpenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (d6-Aceione): 1.44 - 1.47 (3H), 2.02 - 2.06 (3H), 2.09 - 2.12 (6H), 2.19 - 253 (9H), 4.98 - 5.03 , 5.33 - 5.35 , 5.30 - 5.03 , 6.40 - 6.42 . 6.80 - 6.84 , 6.90 - 6.94 (2H} 7.00 - 7.01 (1H), 7.43 -7.4-[(1 H) Example 340 3,4,5-Trifluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.52 -1.54 (3H), 2.22 - 2.24 (3H), 2.29 - 2.31 (3H), 5.02 - 5.03 (1H), 5.20 - 5.24 , 5.30 - 5.34 , 6.45 - 6.47 , 6.83 - 6.86 , 6.93 - 6.97 (2H), 7.10 - 7.16 {2H), 7.57 - 7.58 Example 341 2,5-DifIuorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.52 -1.55 (3H), 2.22 - 2.28 (6H), 5.02 - 5.09 , 5.23 - 5.26 , 5.36 - 5.40 , 6.50-6.52 , 6.82 - 6.86 , 6.92 - 6.96 (2H), 7.05 7.10 , 7.19 - 7.23 (2H), 7.51 - 7.52 Example 342 3,5-Dimethulbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d«-Acetone): 1.50-1.53 (3H), 2.22 - 2.31 (12H), 5.05 - 5.15 , 5.18 - 5.20 (2H), 6.52 - 6.54 , 6.87 - 6.90 (3H), 6.95 - 6.98 (3H), 7.50 - 7.51 Example 343 4-(1H-pyrazol-1 -yl]benzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.51 -1.54 (3H), 2.22-2,28 (6H), 5.05 - 5.14 , 5.25 - 5.31 (2H), 6.43 - 6.45 (2H), 6.83 - 6.86 (1H), 6.96 - 6.99 (2H), 7.39-7.42 (2H), 7.53 - 7.54 , 7.69 - 7.70 , 7.80 - 7.83 (2H), 8.35 - 8.36 Example 344 3-Chloro-4-methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR {d6-Acetone): 1.50 -1.53 (3H), 2.21 - 2.33 (9H), 5.02 - 5.10 , 5.20 - 5.27 (2H), 6.47 - 6.49 , 6.83 - 6.86 , 6.94 - 6.97 (2H), 7.10 - 7.21 (2H), 7.33 - 7,36 , 7.51 - 7.53 Example 345 4-ethoxy-3-methoxybenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate Example 346 3-Cyanobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 (3H), 2.22 - 2.28 (6H), 5,02 - 5.09 , 5.28 - 5.31 , 5.38 - 5.41 , 6.43 - 6.45 , 6.84 - 6.86 , 6.95 - 6.98 (2H), 7.55 - 7.60 (3H), 7,61 - 7.63 , 7.85 - 7.88 Example 347 2-Methoxy-4-methylbenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.50 -1.53 (3H), 2.21 - 2.25 (6H), 2.32 - 2.34 (3H), 3.73 - 3.79 (3H), 5.06 - 5.11 (1H), 5.19 - 5.25 (2H), 6.50 - 6.53 , 6.72 - 6.74 , 6.81 - 6.90 (2H), 6.93 - 6.97 (2H), 7.05 - 6.08 , 7.42- 7.43 Example 348 4-Fluorobenzyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acetone): 1.50 -1.54 (3H), 2.23 - 2.27 {6H), 5.01 - 5.06 , 5.21 - 5.29 (2H), 6.47 - 6.49 , 6.82 - 6.85 , 6.95 - 6.98 {2H), 7.05 -7.T1 (2H), 7.32 - 7.38 (2H), 7.48 - 7.50 Example 349 (7-Methoxy-1.3-benzodioxol-5-yl)methyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate (Formula Removed) To a mixture of the compound of Example 1 (180 rrtg, O.90 mmol} and pyridine (146 jxf. 1.80 rnmof) in anhydrous acetonitrile (3 ml),, at 0°C.and under nitrogen, was added diphosgene (54 µl 89 rng, 0.45 mmol). Trie mixture was al]owed to warm to room temperature and stirred for 10 min, before addition of (7-methoxy-1,3-benzodioxol-5-yl)methanol (137 mg, 0.75 mmol) in acetonitrile (1 ml), via syringe. The reaction mixture was stirred at room temperature for 30 min and then filtered. The filtrate was purified by automated preparative fiquid chromatography (Glison system, 150 mm x 22.4 mm LUNA C18(2) 5 µm column, 20 ml / mln) using an acetonitrile : water gradient [15:85 to 98:2]. The appropriate fractions were combined and concentrated to give the title compound (20 mg). Experimental MH+ 365.9 (minus 44); expected 409.2 or 365,2 1H-NMR (d6-Acetone): 1.50 -1.54 (3H), 2.24 - 2.32 (6H). 3.80 - 3.81 (3H), 5.05 - 5.12 , 5.15 - 5.18 (2H), 6.00 - 6.01 (2H), 6.50 - 6.53 (2H), 6.63 - 6,64 , 6.82 - 6.86 , 6.95 - 6.97 (2H), 7.49 - 7.50 Rhip. Funct. ED100 mg/cm2= 0.03 Similarly prepared from Example 58 were: (Formula Removed) (Table Removed) Example 350 2-Naphthymethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (de-Acefone): 1.53 -1.56 (3H), 2.20 - 2.22 (3H), 2.26 - 2.23 (3H), 5.05 - 5.12 (1 H)r 5.40 - 5.45 (2H), 6.51 -6.53 , 6.65 - 6.96 (3H), 7.18 - 721 , 7.51 - 7.S0 (3H)t 7.80 - 7.81 , 7.83 - 7.S5 (3H) Example 351 (4-Phenyl-2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.48 - 1.56 (3H), 220 - 2.30 (6H), 4.42 - 4.51 , 4.80 - 4.86 (2H), 6.49 - Q.53 (2H), 6.85-7.01 (10H)h Example 352 (S-Phenoxypyridln-3-yl)methyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -1.54 {3H), 2.23 - 2.29 (6H), 5.01 - 5.10 , 5.20 - 5.30 (2H), 6.44 - 6.47 , 6.84 - 6.88 , 6.90 - 6.98 (3H), 7.12 - 7.15 (2H), 7.20 - 7.24 , 7.40 - 7.46 (2H). 7.50-7.51 , 7.65-7.67 (1H), 8.10-8.12 (1H} Example 353 S~(6-Fluoro-1H-indol-1-yl}pentyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (d6-Acetone): 1.22 -128 (2H). 1.52 -1.55 (3H), 1.60 -1.66 (2H)r 1.80 -1,85 (2H), 2.24 - 2.26 (3H), 2.35 - 2-37 (3H), 4.16 - 4.26 (4H), 5.01 - 5.06 , 6.40 - 6.42 (1H}, 6.51 - 6.53 (1 H)r 6.80 - 6.90 (2H), 6.96 - 6.99 (2H), 7.19 - 7.21 , 7.22 - 7.23 , 7.40 - 7.41 , 7.49 - 7.52 Example 354 2-(6-Methoxy-1,5-naphthyridin-4-yl)ethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR {dB-Acatane): 1.43 -1.46 (3H), 2.21 - 2.26(6H)t 3.42 - 3.60 (2H), 4.00 - 4.01 (3H), 4.61 -4.75 (2H), 4.92 - 4.97 , 6.51 - 6.53 , 6.82 - 6.95 (3HJ, 7.08 - 7.10 , 7.29 - 7.30 „ 7.42 - 7.44 , 8.20 - 8.23 , 8.61 - 8-63 Example 355 2-(2-Maphthyl)ethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1 H-NMR (d6-Acetone): 1-52 -1.55 (3H), 2.24 - 2.30 (6H), 3.10 - 3.15 (2H), 4.45 - 4.60 (2H), 5.00 ■ 5.07 , 5.52 - 6.55 , 6.82 - 6-95 (3H), 7.39 - 7.49 (4H), 7.71 - 7,72 . 7.80 - 7.87 (3H) Exampte 356 1-Benzofurary 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMB (d6-Acetone): 1.52-1.56 (3H)t 2.21 -2-23 (3H), 2.30 - 2.32 (3H), 5.03 - 5.10 , 5.39 - 5.42 (2H)n 6.45 - 6,47 , 6.81 - 6.98 (4H), 7.21 - 7.24 , 7.30 - 7.34 (1H}, 7.45 - 7.51 (2H), 7.62 - 7.64 Example 357 2,3-Dihydro-1,4-benzodioxin-6-ylmethyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 - 1.54 {3H), 2.24 - 223 (6H), 4.21 - 4.24 (4H), 5.03 - 5.11 (3H), 6.50 - 6.53 , 6.78 - 6.80 (2H), 6.82 - 6.88 (2H), 6.96 - 6.99 (2H), 7.46 - 7.48 Example 358 (2-Phenyl-1,3-benzothlazol-5-yl]methyl 2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.51 -154 (3H), 2.21 -2,22{3H), 2.27 - 2.28 (3H), 5.02 - 5.09(1 H), 5.20-5.28 (2H), 6.50 - 6.52 , 6.82 - 6.98 (3H), 7.36 - 7.39 , 7.58 - 7.61 (4H), 8.00 - 8.05 (2H), 8.14 - B. 18 (2H) Example 369 (3-Ethyl-5.5.8,8-tetTamethyl-5,67,8-tetrahydronaphthalen-2-yl)methyl2-[(1S)-1-(2,3-dimethylpheny1)ethyl]-1H-imidazole-1-carboxylate 1H-NMR (d6-Acetone): 1.09 -1.15 (3H). 1.20-1.30 (12H), 1-50 -1.54(3H), 1.64 -1.66 (4H),2.20-2,29 (6H), 2.50 - 2.60 (2H), 5.04 - 5.10 , 5.22 - 5.24 (2H), 6.52 - 6.55 , 6.81 - 6.84 , 6.92 - 6.95 (2H), 7.20 - 7.21 , 7.37 - 7.38 , 7.44 - 7.45 Preparations Preparation 1 2-[1-(2,3-Dimethylphenyl)vinyl)-1H-imidazole The compounci of Preparation 13 (80 mg, 0.37 mmot) was stirred at 50°C In thionyl chloride (2 ml) for 1 h. The reaction was quenched into Iced water (5 ml) and then basified with dilute aqueous sodium hydroxide solution. The aqueous phase was then extracted with dichloromethane (2x10 mi}. The combined exiracts were dried (MgSO4) and concentrated in vacuo to give the title compound (72 mg). Alternative syl)thesis A solution of thionyl chloride (37 ml, 498 mmol) In acetonitrole (200 ml) was added to the compound of Preparation 13 (48.90 g, 226 mmol}. The resulting solution was stirred at room temperature for 2 h, then poured Into ice/water {600 ml), during which time the internal temperature was maintained at was filtered at room temperature. The light beige crystal]ine solid obtained was washed with water (100 ml) and dried in vacuo at 60°C to give the title compound (30.6 g). Experimental MH+ 199.2; expected 199.1 Alternative syl)thesis To a solution of the compound of Preparation 195 (1.0kg, 3.25 mol) in 2-propanol (10L) was added pal]adium (10 wt. % on carbon, 100.0 g) and the raactron mixture was heated at 60°C under a hydrogen atmosphere (45 - 60 psi) for 24 h. The mixture was cooled and filtered through hyl]o Super Cel®, washing through with 2-propanol (2 x 250 mi). The filtrate was concentrated in 'vacuo and diluted with acetonitrile (1300ml) and stirred to get a solution. To this solution, was then added dropwise sulphuric add (cone, 1.2L). The reaction mixture was stirred at 55°C for 18 h. The mixture was cooled to -5°C, quenched with water (12.51), and adjusted to pH 10 by addition of aqueous sodium hydroxide solution (50%]. The resulting solid was col]ected by filtration, reslurried with water (15.0L) filtered, washed with water (2.5L) and dried in vacuo at 50°C to give the title compound (0.413kg, purity by HPLC 99.80%). Preparation 2 2-[1-(2,3-Difluorophenyl]vinny]l-1H-imidazole A solution of the compound of Preparation 14 (240 mg, 1.1 mmol) and thJonyt chloride (1.56 ml, 21.4 mmol) In acetonitrile (5 ml) was heated at 70°C for 10 h and then stirred at room temperature for 18 h. The mixture was concentrated in vacuo and to the residue was added toluene. This solution was concentrated in vacuo and the process was repeated. The residue was then partitioned between ethyl acetate (50 m)) and saturated aqueous sodium hydrogen carbonate solution (30 ml). The two layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 40 mi). The combined organic phases were dried (MgSO4) and stirred with activated charcoal, before being filtered and concentrated in vacuo to give the title compound (325 mg). Experimental MH+ 207.1; expected 207.1 Similarly prepared were: (Table Removed) Preparation 13 1-(2,3-Dimethylphenyl)-1-1H-imidazole-1-yl)ethanol 1-(Diethoxymethyl)lmidazole (76.0 g, 446 mmol} and N,N,NN,N-tetramethylethylene diamine (67.6 mL, 446 mmol) were dissolved in 2-methyltetrahydroruran (400 ml) and cooled to -40°C, under nitrogen. n-Butyl lithium (2.5M in hexane, 180 ml, 446 mmol) was added sfowly maintaining the reaction temperature at Alternative syl)thesis To a solution of methylmagnesium bromide (0.63 ml, 0.8B mmol) was added a stirred solution of the compound of Preparation 24 (80 mg, 0.4 mmol) in anhydrous tetrahydrofuran at 0°C. The reaction mixture was stirred tor 30 min, quenched with saturated ammonium chloride solution, basified with saturated sodium hydrogen carbonate solution and extracted with dichloromethane (2x3 ml). The organic layers were dried (MgSO4) and concentrated in vacuo to give the title compound (85 mg) Experimental MH+ 217.2; expected 217.1 Preparation 14 1-(2,3-Difluorophenyl)-1-[1H-imidazol-2-yl)ethanol To a solution of the compound of Preparation 25 (450 mg, 2.2 mmot) in tetrahydrofuran {5 ml), at 0°C, was added methylmagnesium bromide (3M in diethyl ether, 2.16 ml, 6.5 mmot) and the reaction mixture was stirred at room temperature for 1 h. To the mixture was added hydrochloric acid (0.1M, 15 mf) and the mixture basified by addition of saturated aqueous sodium hydrogen carbonate solution. The mixture was extracted with ethyl acetate (3 x 20 ml) and the combined organics were dried (MgSO4) and concentrated in vacuo to give the title compound (240 mg) Experimental MH+ 225.1; expected 225.1 Similarly prepared were: (Table Removed) Preparation 16 1H-NMR (CD3OD): 2.00 - 2.05 (3H), &84- 6.95 (4H), 7.26-7.34 Preparation 18 1H-NMR (CD3OD): 1.89 -1.92 (3H), 6.89 - 6.96 (3H), 7.18 - 7.23 (2H), 7.25 - 7.31 Preparation 19 1H-NMR (CDCi3): 1.20 -1.25 (3H), 2.21 - 2.27 (3H), 6.62 - 6.66 , 6.80 - 7.00 (3H), 7.41 - 7.49 Preparation 21 1-[2-Ctiloro-3-(trHluoromethyl^pheny>M-[1W-imida2ol-2-yl]ethanol To a solution of the compound of Preparation 30 (1.1 g, 4.0 mmol) in tetrahydrofuran (10 ml), at -78°C, was added dropwise methyl]lmium (1.6M in diethyl ether, 3 ml, 4.8 mmol). After stirring for 2 h, co(d hydrochloric acid (0.1 M) was added and the mixture was adjusted to pH 7 by addition ol potassium carbonate. The mixture was extracted with ethyl acetate and the combined extracts were dried (MgSCu) and concentrated in vacuo to give the til]e compound (600 mg). Similarly prepared were: (Table Removed) Preparation 24 |2.3-DimethylphenylMlH-imidazol-2-yl)methanon9 To the compound of Preparation 201 (200 mg, 1.0 mmol) in dichloromethane (10 ml) was added Dess Martin Periodinane (15 % in dichloromethane, 3 ml) and the reaction mixture was stirred at room temperature for 30 min. The mixture filtered through silica, eluting with diethyl ether and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography (silica), with gradient elutlon, diethyl ether: dichloromethane [0:1 to 1:1]. The appropriate fractions were combined and concentrated to give the title compound (100 mg). Experimental MH+ 201.2; expected 201.1 Preparation 25 (2,3-difluorophenyl]f1H-lmldazol-2-yl)methanone To a solution of the compound of Preparation 37 (350 mg, 1.67 mmol) in dichloromethane (20 ml) was added Dess-Martin Periodinane (780 mg, 1.B0 mmol) and the reaction mixture was stirred at room temperature for 1 h. The mtxture was filtered through silica, washing through wrth dichloromethane and ethyl acetate and the filtrate was concentrated in vacuo. To the residue as added ethyl acetate (100 ml) and the solution was washed with aqueous sodium metabisutphite solution (10%, 40 ml). The aqueous phase was extracted with ethyl acetate (100 ml) and the combined organic phases were dried (MgSO4) and concentrated in vacuo to give the title compound (450 mg) Experimental MH* 209.1; expected 209.1 Similarly prepared were: (Table Removed) Preparation 34 1W-lmidazol-2-yl(5-methoxy-2,4-dimetriylphenyl)me1hanone To a solution of the compound of Preparation 45 (433 mg, 1.8 mmol) in ethyl acetate (10 ml) was added manganese (IV) oxide (810 mg, 9.3 mmol) and the reaction mixture was stirred at room temperature for 3 h. The mixture was filtered through Arbocel®, washing through with ethyl acetate, and the filtrate was concentrated in vacuo to give the title compound (440 mg). Experimental MH231.3; expected 231.1 Preparation 35 1-(2,3-dimethylphenyl)propan-1-one A mixture of the compound of Preparation 192 (1.0 g, 6.1 mmol} and Dess-Martm Periodinane (2.58 g, 6.1 mmol) in dlchloromethane (20 ml) was stirred at room temperature for 1 h. The mixture was then purified by column chromatography (silica), eluting with dlchloromethane : cyclofiexane [1:11. The appropriate fractions were combined and concentrated to give the title compound (0.95 g). 1H-NMR (CDCl3): 1.11 -1.19 (3H), 2.23-2,29 (6H), 2.79 - 2.87 (2H), 7.07 -7.12 , 7.17 - 7.27 (3H) Preparation 36 (i-BenzvH rf !midazol-2-ylV2,3-climethylphenyl)methanone A solution of 2,3-dimethylbenzoic acid (100 g, 666 mmol) in thlonyl chloride (350 ml) was heated at 80°C for 1 h, before cooling to room temperature and concentrating in vacuo. To the residue was added toluene (100 mi) and the solution was again concentrated in vacuo. The intermediate acid chloride was added to a mixture of 1-benzyl]midazole (100 g, 632 mmol) and trlethylamine (100 ml) In acetonitrile (1 I) and the reaction mixture was heated at reflux for 18 h. The reaction mixture was concentrated in vacuo and to the residue was added diethyl ether (500 ml) and ethyl acetate (50 ml). This solution was washed with water (500 ml) and saturated aqueous sodium hydrogen carbonate solution (500 ml), filtered through silica gel (100 g) and concentrated in vacuo to give the title compound (182 g). Experimental MH291.4; expected 291.1 Alternative syl)thesis To a solution of 2,3-dimethylbenzoic acid (2.0kg, 13.2 mo() in toluene (20L) was added N,N~ dimethylforrnamide (20ml), fol]owed by oxalyl chloride (2.0kg, 15.Q moi) at room temperature. The reaction mixture was stirred at room temperature for 4 h and monitored by thin layer chromatography. If necessary, excess oxalyl chloride (25 g) was added until no starting material was observed. Excess toluene and oxalyl chloride were removed by distil]ation under vacuum at temperatures below 70°C. To the residue was added toluene (150 ml) and the mixture was again concentrated in vacuo to give 2,3-dimethylbenzoyl chloride (2.0kg). To a solution of 1-benzyl-1H- imidazole (1.69Kg, 10.56 mo!) in dichloramethane (14.0L), at -7°C, was added trlethylamine (1.61kg, 10.56 moi). A solution of 2,3-dimethylbenzoyl chloride (2.0kg, 11.99 moi) in dichloramethane (6.0L) was then added dropwise and the reaction mixture was stirred at room temperature for 16 h. The reaction was monitored by Thin layer Chromatography. After completion of the reaction, the reaction mixture was diluted with water (5.0L) and the mixture was stirred for a further 15 min. The two layers were separated and the organic phase was concentrated in vacuo. To the residue was added toluene (8.0L) and the solution was coofed to -5°C, before addition of hydrochloric acid (5N, 8.0L). The two layers were separated and the aqueous layer was adjusted to pH 9-12, by addition of aqueous sodium hydroxide solution (50%), and extracted with toluene (4.0L and then 8.0L). The combined organic phases were concentrated in vacuo\o give the title compound (2.8kg). Preparation 37 f2,3-Dif]uoropheny[)(1tf-imidazol-2-yl>mettoriol To a solutfon of 1-(dfethoxymethyl)-1H-i-lmidazole (1.65 ml, 10.1 mmol) In telrahydrofuran (15 ml), at -60°C and under nitrogen, was added n-butyl]]thium (2.5 M in hexanes, 4,03 ml, 10.1 mmol). The reaction mixture was stirred at -60°C for 1 h, before addition of 2,3-difluorobenzaldehyde (1.00 ml, 9.2 mmol), and then al]owed to warm to room temperature over 18 h. The mixture was concentrated tn vacuo and to the residue was added ethyl acetate (50 ml) and hydrochloric acid (3M, 50 ml). The two layers were separated and the aqueous phase was basified with aqueous sodium hydroxide solution (20%) and extracted with ethyl acetate (3 x 100 mi). The combined organfc phases were dried (MgSQ,) and concentrated in vacuo and the residue was re-crystal]ised from 2-propanoI fo give the title compound (1.25g) Experimental MH4 211.1; expected 211.1 Similarly prepared were: (Table Removed) Preparation 47 2-11 -(2,3-DimethylphenyOprop-l -en-1-vil-1 ^-Imidazole A solution of the compound of Preparation B3 {350 mg, 1.52 mmol) in hydrochloric acid {2N, 50 ml) was heated at refiux for 18 h. The reaction mixture was concentrated in vacuo and the residue was partitioned between dichtoromethane (20 ml) ar»d aqueous sodium hydrogen carbonate solution (20 ml). The two layers were separated and the aqueous phase was extracted with dichtoromethane (2 x 20 ml). The combined organic phases were dried (MgSO4) and concentrated in vacuoXo give the t'rtte compound (255 mg). Experimental MrT 213.2; expected 213.1 Preparation 48 2-[t-(3-Methylphenyl) Similarly prepared were: (Table Removed) Preparation 67 2-[1-('2-Chloro-3-metriylpheriyl)ylriylmH-lmldazolg A solution of the compound of Preparation 97 (1.22 g, 5.2 mmoJ) in Eaton's Reagent (15 ml) was stirred at room temperature for 18 h. To the mixture was added ethyl acetate and saturated aqueous sodium hydrogen carbonate solution and the two layers were separated. The organic phase was washed with brine, dried (MgSO4) and concentrated in vacuo to give the title compound (1.00 g). Experimental MH4 219.3; expected 219.1 Similarly prepared were: (Table Removed) Preparation 75 2-[1 -(2-Chloro-4-methoxyphenyl)vinyl)-1H-i-imidazole A solution of the compound of Preparation 90 (703 mg, 2.7 mmol) in trifluoroacetic acid (15 ml) was heated at 50°C for 18 h. The reaction mixture was concentrated in vacuo and the residue was neutralised by addition of aqueous sodium hydrogen carbonate solution. The mixture was extracted with ethyl acetate and the combined extracts were concentrated in ^acuoto give the title compound (469 mg}. Experimental MH235.3; expected 235.1 Similarly prepared were: (Table Removed) ** The reaction to yield Preparation 76 gave some of Preparation 77 since Preparation 92 contained some Preparation 91 and vice versa Preparation 78 1-(1tf-lmidazol-2-yl)-1-(3-methylphenyl)etriano1 To a solution of 1-(diethoxym ethyl)-W Imidazole (935 mg, 5.5 mmol) in anhydrous tetrahydrofuran (6 ml), at -78°C, was added n-butyl]ithium (2.5M in hexanes, 2.2 ml, 5.5 mmol). The mixture was al]owed to warm to 0°C and then added to a solution of 1 -{3-methylphenyl}ethanone (670 mg, 5.0 mmol) in anhydrous tetrahydrofuran (5 ml), also at 0°C. The reaction mixture was stirred at 0°C for 30 min and then at room temperature for 1 h. The mixture was poured into cold hydrochloric acid (4N, 10 ml) and stirred for 20 min. The mixture was adjusted to pH 7 by addition of sodium hydrogen carbonate and then extracted with cfichloromethane. The combined extracts were dried (MgSCU) and concentrated In vacuo to give the title compound (850 mg). Experimental MH+ 203.3; expected 203.1 Similarly prepared were: (Table Removed) * The reaction to yield Preparation 91 gave some of Preparation 92 since Preparation 173 contained soma Preparation 174 and vice versa. Preparation 107 1H-NMR (CD3OD): 1.89 -1.94 (3H), 6.93 - 6.97 (2H), 7.08 - 7.13 , 7.33 - 7.41 (3H) Preparation 110 1 -i2-Chloro-3-methylphen vflethano ne To a soiution of 2-chloro-3-methylbenzoic acid (1.71 g, 10.0 mmol) In anhydrous tetrahydrofuran (10 ml), at O'C and under nitrogen, was added methyl]fthium (1.6M in diethyl eiher, 13.1 ml, 21.0 mmol), via syringe. The reaction mixture was stirred at 0°C for 30 mrn and then al]owed to warm to room temperature over 1 h. To the reaction m Ixture was added cold hydrochloric acid (1M, 100 ml) and dlchioromethane (110 ml). The mixture was adjusted to pH 7 by addition of saturated aqueous sodium hydrogen carbonate solution and the two layers were separated. The aqueous layer was extracted with further dlchioromethane and the combined extracts were dried (MgSO4) and concentrated in vacuato give the title compound (1.19 g). 1H-NMR (CDCI3): 2.37 - 2.39 (3H), 2.57 - 2.60 (3H), 7.15 - 7.20 , 7.23 - 7.31 (2H) Similarly prepared were: (Table Removed) Preparation 115 H3-Methoxy-2-methylphenyl)ethanone A solution ol 2-methyl-3-methoxybenzoic acid (10.0 g, 60.2 mmot) in thiony) chloride (50 ml) was heated at reflux for 1 h and then cooled and concentrated in vacuo. To the residue was added tetrahydrofuran (100 ml) and iron (III) acetylacetonate (638 mg, 1.8 mmol) and the solution was coofed to -20°C, before addition of mefhylnagnesium bromide (3M in dietfiyf ether, 22.1 ml, 66.2 mmol). After stirring for 15 mil, the mixture was poured Into saturated aqueous ammonium chloride soJution and extracted with dichloromethane. The combined extracts were washed with saturated aqueous sodium hydrogen carbonate solution, dried (MgSOt) and concentrated In vacuo. The residue was purified by flash chromatography (silica), eluting with pentane : dichloromethane [1:1]. The appropriate fractions were com bined arid concentrated to give the title compound (7.60 g). 1H-NMR (CDCI3): 2.27 - 22.9 (3H), 2.50 - 2.53 (3H), 3.79 - 3.83 (3H), 6.9D - 6.94 , 7.10 - 7.14 , 7.16-7.21 Preparation 116 Chloromethyl 3-cyclopentylpropanoate Cyclopenlylpropionyl chloride (2.0 g, 12.4 mmol) was added to a mixture of paraformaldehyde (377 mg, 13.0 mmol) and zinc chloride at room temperature under nitrogen. The reaction mixture was heated to 75°C for 3 hours, cooled and the mixture dlslil]ed (90° - 100°C) to give the title compound (1.10 g) 1H-NMR (CDCI3): 1.00 - 1.10 (2H), 1.45 - 1.75 (9H), 2.35 - 2.40 (2H), 5.70 - 5.75 (2H) Similarly prepared were: (Table Removed) Preparation 119 Chloromethyl cyclopropylmethyl carbonale To a solution of cyclopropylmethanol (0.39 ml, 5.0 mmol) and pyridine (0.40 ml, 5.0 mmol} In dlchloromethane (4 mi), at 0°C and under nitrogen, was added dropwise chloromethyl chlorocarbonate (0.40 ml, 4.5 mmof). The reaction mixture was stirred at 0°C for 30 min and then at room temperature for 2 h. To the mixture was added diethyl ether (15 ml) and the solid material was col]ected by filtration and washed with diethyl ether (10 ml). The combined organic phases were dried (MgSO*) and concentrated in vacuo ta give the title compound (725 mg) which was used directly. Similarly prepared were: (Table Removed) Preparation 125 Chloromethyl (2,4-DlchtarobenzvQcarbamate To a solution of the compound of 1-{2,4-dichlorophenyl)rnethanamine (0.15 ml, 1.1 mmol) in anhydrous dichloromethane (2 ml), at -10°C and under nitrogen, was added dropwise 3-chloropropanoyl chloride (0.12 mi, 1.1 mmol). The reaction mixture was al]owed to warm to room temperature and stirred for 18 h. To the mixture was added dichloromethane (5 ml) and water (5 ml) and the two layers were separated. The aqueous layer was extracted with dichloromethane (10 mf) and the combined organic layers were dried (MgSO4) and concentrated in vacuo to grva the title compound (235 mg). 1H-NMR (CDC!3>: 4.35 - 4.39 (2H), 5.76 - 5.79 (2H), 7.11 - 7.15 , 7.37 - 7.44 (2H) Similarly prepared were: (Table Removed) Preparation 133 1-Chloroethyl r2-(methylsurfonyl)ethyl)carbamate To a solution of 2-{methylsulfonyi}ethanamine (17S mg, 1.1 mmol) and W,W-dilsopropylelhylamine (0.38 ml, 2.2 mmol) in anhydrous dichloromethane (2 ml), at 0DC, was added dropwise 3-chloropropanoyl chloride (0.12 ml, 1.1 mmol). The reaction mixture was al]owed to warm to room temperature and stirred for 62 h. To the mixture was added water (5 ml) and the two layers were separated. The aqueous layer was extracted with dichloromethane (2 x 5 mi) and the combined organic layers were dried (WlgSO*) and concentrated in vacuo to give the title compound (260 mg). Similarly prepared were: (Table Removed) Preparation 136 1-Banzv>-2-[1-[3-cyclopropyl-2-methylDrienyl]ylnyU-1H-lmidazole To a solution of the compound of Preparation 140 (1.04 g, 3.0 mmol) In toluene (30 ml) was added potassium phosphate (1.88 g, 8.9 mmol) and cydopropyl boronic acid (304 mg, 3.5 mmol). Trie mixture was de-gassed and tricyctohexylphosphine (83 mg, 0.3 mmol) was added. The mixture was de-gassed again, before addition of pal]adium (II) acetate {33 mg). The reaction mixture was then heated at reflux for 18 h. The mixture was poured into ethyl acetate and water and the two layers were separated. The organic phase was washed with brine, dried (MgSO4) and concentrated in vacua The residue was filtered through silica, eluttng with ethyl acetate: cyclohexane [1:1] and the titrate was concentrated JTT vacuo to give the title compound (720 mg). 1 H-NMR (d6-DMSO): 0.44 - 0.47 (2H), 0.30 - 0.83 (2H), 1.20 -1.25 , 1.70 - 1.80 (2H), 1.39 - 1.91 (3H) 5.22 - 5.24 , 5.61 - 5.63 , 6.80 - 6.84 (2H), 6.84 - 6.86 r 6.86 - 6.89 (2H), 7.00 - 7.02 , 7.17 - 7.23 (3H), 7.40 - 7.45 Similarly prepared were: (Table Removed) Preparation 139 1-Ben2yl-2-n-(2-bromo-3-methylphenyl)y1nyl)-1H-1mldazole To a suspension of the compound of Preparation 149 (3.1 g, 8.3 mmol) in acefonitrile (30 ml) was added thionyl chloride (12.2 ml, 167 mmol) and the reaction mixture was heated at 60°C, under nitrogen, for 11 h. The mixture was concentrated in vacuo and to the residue was added acetonftriie. This solution was concentrated in vacuo and the process was repeated To the final residue was added 2-propanol (40 ml) and activated charcoal and the mixture was heated at eCr'C for 1 h. The rnixlure was concentrated in vacuo to give the title compound (3.1 g). Experimental MH* 353.3; expected 353.1 Similarly prepared were: (Table Removed) Preparation 145 1H-NMH (CDCI3): 2.20 - 2.25 (3H), 4.80 - 4.84 (2H), 5.66 - 5.70 , 5.81 - 5.84 (1 H), 6.88 - 6.95 (4H), 7.10 - 7.14 , 7.21 - 7.29 (5H) Preparation 148 1-Ben2yl-2-[1-[2-methyl-3-(trIfluoromethyl)phenyl]vlnyl}-1H-imidazole A solution of the compound of Preparation 157 (4.90 g, 13.6 mmol) in Eaton's Reagent (50 ml) was stirred at room temperature for 40 h. The mixture was poured into ice/water (200 ml) and adjusted to pH 7 by addition of saturated aqueous sodium hydrogen carbonate solution. The mixture was extracted with ethyl acetate (2 x 100 ml) and the combined extracts were dried (MgSO4) and concentrated in vacuo to give the title compound (3.1 g). Experimental MH* 343.3; expected 343.1 Preparation 149 1-(1-B6nzyl-1H-imidazol-2-yl)-1-{2-bromo-3-methylrjhenyl)ethanol To a solution of the compound of Preparation 158 (3.38 g, 9.5 mmol) in tetrahydrofuran (30 mi), at 0°C and under nitrogen, was added dropwise methylmagnesium bromide (3M, 6.34 ml, 19 mmol). The reaction mixture was al]owed to warm to room temperature and stirred for 18 h. To the mixture was added hydrochloric acid (0.1 M, 25 ml), and Ihe solution was basified by addition of saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate (4 x 30 ml). The combined extracts were washed with brine (20 ml), dried (MgSO4) and concentrated in vacuo to give the title compound {3.10 g). Experimental MH+ 371.3; expected 371.1 Similarly prepared were : (Table Removed) Preparation 156 1H-NMR (CDGI3): 2.07 - 2.15 (3H), 2.42 - 2.4fl (3H), 4.93 - 5.00 (2H), 6.75 - 6.93 (5H), 7.05 - 7.16 (5H) Preparation 158 (1-Benzvl-1H-imldazol-2-yl)(2-bromo-3-methylphenyl)methanone A solution of 2-bromo-3-methylbenzoic add {2.0 gr 9.3 mmol) in thionyl chloride (4.75 ml, 65.1 mmol) was heated at 65°C, under nitrogen, for 3 h. The mixture was concentrated in vacuo and to the residue was added acetonltrite (25 ml). This solution was concentrated in vacuo and the process was repeated. To the final residue was added acetonitrile (25 mi), 1-benzyl]midazole (1.62 g, 10.2 mmol) and triethylamine (1.44 ml, 10.2 mmol) and the reaction mixture was heated al 60°C, under nitrogen, for 18h, The mixture was concentrated in vacuo and to the residue was added ethyl acetate (80 ml). The solution was washed with water (40 ml) and saturated aqueous sodium hydrogen carbonate solution (40 ml), dried (MgSO4) and concentrated in vacuo to give the title compound (3.38 g). Similarly prepared were: (Table Removed) Preparation 162 1H-NMR (CDCIs): 5.69 - 5.71 (2H), 6.81 - 6.85 (1H), 7.17 - 7.20 (2H), 7.21 - 7.24 (2H), 7.30 - 7.40 (3H), 7.71 - 7.73 , 8.39 - 8.42 (2H) Preparation 165 1H-NMR (CDCI3): 2.35 - 2.38 (3H), 5.61 - 5.65 (2H), 7.15 - 7.37 (8H), 7.46-7.50 , 7.92 - 7.97 Preparation 167 2-[1-[1-benzyl-1H-imldazol-2-yl)vinyl]-6-methylbenzonitrile A mixture of the compound of Preparation 139 (150 mg, 0.43 mmol), potassium hexacyanoferrate(H) (dried in vacuo at 85aC, 36 mg, 0.08 mmol}, copper(l) iodide (8 mg), potassium iodide (7 mg), 1 -methyl-2-pyrrolidinone (2 ml) and dimethylethylenediannine (49 ul) was placed in a pressure tube and degassed with nitrogen (x 3). The tube was sealed and heated at 140°C for 100 h. To the mixture was added ethyl acetate (10 ml) and water (10 ml) and the two layers were separated. The organic phase was dried (MgSO4) and concentrated in vacuo to give the title compound (160 mg) Experimental MH4 300.3; expected 300.2 Preparation 168 3-[1-(1-Benzyl-1H-imidazol-2-yl)yinyl)-2-methylbenzonrtrile To a solution of the compound of Preparation 140 (100 mg, 0.28 mmol) in 1-methyl-2-pyrrolidinone (3 ml) was added sodium cyanide (28 mg, 0.57 mmol) and nickel (II) bromide (62 mg, 0.28 mmol), The reaction mixture was sealed and heated in a microwave (150W) at 150°C for 5 min. To the mixture was added water (10 ml) and the solution was extracted with diethyl ether (4 x 10 ml). The combined extracts were washed with water (10 ml) and brine {10 ml), dried (MgSO4 and concentrated in vacuo. To the residue was added 2-propanol (15 ml) and activated charcoal and the solution was heated at 60°C for 1 h. The mixture was then filtered through Arbocel® and 1he filtrate was concentrated in vacuo to give tfie title compound (40 mg). Experimental MH+ 300.4; expected 300.2 Preparation 169 3-H-[1-Benzyl-1H-imida2ol-2-yl)yinyl]-5-methylbenzonitrile Toasolution of the compound of Preparation 145(1.1 g, 3.1 mmol) In N,N-dimethylacetamide(30ml) was added copper (I) cyanide (641 mg, 7.1 mmol) and the reaction mixture was heated at 150°C for 3 days. The reaction mixture was poured into ethyl acetate and the mixture was washed with water and brine. The aqueous phase was filtered and the solid material was col]ected by 1fltratfon and dissolved in ethyl acetate, water and N,N,N,N'-tetramethy!ethylenecEarnine. The two layers were separated and the organic phase was washed with brine, dried (MsSO4) and concentrated in vacuo. The residue was filtered through charcoal and silica, eluting with ethyl acetate and the filtrate was concentrated rn vacuo to give the title compound (210 mg). 1 H-NMR (CDCI3): 2.24 - 2.28 (3H), 4.80-4.92 (2H), 5.56 - 5.60 , 5.78 - 5.82 , 6.88 - 6.97 (3H), 7.10- 7.14 , 7.19 - 7.33 (6H) Preparation 170 1-[3-Methy]-2-(trifluoromethyl)phenyl)ethanorie To a solution of the compound of Preparation 171 (427 mg, 2.1 mmol) in dichloromethane (20 ml) was added Dess-Martin periodinane (25%, 3.83 ml, 2.3 mmol) and the reaction mixture was stirred at room temperature for 18 h. The reaction mixture was filtered through silica, eluting with dichloromethane, fol]owed by diethyl ether. The filtrate was washed with saturated aqueous sodium hydrogen carbonate solution, dried (MgSO4) and concentrated in vacuo. To the residue was added dichloromethane and the solution was filtered through silica. The filtrate was dried (MgSO4) and concentrated AT vacuo. The residue was dissolved in tetrahydrofuran and re-concentrated to give the title compound (332 mg). 1H-NMR (CDCI3): 1.80-1.85 (3H), 3.75 - 3.79 (3H), 7.04-7.07 , 7.31 -7.33 , 7.40-7.43 Preparation 171 1-[3-Methyl-2-(trifluoromethyl)phenyl)ethanol To a solution of the compound of Preparation 172 (500 mg, 2.1 mmol) in tetrahydrofuran (22 ml), at -78°C, was added π-butyl]ithium (2.5M in hexanes, 0.92 ml, 2.3 mmol). After stirring for 45 min, acetaldehyde (0.14 ml, 2.5 mmol) was added and the reaction mixture was al]owed to warm to room temperature over 18 h. To the mixture was added saturated aqueous ammonium chloride solution and the mixlure was extracted with ethyl acetate. The combined extracts were washed with brine, dried (MgSO,,) and concentrated in vacuo to give the title compound (600 mg). 1H-NMR (GDCIa): 1.42 - 1.45 (3H), 2.49 - 2.53 (3H), 5.38 - 5.42 , 7.16 - 7.19 , 7.40 - 7.43 (1H), 7.65 - 7.68 Preparation 172 1-Bromo-3-methyl-2-[lrifluoromethyl)benzene A mixture of 2-bromo-6-methylbenzoic acid (10.0 g, 47.0 mmol} and sulphur tetrafluorlde (5.02 g, 46.5 mmol) was heated In hydrofluoric add (930 mgr 46.5 mmol) at 110°C. To the reaction mixture was added ethyl acetate and water and the two layers were separated. The organic phase was dried (lgS) and concentrated in vacuo. The residue was disrjled under reduced pressure (bp 30-33°C at 1 mmHg) to give the title compound (1.83 g). Preparation 173 1-(3-Chloro-2-methoxyphenyl)ethanone To the compound of Preparation 193 (697 mg, 4.1 mmol) in acetone (30 ml) was added potassium carbonate (1.13 g, 8.2 mmol), fol]owed by methyl iodide (2.0 ml, 4.66 g, 32.8 mmol). The reaction mtxlure was heated at 40°C for 18 h, cooled and concentrated in vacuo. The residue was partitioned between ethyl acetate and water and the organic phase was separated, washed wfth brine, dried (MgSO4) and concentrated in vacuo Jo give the title compound (450 mg) as a m ixture of regioisomers. 1H-NMH (CDCI3): 2.58-2.62 (3H), 3.92 - 3.95 (3H)f 7.47 - 7.51 , 7.82-7.86 , 7.94 - 7.97 Similarly prepared was: (Table Removed) *** The reaction to yield Preparation 174 gave some of Preparation 173 since Preparation 193 contained a mixture of 1-(3-chioro-2-hydroxyphenyl)ethanone and 1-(3-chloro-4-hydroxyphenyl)ethanone Preparation 174 1H-NMR (CDCI3): 2.58 - 2.62 (3H), 3.92 - 3.95 (3H), 7.47 - 7.51 , 7.82 - 7.86 , 7.94 - 7.97 Preparation 175 1-(2-Chloro-5-methoxyphenyl)ethanone To a solution of SELECTFLUOR™ (5.0 g, 14.1 mmol) and sodium chloride (825 mg, 14.1 mmoQ in acetonitrile (200 ml), under nitrogen, was added 1-(3-methoxyphenyl)ethanone (1.94 ml, 14.1 mmol) and the reaction mixture was stirred at room temperature for 5 days. To the mixture was added distil]ed water (200 ml} and the solution was extracted with dichtoromethane (2 x 100 ml). The combined extracts were dried (MgSO4) and concentrated in vacuo. The residue was purified by column chromatography (sifica) with gradient elution, ethyl acetate : cyclohexane [5:95 to 10:90]. The appropriate fractions were combined and concentrated to give the title compound (1.12 g). 1H-NMR (CDCIs): 2.59 - 2.65 (3H), 3.76 - 3.80 (3H). 6.88 - 6.91 (1H), 7.01 - 7.04 , 7.25 - 7.2B Preparation 176 1-Benzyl-2-n-(3-ethy1-2-methylphen^)vinAftMtf-im1dazole To a solution of the compound of Preparation 140 (207 mg, 0.3 mmol) In N,N-dimethylformide (2a ml) was added potassium carbonate (1.17g, 8.5 mmol), [1,1'-bis(dtprtenylphosphino)ferrooer>e]pal]adium (II) chloride (550 mg) and triethylborane (1M, 6.79 ml, 6.8 mmol). The reaction mixture was heated at reflux for 60 n, cooled and concentrated in vacuo. To the residue was added elhyl acetate and water and the two layers were separated. The organic phase was washed with wafer and brine, dried (MgSO4) and concentrated in vacuo to give the title compound {110 mg). Experimental MH+ 303.2; expected 303.2 Preparation 177 1-(1-Benzyl-1H-imidazol-2-yl)-(3-ethylphenyl)ethanol Toasolution of the compound of Preparation 150(500mg, 1.4mmol)in N,N-dimethylforma!nide{14ml) was added potassium carbonate (193 mg, 1.4mmol) and triethylborane (1M, 3.36 ml, 3.4 mmol). The mixture was de-oxygenated and [1,1'-bis{diphenylphosphino)ferrocenetpairadium (I'D chloride (t 14 mg) was added. The reaction mixture was heated at 50°C for 18 h, cooled and concentrated in vacuo. To the residue was added ethyl acetate and water and the two layers were separated. The organic phase was washed with water and brine, dried (MgSO4) and concentrated in vacuo to give the l]l]e compound (500 mg). Experimental MH+ 307.3; expected 307.2 Preparation 178 1-(2-ethyl-3-methylphenyHethanone To a solution of the compound of Preparation 179 (367 mg, 1.7 mmol) in anhydrous N,N-dimethylformamide (10 ml), under nitrogen, was added potassium carbonate (4.52 g, 32.7 mmof), fol]owed by [1,1'-bis(diphenylphosphino)ferrocene]pal]adium (li) chloride (141 mg) and triethylborane (1M in tetrahydrofuran, 4.13 ml, 4.13 mmol). The reaction mixture was heated at 50°C for 18 h, filtered and concentrated in vacuo. The residue was purified by flash chromatography (Biotage™ 40M cartridge), eluting with ethyl acetate : pentane [5:95]. The appropriate fractions were combined and concentrated to give the title compound (160 mg). 1H-NMR (CDCI3): 1.15 - 1.20 (3H), 2.35 - 2.38 (3H), 2.55 - 2.58 (3H), 2.74 - 2.81 (2H), 7.12-7,17 , 7.23 - 7.27 , 7.36 - 7.40 Preparation 179 1-(2-Bromo-3-methylphenyl)ethanone To a solution of 1 -(2-amino-3-methylphenyl)ethanone (Helv. Chim. Acta; EN; 62, 1979, 271 - 303,) (850 mg, 5.7 rnmo!) in hydrcbromic acid (9 ml, 5.7 mmol) and water {6 ml), at 0°C, was added aqueous sodium nitrite solution (503 mg, 7.3 mmol) and the mixture was stirred for 15 min. This mixture was added to copper (I) bromide (899 mg, 6.3 mmol) in hydrobromic acid {9 ml, 5.7 mmol) at 60oC and the reaction mixture was heated at 95CC for a further 30 min. After cooling, the mixture was poured into an ice J water slurry and extracted with ethyl acetate. The combined extracts were dried (MgSO4j) and concentrated in vacua. To the residue was added ethyl acetate: cydohexane [1:41 and the solution was filtered through silica. The filtrate was concentrated In vacuo to give !he title compound (1.06 g). Preparation 180 1-(2-Bromo-3,5.6-trimethylphenyl)ethanona To a mixture of 1 -brorrto-2,4,5-trimethy1benzene (5.0 g, 25.0 mmol) and acetyl chloride (2.45 ml, 34.5 mmol) in dichloromethane (50 ml) was added aluminium chloride (4.42 g, 33.1 mmol) m dichloromethane (50 ml) and the reaction mixture was stirred at room temperature for 18 h. The mixture was poured into water and the two layers were separated. The organic phase was washed with saturated aqueous sodluii hydrogen carbonate solution, dried (MgSO4) and filtered through silica The Htrate was concentrated in vacuo to give the title compound (5.50 g). 1H-NMR (CDCl3): 2.13 - 2.17 (3H), 2.22 - 2.27 (3H), 2.28 - 2.34 (3H), 2.43 - 2.54 (3H), 6.89 - 6.92 Preparation 181 1-Benzyl-2-{1-[2-(difluoromethyl)-3-methylphenyf]vinyl]-1H-imidazola To a solution of the compound of Preparation 141 (140 mg, 0.36 mmol) in 1,4-dioxane: water (9:1,10 mi) was added (trimethylboroxtne (50 µT, 0,36 mmol) and sodium carbonate (114 mg, 1.03 mmol}. The mixture was degassed, before addition of [1,1'-bis(diphenylphosphino)ferrocene]palladium (II) chloride (30 mg). The reaction mixture was heated at 100°C for 13 h, cooled and concentrated in vacuo. To the residue was added ethyl acetate and the solution was washed with water, dried (MgSO4) and tittered through silica. The filtrate was concentrated in vacuo to give the title compound (110 mg}. Experimental MH+ 325.3; expected 325.2 Preparation 182 3-Bromo-2-(difluoromethyl)benzoic acid To a solution of the compound of Preparation 133 (4.05 g, 11.9 mmol) in tetrahydrofuran (120 ml) was added aqueous sodium hydroxide solution (1M, 24.30 ml, 24.3 mmol) and the reaction mixture was stirred at room temperature for 18 h. The mixture was partitioned between diethyl ether and water and the two layers were separated. The aqueous layer was acidified with hydrochloric acid (2M) and extracted with ethyl acetate. The combined extracts were dried (MgSO4) and concentrated in vacuo to give the title compound (3.06 g). Experimental MH4" 251.1; expected 251.0 Preparation 183 Benzyl 3-bromo-2-(difiuoromethyl)benzoate To a solution of the compound of Preparation 185 (4.1 g, 12.9 mmol) In didhloromethane (130 mi) was added (diethylamina)sulphur bifiuoride (5.06 mf, 38.6 mmol) and the reaction mixture was stirred at room temperature for 18 h. To the mixture was added additional dichlQfomethane and saturated aqueous sodium hydrogen carbonate solution and the two layers were separated. The organic phase was concentrated in vacuo and the residue was iiltered through silica, eluting with dichloromethane. The filtrate was concentrated in vacuo to give the title compound {4.05 g). 1H-NMR (CDCI3): 5.23 - 5.25 , 5.33 - 5.35 (2H), 7.30 - 7.41 (4H), 7.59 - 7.64 (2H), 7.85 7.90 Similarly prepared was: (Table Removed) Preparation 185 Benzyl 3-bromo-2-[ormylbenzoate To a solution of the compound of Preparation 186 (4.77 g, 14.9 mmol) in ethyl acetate (150 ml) was added manganese (IV) oxide (12.95 g, 148.9 mmol) and the reaction mixture was stirred at room temperature for 1 h. The mixture was filtered and the filtrate was concentrated in vacuo to give the title compound (4.11 g}. Experimental MH+319.1; expected 319.0 Preparation 186 Benzyl 3-bromo-2-[hydroxymethyl)benzoate A solution of 4-aromo-2-benzofuran-1(3H)-one (4.02 g, 18.9 mmol) fn aqueous sodium hydroxide solution (1M, 18.9 mi) was heated at 100o0 for 1 h. The solution was concentrated in vacuo and the residue was dissolved in toluene and re-concentrated. To a solution of the residue In N,N-dlrnethylformamide (20 ml) was added benzyl bromide (2.26 ml, 18.90 mmol) and the reaction mixture was stirred at room temperature for 14 days. The mixture was poured into water and the resulting precipitate was col]ected by filtration, washed with water and pentane and dried to give the title compound (4.77 g). Experimental MH+ 321.1; expected 321.0 Preparation 187 3-(Difluoromethyl}benzoio acid To a solution of the compound of Preparation 184 (188 mg, 1.0 mmol) in tetrahydrofuran (5 ml) was added lithium hydroxide monohydrate (85 mg, 2.0 mmol). The reaction mixture was stirred at room temperature for 18 h and then acidified by addition of hydrochloric acid (1M). To the mixture was added water (5 ml) and brine (5 ml) and the solution was extracted with ethyl acetate (3x10 ml). The combined extracts were dried (MgSO4) and concentrated in vacuo to give the title compound (290 mg). 1 H-NMR (CDCI3): 6.50 - 6.80 , 7.50 - 7.57 , 7.69 - 7.74 (1H), 8.14 - 8.21 (2H) Preparation 188 3-Bromo-5-methylbenzoic acid To a solution of the compound of Preparation 189 (10.0 g, 43.5 mmof) in acetic acid (45 mi) was added hydrochloric acid (12M, 14.1 ml) and the reaction mixture was heated at 70°C for 1 ft. The solution was cooled to 0°C and aqueous sodium nitrite solution (5M, 3.0 g, 43.5 mmol) was added. After 1 h, the mixture was cooled to -15°C and aqueous hypophosphorous acid (50%, 23 ml, 170 mmol) was added dropwise. The reaction mixture was al]owed to warm to 10oC over 2 h and filtered. The solid material was washed with water and cyclohexane and the product was dried to give the title compound (8.6 g). 1H-NMR (CDCI3): 2.32 - 2.36 (3H), 7.64 - 7.66 , 7.71 - 7.74 , 7.79-7.82 Preparation 189 2-Amino-3-bromo-5-methylbenzoic acid To a solution of 2-amino-5-methylbenzoic acid (25.0 g, 170 mmol) in acetic acid (250 ml) was added bromine (10 ml, 195 mmol) and the reaction mixture was stirred at room temperature for 2 h. The mixture was filtered and the solid material was washed with water and cyclohexane and dried to give the title compound (33.4 g). 1H-NMR (CDCl3): 2.08 - 2.13 (3H), 7.42 - 7.45 , 7.53 - 7.56 Preparation 190 5-Methoxy-2,4-dimethylbenzaldehyde To asolution of the compound of Preparation 191 (4.12g, 14 mmol) in 1,4-dioxane (30 ml) was added aqueous sodium carbonate solution (15M, 2.80 ml, 42 mmol). After purging with nitrogen, trimethylboroxine (1.95 ml, 14 mmol) was added, fol]owed by {1,1'- bis(dipheny]phosphino)ferrocene]dlchloropailadium(l]) (1.03 g). The reaction mixture was heated at 100°C for 18 h, cooled and filtered through Arbocel®. The filtrate was concentrated in vacuo and to the residue was added dichloromethane. The solution was filtered through silica and the filtrate was concentrated in vacuo to give the title compound (988 mg). 1H-NMR (CDCI3): 2.19 - 2.23 (3H), 2.53 - 2.57 (3H), 3.80 - 3.85 (3H), 7.21 - 7.24 (2H), 10.23 -10.25 Preparation 191 2,4-Dibromo-5-methoxybenza)derivde To a solution of 3-methoxybenzaldehyde (5.00 g, 4.47 m), 36.7 mmol) in methanol {245 ml) was added aqueous sodium bromide solution (5M, 36.7 ml, 184 mmol) and aqueous OXONE® solution (45.00 g, 73.4 mmol), The reaction mixture was stirred at room temperature for 18 hi, before addition of aqueous sodium thiosulphate solution (1M, 200 ml) and ethyl acetate (400 ml). The two layers were separated and the organic phase was washed with water and brine, dried (MgSO4) and concentrated in vacuo. The residue was purified by flash chromatography (Biotage) elutlng with ethyl acetate: cyctohexane [10:90]. The appropriate fractions were combined and concentrated to give the title compound (4.12 g). 1H-NMR (CDCI3): 3.89-3.93 (3H), 7.37 - 7.39 , 7.79-7.82 , 10.20 - 10.23 Preparation 192 t-(2,3-dimethylphenyl)propan-1-ol To a solution of 2,3-dimethylbenzaidehyde (1.0 g, 7.5 mmol) In anhydrous tetrahylfrofuran (50 ml), at -78°C and under nitrogen, was added ethylfrthium (0.5M in benzene: cyclohexane 9:1,14.9 ml, 7.5 mmol), dropwise via syringe. The reaction mixture was stirred at -78aC for 30 min and then poured into Ice cold hydrochloric acid (2N, 20 ml). The mixture was extracted with ethyl acetate (2 x 50 m I) and the combined extracts were dried (MgSO4) and concentrated in vacuo to give the title compound (1.22 g). 1H-NMR (CDCI3): 0.93 - 0.99 (3H), 1.68 -1.75 (2H), 2.18 - 2.22 (3H), 2.25 - 2.28 (3H), 4.87 - 4.92 , 7.03 - 7.13 (2H), 7.28 - 7.38 Preparation 193 1-(3-Chloro-2-hydroxyphenyl)ethanone and 1-(3-chloro-4-hydroxyphenyl)ethanone A solution of 2-chlorophenyi acetate (1.98 g, 11.6 mmol) in 1,2-dichloroben2ene (10 ml) was added dropwise to a solution of aluminium chloride (1.90 g, 13.9 mmol) in 1,2-dichlorobenzene (10 ml). The reaction mixture was heated at 100oC for 24 h and then cooled, before addition of dichloromethane (10 ml). The mixture was poured into hydrochloric acid (10%, 12 ml), at 0°C, and the two layers were separated. The aqueous phase was extracted with dichloromethane and the combined organic phases were washed with water, dried (MgSO4) and concentrated in vacuo. The residue was purified by column chromatography (silica), eluting with cyclohexane. The appropriate fractions were combined and concentrated to give the title compound as a 1:1 mixture of regioisomers (1.0 g). Preparation 194 1-Benzyl-2-[1-(2,3-dimethylDhenyl)vinyl)-1H-imidazola To a suspension of the compound of Preparation 195 (500 mg, 1.63 mmol) in acetonitrile (10 ml) was added thionyl chloride (0.2 mmol, 2.74rnmol) and the reaction mixture was stirred a) room temperature for 18 h. The reaction mixture was concentrated In vacuo and the residue was triturated with ethyl acetate to give the title compound (450 mg). Experimental MH* 289.3; expected 289.2 Alternative syl)thesis A solution of the compound of Preparation 195 (82.00 g, 267.6 mmol) in Eaton's Reagent (380 ml) was stirred at room temperature for 18 h. The reaction mixture was poured onto Ice and (he solution was washed with diethyl ether and adjusted to pH 7 by addition sodium carbonate. The aqueous layer was extracted with ethyl acetate and the combined organic extracts were concentrated \n vacua to give the title compound (79.0g). Experimental MH289.4; expected 289.2 Preparation 195 1-[1-Benzyl-1H-imidazol-2-yl)-1-2.3-dimethylphenyl)ethanol To a solution of the compound of Preparation 36 {182 g, S26.8 mmol) in tetrahydrofuran (1 I), at 0°C, was added methylmagnesium chloride (3M in tetrahydrofuran, 271 ml, 814 mmol). The reaction mixture was stirred at room temperature for 18 h and then poured into hydrochloric acid (2M, 500 ml). To the mixture was added diethyl ether (500 ml) and saturated aqueous sodium chloride solution (100 ml) and the two layers were separated. To the aqueous layer was added ethyl acetate (500 ml) and sodium carbonate (50 g) and the organic layer was separated. The resulting solid material was col]ected by filtration and triturated with diethyl ether (300 ml) to give the title compound (82 g). Experimental MH+ 307.4; expected 307.2 Alternative syl)thesis To a solution of methylmagnesium chloride (3M in tetrahydrofuran, 5.0L, 15.2 mol), under nitrogen, was added a solution of the compound of Preparation 36 (2.8kg, 9.6 mol) in toluene (6.0L), at -10CC. The reaction mixture was stirred at -10°C for 4 h and then quenched by the dropwise addition of aqueous ammonium chloride solution (20%, 14.0L), The resulting solid was col]ected by filtration and then was slurried with water (2 x 10L) and filtered. The residue obtained is further slurried in acetonitrile (14L) and filtered. The solid material col]ected by filtration was washed with acetonitrile (2 x 4L) and dried in vacuo at 50°C to give the title compound (2.63kg, 99.75% pure by HPLC). Preparation 196 3-[1-(1H-imidazoi-2-yl)ethyl]benzamlde A solution of the compound of Preparation 197 (311 mg, 1.35 mmol) in ammonium hydroxide (28% in water, 15 ml) was heated at 85°C for 2 h. The mixture was then cooled and concentrated in vacuoto give the title compound (364 mg). Experimental MH+ 216.2; expected 216.1 Preparation 197 Methyl 3-P1-(1H-lmidazol-2-yl]etriyl)benzoate To a solution of the compound of Preparation 198 (477 mg, 1.5 mmol) In 2-propanol (10 ml) was added ammonium formate (945 mg, 15.0 mmol) and pal]adium (10 wt % on carbon, 168 mg) and the reaction mixture was heated at 80°C for 18 h. The mixture was filtered through Arbocel® and the filtrate was concentrated in vacuo to give the title compound (270 ring). Experimental MH*231.4; expected 231.1 Preparation 19B Methyl 3-[ 1-(1-benzyl-1H-imidazol-2-yl)ylnyl)benzoate A mixture of the compound of Preparation 199 (2.55 g, 7.3 mmol) and thionyl chloride (2.12 ml, 29.1 mmol) in acetonitrffe (20 ml) was stirred at room temperature for 18 h. The mixture was concentrated in vacuo and the residue was partitioned between ethyl acetate and aqueous sodium hydrogen carbonate solution. The two layers were separated and the organic phase was fitered through silica and charcoar and concentrated in vacuo. The residue was purified by column chromatography (silica}, with, gradient elutlon, ethyl acetate : cyclohexane [1:1 to 4:1 to 1:0]. The appropriate fractions were combined and concentrated to give the title compound (2.32 g). Experimental MH+ 319.3; expected 319.1 Preparation 199 Methyl 3-n-[ 1-benzyl-1H-i-imldazol-2-yl)-1-hydroxyethyl]benzoate To a solution of the compound of Preparation 200 (3.82 g, 11.9 mmol) in tefrahydrof uran (25 ml), at 0°C, was added methylmagneslum chloride (3M In tetrahydrofuran, 5.17 ml, 15.5 mmol) and the reaction mixture was stirred at room temperature for 18 h. The mixture was poured into a mixture of ice, hydrochloric acid (2M) and diethyl ether and the two layers were separated. The aqueous layer was adjusted to pH 7 by addition of solid sodium hydrogen carbonate and then extracted with ethyl acetate. The combined extracts were dried (MgSO4) and concentrated in vacuo to give the title compound (2.55 g)- Experimental MH+ 337.4; expected 337.1 Preparation 200 Methyl 3-[(1 -benzyl- 1H-imidazol-2-yl)carbonyl)benzoate A solution of 3-(methoxycarbonyl)benzolc acid (2.53 g, 14.0 mmol) in thionyl chloride (7.17 ml, 98.30 mmol) was heated at reflux for 1 h. The mixture was cooled and concentrated in vacuo and to the residue was added toluene. This solution was concentrated in vacuo and to the residue was added anhydrous acetonitrile (24 ml), 1-benzyl-1H-imidazole (2.22 g, 14.0 mmol) and triethylamine (2.35 ml, 16.9 mmol). The reaction mixture was heated at reflux for 18 h and then cooled and concentrated in vacuo. To the residue was added ethyl acetate and the solution was washed with water and saturated aqueous sodium hydrogen carbonate solution. The organic phase was filtered through silica, eluting with ethyl acetate, and the filtrate was concentrated in vacuo to give the title compound (3.82 g). Experimental MH+ 321.3; expected 321.1 Preparation 201 (2,3-DimethylPhenyl)(1H-imidazol-2-yl)methanol To a solution of 1-(dlethoxymethyl)--H-lmidazole (698 mg, 4.10 mrnol) in anhydrous tetrahydrofuran (7 ml), at -78°C, was added n-butyl]ithium (2.5 M In hexane, 1.64 ml, 4.1 mrnol). The reaction mixture was stirred at -78°C for 1 h, before addition of a solution of 2,3-dimethylbenzaldehyde (500 mg, 3.73 mmol) in tetrahydrofuran (3 ml). The reaction mixture was stirred at -78°C for 2 h, warmed to roam temperature and quenched with ice cold hydrochloric acid (4M, 20 ml). The reaction mixture was concentrated in vacuo and to the residue was added water (20 ml). The solution was extracted with diethy] ether (2 x 20 ml) and the aqueous layer was basified by addition of soiid sodium hydrogen carbonate. This solution was extracted with ethyl acetate (3 x 20 ml) and trie combined organic phases were dried (MgSO4) and concentrated in vacuo to give the title compound (543 mg) Experimental MH+ 203.1; expected 203.1 If} WE CLAIM: 1. A substituted imidazole compound of formula (I): R' R' R' R' R Y^ R R^ ^ Formula (I) wherein: R', R^, R^, R'*, R^ are independently selected from the group consisting of hydrogen, halo, CM alkyl, Cs^ cycloalkyl, C ^ alkoxy, C ^ haloalkyl, C ^ haloalkoxy, and SR"*, where R"' is CM alkyl or CM haloalkyl; R^ is selected from the group consisting of hydrogen, -Co-2alkyleneR^, -Ci. 2alkyleneOR', -Ci.2alkyleneOC(0)R^ -Co.2alkyleneC(0)OR^ -Ci.2aikyleneOC(0)NHR^ and -C,.2alkyleneOC(0)NR'^R'^; where each R^, R'^ and R'*, where chemically possible, is independently selected from the group consisting of hydrogen, Ci^ alkyl, and CM alkylene(C3-6 cycloalkyl); R^ and R^ are independently selected from the group consisting of hydrogen. CM alkyl, C]^ alkoxy. CM haloalkyl, and C0-4 alkylenephenyl but with the proviso that R^ and R^ are not both hydrogen; R^'andR^^ are independently selected from the group consisting of hydrogen, halo, cyano. CM alkyl. CM alkoxy. CM haloalkyl, and CM haloalkoxy; or a pharmaceutically acceptable salt thereof. 2. A compound as claimed in Claim 1 wherein R' and R^ are methyl and R^, R'^, and R^ are hydrogen. 3. A compound as claimed in Claim 1 or 2 wherein R^ is selected from the group consisting of hydrogen, -Co-2alkyleneR^, and -Ci.2alkyleneOC(0)R^. 4. A compound as claimed in Claim 3 where R^ is selected from the group consisting of hydrogen, 2,2-dimethylpropionyloxymethyl, propionyloxymethyl, 3- cyclopentylpropionyloxymethyl, 3-methylbutyryloxymethyl, heptanoyloxymethyl, butyryloxymethyl, pentanoyloxymethyl, cyclopropylmethyl, methyl, cyclopropylmethyloxycarbonyloxymethyl, 3-methylbutoxycarbonyloxymethyl, isopropoxycarbonyloxymethyl, cyclobutoxycarbonyloxymethyl, ethyl, methoxymethyl, isobutoxycarbonyl, and isopropoxycarbonyl. 5. A compound as claimed in any one of Claims 1 to 4 wherein R^ is methyl and R^ is hydrogen. 6. A compound as claimed in any one of Claims 1 to 5 wherein R " and R^^ are both hydrogen. 7. A compound as claimed in Claim 1 selected from: 2-[l-(2,3-dimethylphenyl)ethyl]-lH-imidazole; 2-[(15)-l-(2,3-dimethylphenyl)ethyl]-lH-imidazole; 2-[(l^)-l-(2,3-dimethylphenyl)ethyl]-lH-imidazole; {2-[l -(2,3-dimethylphenyl)ethyl]-1 H-imidazol-1 -yl}methyl pivalate; {2-[(lS)-l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methylpivalate; {2-[(lR)-l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methylpivalate; {2-[l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methyl propionate; {2-[l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methyl 3-methylbutanoate; {2-[l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methyl butyrate; {2-[l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methyl 3-cyclopentylpropanoate; {2-[l-(2,3-dimethylphenyl)ethyl]-lH-imidazol-l-yl}methyl heptanoate; {2-[l-(2,3-dimethyIphenyl)ethyl]-lH-imidazol-l-yl}methyl pentanoate; 2- {1 -[2-(trifluoromethyl)phenyl]ethyl} -1H-imidazole; 2-[l-(2,5-dimethylphenyl)ethyl]-lH-imidazole; 2-[l-(4-chloro-3-methylphenyl)ethyl]-lH-imidazole; 1 ^ / 2-[l-(3,5-diniethylphenyl)ethyl]-lH-imidazole; 1 -(cyclopropylmethyl)-2-[ 1 -(2,3-dimethylphenyl)ethyl]- l//-imidazole; 2-[ 1-(2,3-dimethylphenyl)ethyl]-1-methyl-1//-imidazole; cyclopropylmethyl {2-[ 1 -(2,3-dimethylphenyl)ethyl]-l//-imidazol-1 -yl}methylcarbonate; {2-[l-(2,3-dimethylphenyl)ethyl]-l//-imidazol-l-yl}methyl 3-methylbutyl carbonate; {2-[l-(2,3-dimethylphenyl)ethyl]-l//-imidazol-l-yl}methyl isopropyl carbonate; 2-[ 1 -(2,3-dimethylphenyl)ethyl]-1 -ethyl-1 //-imidazole; 2-[ 1 -(2,3-dimethylphenyl)ethyl]-1 -(methoxymethyl)-1 H-imidazole; isobutyl 2-[l-(2,3-dimethylphenyI)ethyl]-l//-imidazole-l-carboxylate; isopropyl 2-[ 1 -(2,3-dimethylphenyl)ethyl]-1 //-imidazole-1 -carboxylate; and 2-[l-(3-methylphenyl)ethyl]-l//-imidazole, or a pharmaceutically acceptable salt thereof. 8. The compounds as claimed in Claim 1 as and when used in the preparation of a pharmaceutical, veterinary, or agricultural preparation. Dated this 27/06/2008 \j fn)/^ [RANJNA MEHTA-DUTT] OF REMFRY & SAGAR ATTORNEY FOR THE APPLICANTS |
|---|
5605-delnp-2008-Abstract-(04-09-2012).pdf
5605-delnp-2008-Abstract-(22-02-2013).pdf
5605-delnp-2008-Abstract-(22-08-2013).pdf
5605-delnp-2008-Claims-(04-09-2012).pdf
5605-delnp-2008-Claims-(22-02-2013).pdf
5605-delnp-2008-Claims-(22-08-2013).pdf
5605-delnp-2008-Correspondence Others-(22-08-2013).pdf
5605-delnp-2008-Correspondence Others-(04-09-2012).pdf
5605-delnp-2008-Correspondence Others-(23-08-2012).pdf
5605-delnp-2008-Correspondence Others-(29-10-2013).pdf
5605-delnp-2008-Correspondence-others (15-11-2012).pdf
5605-delnp-2008-Correspondence-Others-(06-06-2014).pdf
5605-delnp-2008-Correspondence-Others-(22-02-2013).pdf
5605-delnp-2008-correspondence-others.pdf
5605-delnp-2008-description (complete).pdf
5605-delnp-2008-Form-1-(04-09-2012).pdf
5605-delnp-2008-Form-2-(04-09-2012).pdf
5605-delnp-2008-Form-2-(06-06-2014).pdf
5605-delnp-2008-Form-2-(22-02-2013).pdf
5605-delnp-2008-Form-2-(22-08-2013).pdf
5605-delnp-2008-Form-2-(29-10-2013).pdf
5605-delnp-2008-Form-3 (15-11-2012).pdf
5605-delnp-2008-Form-3-(22-02-2013).pdf
5605-delnp-2008-Form-3-(23-08-2012).pdf
5605-delnp-2008-GPA-(04-09-2012).pdf
5605-delnp-2008-GPA-(29-10-2013).pdf
5605-delnp-2008-Petition-137-(23-08-2012).pdf
| Patent Number | 261073 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indian Patent Application Number | 5605/DELNP/2008 | ||||||||||||||||||
| PG Journal Number | 23/2014 | ||||||||||||||||||
| Publication Date | 06-Jun-2014 | ||||||||||||||||||
| Grant Date | 02-Jun-2014 | ||||||||||||||||||
| Date of Filing | 27-Jun-2008 | ||||||||||||||||||
| Name of Patentee | ZOETIS UK LIMITED | ||||||||||||||||||
| Applicant Address | 5th FLOOR, 6 ST. ANDREW STREET, LONDON EC4A,3AE, UNITED KINGDOM, | ||||||||||||||||||
Inventors:
|
|||||||||||||||||||
| PCT International Classification Number | C07D 233/54 | ||||||||||||||||||
| PCT International Application Number | PCT/IB2007/000071 | ||||||||||||||||||
| PCT International Filing date | 2007-01-08 | ||||||||||||||||||
PCT Conventions:
|
|||||||||||||||||||